[COMPANY_011]  Pasteur PSK00008  
515 – PNEUMOPCV Protocol  Version  6.0 
 
Confidential/Proprietary Information  
Page 1 of 126 Safety and Immunogenicity of a Pneumococcal Conjugate 
Vaccine when Administered Concomitantly with Routine 
Pediatric Vaccines in Healthy Toddlers and Infants  
Phase II, randomized, observer -blind, controlled, age de-escalation study in approximately 
140 toddlers and 700 infants in the US, Canada, and Honduras. 
Clinical Study Protocol, Amendment 4 
Health Authority File Number(s):  BB-IND #:  018207 
WHO Universal Trial Number 
(UTN):  U1111- 1238 -1638 
Study Code:  PSK00008 
Development Phase:  Phase II 
Sponsor:  [COMPANY_011] Pasteur Inc.  
Discovery Drive, Swiftwater, PA [ADDRESS_1221885](s):  Pneumococcal Conjugate Vaccine  
Form / Route:  Liquid / Intramuscular (IM)  
Indication For This Study:  PCV 21 as a single dose in toddlers aged 12 to 15 months and as 4 doses in infants at 2, 4, 6, and 12 to 15 months of age  
Manufacturer:  
SK bioscience Co., Ltd  
310, Pangyo -ro, Bundang- gu, Seongnam -si, Gyeonggi -do, Korea [[ZIP_CODE]]  
Coordinating Investigator 
(Stage  I) 
Coordinating Investigator (Stage  II) [STUDY_ID_REMOVED]

[COMPANY_011]  Pasteur PSK00008  
515 – PNEUMOPCV Protocol  Version  6.0 
 
Confidential/Proprietary Information  
Page 2 of 126 Sponsor’s Responsible Medical 
Officer:  
Global Clinical Development Strategy Expert:   
Global Safety Officer:  
 
Regional Trial Manager:  
 
Version and Date of the Protocol:  Version 6.[ADDRESS_1221886] parties without written authorization from [COMPANY_011] Pasteur. This document may not be reproduced, stored in a 
retrieval system, or transmitted in any form or by [CONTACT_61076] –electronic, mechanical recording, or otherwise –without prior 
authorization from [COMPANY_011] Pasteur. This document must be returned to [COMPANY_011] Pasteur upon request.  

[COMPANY_011]  Pasteur PSK00008  
515 – PNEUMOPCV Protocol  Version  6.0 
 
Confidential/Proprietary Information  
Page 3 of 126 History of Protocol Versions   
Version * Date Comments  
1.0 09 January 2020  Version submitted to the IEC/IRB.  
Updated in response to comments provided by [CONTACT_875005] (CBER) prior to study initiation .  
2.0 15 April 2020 Version submitted to the IEC/IRB  
First version used in the study at the time of FVFS 
3.0 30 November 2020  Version submitted to the IEC/IRB  
Amendment 1  
4.0 21 April 2021 Version submitted to the IEC/IRB  
Amendment 2  
5.0 25 June 2021  Version submitted to the IEC/IRB  
Amendment 3  
*Versions in bold font have been approved by [CONTACT_8134]/IRB and used in the study 
[COMPANY_011]  Pasteur PSK00008  
515 – PNEUMOPCV Protocol  Version  6.0 
 
Confidential/Proprietary Information  
Page [ADDRESS_1221887] of Tables  .......................................................................................................................... 9  
Synopsis  ................................................................................................................................ 10  
Table of Study Procedures 1 (Toddlers)  ............................................................................ 27  
Table of Study Procedures 2 (Infants) (Applicable before protocol Version 5.0)  ......... 28  
Table of Study Procedures 2 (Infants) (applicable from protocol Version 5.0) ............. [ADDRESS_1221888] ........................................................... 36  
1.3 Potential Benefits and Risks ................................................................................. 39  
1.3.1  Potential Benefits to Subjec ts ............................................................................. 39  
1.3.2  Potential Risks to Subjects ................................................................................. 39  
1.4 Rationale for the Study  ......................................................................................... 40  
2 Study Objectives  .................................................................................................... 40  
2.1 Primary Objectives  ................................................................................................ 40  
2.2 Secondary Objectives  ............................................................................................ 41  
3 Investigators and Study Organization ................................................................. 42  
4 Independent Ethics Committee / Institutional Review Board ........................... 42  
5 Investigational Plan  ............................................................................................... 43  
5.1 Description of the Overall Study Design and Plan ............................................... 43  
5.1.1  Study De sign ....................................................................................................... 43  
5.1.2  Justification of the Study Design  ........................................................................ 45  
5.1.3  Study Plan ........................................................................................................... 46  
5.1.4  Visit Procedures  .................................................................................................. 48  
5.1.5  Planned Study Calendar ...................................................................................... 59  
5.1.6  Early Safety Data Review  ................................................................................... 59  
5.2 Enrollment and Retention of Study Population .................................................... 60  
5.2.1  Recruitment Procedures  ...................................................................................... 60  
[COMPANY_011]  Pasteur PSK00008  
515 – PNEUMOPCV Protocol  Version  6.0 
 
Confidential/Proprietary Information  
Page 5 of 126 5.2.2  Informed Consent Procedures ............................................................................ 61  
5.2.3  Screening Criteria  ............................................................................................... 61  
5.2.4  Inclusion Criteria  ................................................................................................ 61  
5.2.5  Exclusion Criteria  ............................................................................................... 62  
5.2.6  Medical History  .................................................................................................. 64  
5.2.7  Contraindications for Subsequent Vaccinations ................................................. 64  
[IP_ADDRESS]  Temporary Contraindications  ........................................................................... 64  
[IP_ADDRESS]  Definitive Contraindications  ............................................................................ 65  
5.2.8  Contraindication for Subsequent blood draw ..................................................... 67  
5.2.9  Coronavirus Disease 2019 (COVID-19) Vaccine .............................................. [ADDRESS_1221889] 1 ................................................................................. 71  
[IP_ADDRESS]  Composition ..................................................................................................... 71  
[IP_ADDRESS]  Preparation and Administration  ....................................................................... 71  
[IP_ADDRESS]  Dose Selection and T iming  .............................................................................. [ADDRESS_1221890] 2 ................................................................................. 72  
[IP_ADDRESS]  Composition ..................................................................................................... 72  
[IP_ADDRESS]  Preparation and Administration  ....................................................................... 73  
[IP_ADDRESS]  Dose Selection and Timing .............................................................................. [ADDRESS_1221891] 3 ................................................................................. 73  
[IP_ADDRESS]  Composition ..................................................................................................... 73  
[IP_ADDRESS]  Preparation and Administration  ....................................................................... 73  
[IP_ADDRESS]  Dose Selection and Timing .............................................................................. [ADDRESS_1221892] ................................................................................. 74  
[IP_ADDRESS]  Composition ..................................................................................................... 74  
[IP_ADDRESS]  Preparation and Administration  ....................................................................... 74  
[IP_ADDRESS]  Dose Selection and T iming  .............................................................................. [ADDRESS_1221893] 1  ................................................................................. 75  
[IP_ADDRESS]  Composition ..................................................................................................... 75  
[IP_ADDRESS]  Preparation and Administration  ....................................................................... 76  
[IP_ADDRESS]  Dose Selection and Timing .............................................................................. 76  
[COMPANY_011]  Pasteur PSK00008  
515 – PNEUMOPCV Protocol  Version  6.0 
 
Confidential/Proprietary Information  
Page [ADDRESS_1221894] 2  ................................................................................. 76  
[IP_ADDRESS]  Composition ..................................................................................................... 76  
[IP_ADDRESS]  Preparation and Administration  ....................................................................... 76  
[IP_ADDRESS]  Dose Selection and Timing .............................................................................. [ADDRESS_1221895] 3  ................................................................................. 77  
[IP_ADDRESS]  Composition ..................................................................................................... 77  
[IP_ADDRESS]  Preparation and Administration  ....................................................................... 77  
[IP_ADDRESS]  Dose Selection and Timing .............................................................................. [ADDRESS_1221896] 4  ................................................................................. 78  
[IP_ADDRESS]  Composition ..................................................................................................... 78  
[IP_ADDRESS]  Preparation and Administration  ....................................................................... 79  
[IP_ADDRESS]  Dose Selection and Timing .............................................................................. [ADDRESS_1221897] 5  ................................................................................. 79  
[IP_ADDRESS]  Composition ..................................................................................................... 79  
[IP_ADDRESS]  Preparation and Administration  ....................................................................... 80  
[IP_ADDRESS]  Dose Selection and Timing .............................................................................. [ADDRESS_1221898] Shipment, Storage, and Accountability ................................................. 81  
[IP_ADDRESS]  Product Shipment ............................................................................................. 81  
[IP_ADDRESS]  Product Storage ................................................................................................ 81  
[IP_ADDRESS]  Product Accountability ..................................................................................... 81  
6.3.3  Replacement Doses  ............................................................................................. 82  
6.3.4  Disposal of Unused Products .............................................................................. 82  
6.3.5  Recall of Products  ............................................................................................... 82  
6.4 Blinding and Code-breaking Procedures .............................................................. 82  
6.5 Randomization and Allocation Procedures ........................................................... 84  
6.6 Treatment Compliance  .......................................................................................... 85  
6.7 Concomitant Medications and Other Therapi[INVESTIGATOR_014]  ................................................... 85  
7 Management of Samples ....................................................................................... 86  
7.1 Sample Collection  ................................................................................................. 86  
7.2 Sample Preparation  ............................................................................................... 87  
7.3 Sample Storage and Shipment .............................................................................. 87  
7.4 Future Use of Stored Biological Samples for Research  ........................................ 88  
8 Clinical Supplies  .................................................................................................... 88  
9 Endpoints and Assessment Methods  ................................................................... 89  
[COMPANY_011]  Pasteur PSK00008  
515 – PNEUMOPCV Protocol  Version  6.0 
 
Confidential/Proprietary Information  
Page 7 of 126 9.1 Primary Endpoints and Assessment Methods ....................................................... 89  
9.1.1  Safety  .................................................................................................................. 89  
[IP_ADDRESS]  Safety Definitions  ............................................................................................. 89  
[IP_ADDRESS]  Safety Endpoints .............................................................................................. 91  
[IP_ADDRESS]  Safety Assessment Methods ............................................................................. 92  
[IP_ADDRESS].[ADDRESS_1221899]-vaccination Observation Period ........................................... 92  
[IP_ADDRESS].2  Reactogenicity (Solicited Reactions From Day  0 to Day 7 After Each 
Vaccination)  ................................................................................................... 92  
[IP_ADDRESS].3  Unsolicited Adverse Events  ........................................................................... 96  
[IP_ADDRESS].[ADDRESS_1221900]  ................................................................ 97  
[IP_ADDRESS].5  Assessment of Causality  ................................................................................ 98  
9.1.2  Immunogenicity  .................................................................................................. 98  
[IP_ADDRESS]  Immunogenicity Endpoints .............................................................................. 98  
[IP_ADDRESS]  Immunogenicity Assessment Methods ............................................................. 99  
9.1.3  Efficacy  ............................................................................................................... 99  
9.2 Secondary Endpoints and Assessment Methods ................................................... 99  
9.2.1  Safety  .................................................................................................................. 99  
9.2.2  Immunogenicity  ................................................................................................ 100  
[IP_ADDRESS]  Immunogenicity Endpoints ............................................................................ 100  
[IP_ADDRESS].1  Immunogenicity of SP0202 or Prevnar 13 .................................................. 100  
[IP_ADDRESS].2  Immunogenicity of Concomitant Licensed Vaccines When Co- administered 
With SP0202 or Prevnar 13 ......................................................................... 100  
[IP_ADDRESS]  Immunogenicity Assessment Methods ........................................................... [ADDRESS_1221901] Has Completed the Study  .......... 108  
10.4  Assessment of Causality  ..................................................................................... 108  
10.5  Reporting SAEs to Health Authorities and IECs / IRBs  ..................................... 109  
11 Data Collection and Management ..................................................................... 109  
11.1  Data Collection and CRB Completion ................................................................ 109  
11.2  Data Management  ............................................................................................... 110  
11.3  Data Review  ........................................................................................................ 111  
12 Statistical Methods and Determination of Sample  Size ................................... 111  
[COMPANY_011]  Pasteur PSK00008  
515 – PNEUMOPCV Protocol  Version  6.0 
 
Confidential/Proprietary Information  
Page 8 of 126 12.1  Statistical Methods  .............................................................................................. 111  
12.1.1  Hypotheses and Statistical Methods for Primary Objective(s)  ......................... 111  
[IP_ADDRESS]  Hypotheses ..................................................................................................... 111  
[IP_ADDRESS]  Statistical Methods  ......................................................................................... 111  
12.1.2  Hypotheses and Statistical Me thods for Secondary Objective(s) ..................... 113  
[IP_ADDRESS]  Hypotheses ..................................................................................................... 113  
[IP_ADDRESS]  Statistical Methods  ......................................................................................... 113  
[IP_ADDRESS].1  Stage I toddlers  ............................................................................................ 113  
[IP_ADDRESS].2  Stage II infants  ............................................................................................. 113  
12.2  Analysis Sets ....................................................................................................... 114  
12.2.1  Full Analysis Set ............................................................................................... 114  
12.2.2  Safety Analysis Set  ........................................................................................... 114  
12.2.3  Per-Protocol Analysis Set ................................................................................. 115  
12.2.4  Populations Used in Analyses .......................................................................... 116  
12.3  Handling of Missing Data and Outliers .............................................................. 116  
12.3.1  Safety  ................................................................................................................ 116  
12.3.2  Immunogenicity  ................................................................................................ 116  
12.4  Interim / Preliminary Analysis  ............................................................................ 117  
12.5  Determination of Sample Size and Power Calculation  ....................................... 118  
13 Ethical and Legal Issues and Investigator / Sponsor Responsibilities  ............ [ADDRESS_1221902] of the Study / Good Clinical Practice  ....................................... [ADDRESS_1221903]  ...................................................................................................... 123  
15 Signature [CONTACT_3490]  ..................................................................................................... 126  
 
[COMPANY_011]  Pasteur PSK00008  
515 – PNEUMOPCV Protocol  Version  6.0 
 
Confidential/Proprietary Information  
Page [ADDRESS_1221904] of Tables   
Table  1.1: Specificities of the 4 formulations evaluated in Phase I study PSK00007 ................... 37  
Table  1.2: Composition of the 3 investigational products and Prevnar 13 vaccine (theoretical 
composition* per 0.5 mL dose) ...................................................................................................... 38  
Table  5.1: Study Design ................................................................................................................. 44  
Table  5.2: Injection schedul e for study and pediatric vaccines in infants ...................................... 47  
Table  5.3: Vaccinations and route of administration at V01, V02, and V03 ................................. 52  
Table  5.4: Vaccinations and route of administration at V05 .......................................................... 57  
Table  9.1: Solicited injection site reactions: terminology, definitions, and intensity scales .......... 94  
Table  9.2: Solicited systemic reactions: terminology, definitions, and intensity scales  ................ 95  
Table  9.3: Summary of tests per time point in toddlers  ............................................................... 102  
Table  9.4: Summary of tests per time point in infants  ................................................................. 102  
 
[COMPANY_011]  Pasteur PSK00008  
515 – PNEUMOPCV Protocol  Version  6.0 
 
Confidential/Proprietary Information  
Page 10 of 126 Synopsis  
Company:  [COMPANY_011] Pasteur  
Investigational Product:  SP0202 - 21–valent pneumococcal conjugate vaccine  
Active Substances:  Streptococcus pneumoniae  serotypes 1, 3, 4, 5, 6A, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 
14, 15B, 18C, 19A, 19F, 22F, 23F, and 33F  
  
Title of the Study:  Safety and Immunogenicity of a Pneumococcal Conjugate Vaccine (PCV) when 
Administered Concomitantly with Routine Pediatric Vaccines in Healthy 
Toddlers and Infants  
Development Phase:  Phase II  
Coordinating Investigator (Stage  I): 
Coordinating Investigator 
(Stage II):  
Study Sites:  This will be a multi -center study conducted at approximately 42 sites in the 
[LOCATION_002] (US), 8 sites in Canada and 2 sites in Honduras  
Investigators and sites will be listed in the “List of Investigators and Centers Involved in the Trial” document.  
Planned Study Period:  Quarter 2 of 2020 (first visit of the first subject) to Quarter 2 of 2023 (last contact 
[CONTACT_875006])  
Study Design, Schedule of 
Study Procedures,  and 
Methodology:  This will be a Phase II, randomized, active -controlled, observer -blind (double -
blind across investigational vaccine formulations), age de -escalating, multi-
centered study to assess the safety and the immunogenicity of 3  different 
formulat ions of an investigational pneumococcal conjugate vaccine (PCV) in 
approximately 140 healthy toddlers (12 –15 months of age [MoA]), and 700 
healthy infants (aged 42 to 89  days). The vaccine is referred to as SP0202 in what 
follows.  
The study will involve 2 stages: 
• In Stage I, toddlers aged between 12 and 15 months, who previously received 
the 3 -dose primary series of Prevnar®13, will receive 1  dose of either one 
SP0202 formulation (Group 1, 2, and 3) or Prevnar  13 (Group 4), 
concomitantly administered with Pentacel®  
• In Stage II, infants aged 2  months will receive 3 doses of either one SP0202 
formulation or Prevnar 13 approximately at 2, 4, and 6 MoA and a 4th dose at 
12 to 15 MoA (Groups 5, 6, 7, and 8), co -administered with pediatric vaccines 
recommended at  this age  
All infants will receive the following routine vaccines (summarized in Table 1):  
• Pentacel (DTaP -IPV/Hib) at 2,  4, 6 months of age*  
• RotaTeq® (pentavalent rotavirus vaccine [RV5]) at 2,  4, and 6 months of age  
• M-M- R® II (measles, mumps, rubella [MMR] vaccine) at 12 to 15 months of 
age 
• VARIVAX® (varicella vaccine) at 12 to 15 months of age  
 *   Dose [ADDRESS_1221905] study visit. The study 
personnel / Investigator will be responsible for administering this d ose at the 
recommended age as per their standard practices.  

[COMPANY_011]  Pasteur PSK00008  
515 – PNEUMOPCV Protocol  Version  6.0 
 
Confidential/Proprietary Information  
Page 11 of 126 Note 1 : In addition to routine vaccines mentioned above, hepatitis B vaccination 
(ENGERIX -B®) can be administered concomitantly with Pentacel and PCV 
doses at V01, V02 and V03. A first dose of hepatitis B vaccine can be given at 
least 28 days prior to study enrollment.  
Note 2: Other pediatric vaccines (eg, hepatitis A, meningitis C) should be 
administered after the completion of the last study visit. They will be considered as out of the scope of the study and will not be provided by [CONTACT_875007].  
 Table 1: Injection schedule for study and pediatric vaccines in infants  
Visit (V)  V01 V02 V03 V05 
Approximate age (months)  2 4 6 12 to 15 
PCV for 
Group 5, 6, 
and 7 SP0202 
(IIb, VI, or VII)  SP0202 
(IIb, VI, or VII)  SP0202 
(IIb, VI, or VII)  SP0202 
(IIb, VI, or VII)  
Group 8  Prevnar 13  Prevnar 13  Prevnar 13  Prevnar 13  
Concomitant pediatric vaccines  Pentacel*  
RotaTeq†  Pentacel*  
RotaTeq†  Pentacel*  
RotaTeq†  
M-M-R II + 
VARIVAX§  
ENGERIX -B‡ ENGERIX -B‡ ENGERIX -B‡  
*    Pentacel (Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed, 
Inactivated Poliovirus and Haemophilus b Conjugate [Tetanus Toxoid 
Conjugate]; [COMPANY_011] Pasteur Ltd) 
†   RotaTeq (Rotavirus Vaccine, Live, Oral, Pentavalent); [COMPANY_006] & Co, Inc.  
‡   ENGERIX -B (Purified Recombinant Hepatitis B Surface Antigen; 
GlaxoSmithKline Inc.). Hepatitis B vaccination can be administered 
concomitantly with Pentacel and PCV doses at  V01, V02, and V03.  
§    M-M-R II (Measles, Mumps, and Rubella Virus Vaccine Live) and 
VARIVAX® (Varicella Virus Vaccine Live); [COMPANY_006] & Co, Inc.  
A total of 140  subjects (35  subjects per group) will be enrolled in Stage I and 
randomized in a 1:1:1:1 ratio to receive a single dose of either one SP0202 
formulation (Groups  1 to Group  3) or Prevnar  13 (Group 4).  
A total of 700 subjects (175 subjects per group) will be enrolled in Stage II and 
randomized in a 1:1:1:1 ratio to be vaccinated with 1 of the 3 SP0202 formulations 
(Group  5 to Group  7) or with Prevnar 13 (Group  8), as shown in Figure 1.  
 
 
[COMPANY_011]  Pasteur PSK00008  
515 – PNEUMOPCV Protocol  Version  6.0 
 
Confidential/Proprietary Information  
Page 12 of 126  Figure 1: Overview of the step -down enrollment  
 
Randomization:  
Interactive Response Technology (IRT) will be used to assign subject numbers and 
study group at each clinical site.  
Visits and Phone Contacts : 
During Stage I there will be 2 planned visits for toddlers (Groups 1 -4). During 
Stage II there will be 6 planned visits for infants (Groups 5 -8).  
Subjects’ parents / guardians will be contact[CONTACT_3012] 8 days [+2 days] after 
each vaccine injection, and 6  months [+14  days] after the last vaccine injection.  
Injection:  
Toddlers will receive 1 dose of either one SP0202 formulation or Prevnar  13 and 
1 dose of Pentacel concomitantly at 12 -15 MoA.  
Infants will receive 1 dose of either one SP0202 formulation or P revnar  13 at 2, 4, 
6, and 12 -15 MoA. Pentacel, RotaTeq, M -M-R II, and VARIVAX doses will be 
administered concomitantly with the PCV doses. ENGERIX -B can be 
administered concomitantly with Pentacel and PCV doses at V01, V02, and V03.  
 Blood sampling:  
During Stage I, all toddlers will provide 2  blood samples (BLs; 6  mL each) for the 
assessment of SP0202 and DTaP -IPV/Hib antigens (Pentacel) immunogenicity: a 
first sample before injection (BL0001) and a second sample (BL0002) at D30 
[+14  days] post -injection.  
During Stage II, all infants will provide 3 or 4 blood samples for the assessment of study and pediatric vaccines' immunogenicity: a sample before injection (BL0001; 3 mL) at D0*, a sample 1  month after PCV Dose  3 (BL0002; 6  mL) at D150 
[
±14 days] (Vi sit 4 [V04]), a sample before PCV Dose  4 (BL0003; 6  mL) at D300 
[±14 days] (V05), and a sample 1 month after PCV Dose  4 (BL0004; 6  mL) at 
D330 [+14  days].  
* Not applicable from protocol Version 5.0  

[COMPANY_011]  Pasteur PSK00008  
515 – PNEUMOPCV Protocol  Version  6.0 
 
Confidential/Proprietary Information  
Page 13 of 126 Immunogenicity  
Immunogenicity of SP0202 formulations and P revnar  13 will be assessed through 
the measurement of serotype specific type G immunoglobulin (IgG) and 
opsonophagocytic activity (OPA) of pneumococcal serotypes. IgG concentrations 
for all pneumococcal serotypes included in each of the SP0202 formulations  and 
Prevnar  13 will be measured in all subjects. OPA will be measured in all toddlers 
enrolled in Stage I and in a random subset of 125 infants per group (depending on the available serum volume) enrolled in Stage II in samples collected [ADDRESS_1221906]- dose (PD) 4.  
For toddlers, the immunogenicity of Pentacel will be assessed [ADDRESS_1221907] injection in the study, ie, 1- month P D3 for Pentacel, 
ENGERIX -B*, and RotaTeq; 1- month PD4 for M-M-R
II and VARIVAX.  
* Immunogenicity to ENGERIX -B will be presented according to the number of 
doses received  
Safety  
Reactogenicity data will be collected in all subjects after each injection. Inje ction 
site reactions will be collected for both study and concomitant pediatric vaccines.  
All subjects will be observed for [ADDRESS_1221908] any unsolicited systemic adverse events (AEs) occurring 
during  that time as immediate unsolicited systemic AEs in the case report book 
(CRB).  
Subjects’ parents / guardians will record in the diary card (DC) / electronic DC (eDC) information about AEs (solicited and unsolicited), concomitant medications, 
and any medic al visits or hospi[INVESTIGATOR_602].  
Solicited injection site and systemic reactions will be collected from D0 to D7 
following injection. Unsolicited events will be collected from D0 to D30 following 
injection. Serious adverse events (SAEs) and adverse events o f special interest 
(AESIs) will be collected throughout the study (from D0 until the [ADDRESS_1221909]).  
At Visit 2 (V02) for toddlers and Visit 5 (V05) for infants, all parents / guardians will be given a memory aid (MA) in which to r ecord safety information. At 
approximately [ADDRESS_1221910]’s parents / guardians by [CONTACT_875008]. 
Note:  For both toddlers and infants, anaphylaxis/hypersens itivity, convulsions 
(including febrile convulsions), hypotonic -hyporesponsive epi[INVESTIGATOR_1865], and apnea will 
be considered as AESIs  
Early Safety Data Review:  The safety of investigational products will be continuously monitored by [CONTACT_429]. An ESDR will be performed, the goal of which is to allow for a cautious, 
stepwise approach to vaccine administration.  
 
 
The safety data collected will be entered into the CRB and summarized by [CONTACT_429]. A blinded review will be performed by [CONTACT_875009] (SMT) meetings. An unblinded review by [CONTACT_875010]. It is understood that this review is based on 

[COMPANY_011]  Pasteur PSK00008  
515 – PNEUMOPCV Protocol  Version  6.0 
 
Confidential/Proprietary Information  
Page [ADDRESS_1221911]:  
• Immediate unsolicited systemic AEs  
• Solicited injection site an d systemic reactions  
• Unsolicited AEs reported as related by [CONTACT_737]  
• SAEs 
• AESIs  
Enrollment of infants will not begin until the end of the review. In addition, the 
data will be examined for the following:  
• Any deaths, regardless of causality  
• Any vaccine -related SAEs  
• Any AESIs  
• Any signs of injection site necrosis or exfoliative dermatitis  
• Grade 3 fever reported in more than 10% of subjects; presence of concurrent infectious disease will be documented  
If any of the above criteria are met, a decision based on the SMT and DMC 
recommendations will be made as to whether enrollment of infants will be allowed 
to begin or whether any adjustments ought to be done.  
The DMC will review the unblinded data by [CONTACT_875011] p to be able to identify any trend 
for differences between each SP0202 formulation and Prevnar  13 for each safety 
criterion and overall safety profile. The DMC may recommend removing 1 or more SP0202 formulation from Stage II. Further details will be provi ded in the 
DMC Charter (before the start of trial).  
Moreover, the option of partial or full unblinding can be available to the Sponsor through an independent statistician, if required, for a further in -depth review of the 
data.  
The Sponsor’s SMT is empower ed to recommend a pause in recruitment while it 
investigates any potential signal or concern. The clinical team and SMT will review the data being generated from the study at regular intervals for any new safety signals or safety concerns.  
Interruption of  the Study  The study may be discontinued as per ESDR decision or if new data about the 
investigational product resulting from this study or any other studies become available; or for administrative reasons; or on advice of the Sponsor, the 
Investigators, Independent Ethics Committees / Institutional Review Boards 
(IECs/IRBs), or the governing regulatory authorities in the [LOCATION_002], Canada, and Honduras.  
If the study is prematurely terminated or suspended, the Sponsor shall promptly 
inform the Investiga tors, the IECs/IRBs, the regulatory authorities, and any 
contract research organization(s) used in the study of the reason for termination or 
suspension, as specified by [CONTACT_1214]. The 
Investigator shall promptly inform the stu dy subjects’ parents / guardians and 
should assure appropriate subject therapy and/or follow -up. 
Primary Objectives:  Safety  
To assess the safety profile of each SP0202 formulation and Prevnar  13 in 
toddlers and infants (after each and any injection).  
[COMPANY_011]  Pasteur PSK00008  
515 – PNEUMOPCV Protocol  Version  6.0 
 
Confidential/Proprietary Information  
Page 15 of 126 Immunogenicity  
• To assess the immune response (serotype specific IgG concentration) of the 
SP0202 formulations and Prevnar  13 1 month after the administration of one 
dose in toddlers (Groups 1 -4) 
• To assess the immune response (serotype specific IgG concentration) of the SP0202 formulations and Prevnar  13 1 month after the administration of 
3 doses in infants (Groups 5 -8) 
• To assess the immune response (serotype specific IgG concentration) of the SP0202 formulations and Prevnar  13 1 month after adminis tration of a 4 -dose 
schedule in infants (Groups 5 -8) 
Primary Endpoints:  Safety:  
The following endpoints will be used for all subjects for the evaluation of the 
Safety Objectives:  
• Occurrence of any unsolicited systemic AEs reported in the 30 minutes after 
each and any injection of a SP0202 formulation or Prevnar  13, as applicable  
• Occurrence of solicited (ie, pre- listed in the subject’s DC / eDC and in the 
CRB) injection site reactio ns occurring up to D7 after each and any injection 
of a SP0202 formulation, Prevnar  13, or a concomitant pediatric vaccine, as 
applicable  
• Occurrence of solicited systematic reactions occurring up to D7 after each and any injection of a SP0202 formulation o r Prevnar  13, as applicable  
• Occurrence of unsolicited (spontaneously reported) AEs up to 30  days after 
each and any injection of a SP0202 formulation or Prevnar  13, as applicable.  
• Occurrence of SAEs and AESIs throughout the study period.  
Other endpoints will be recorded or derived as described in the statistical analysis 
plan. Depending on the item, these could include: nature (Medical Dictionary for 
Regulatory Activity [MedDRA] preferred term), time of onset, duration, number 
of days of occurre nce, Grade of severity, relationship to vaccine, action taken, 
whether the AE led to early termination from the study, seriousness, or outcome.  
Immunogenicity:  
Toddlers (1 dose)  
• Serotype specific IgG concentrations for all pneumococcal serotypes 
included in the SP0202 formulations, as measured by [CONTACT_29492]-
chemiluminescence assay (ECL) at baseline and [ADDRESS_1221912] -injection  
• Serotype specific IgG concentrations ratios (post -/pre-injection) for each 
pneumococcal serotype included in the SP0202 formulations, as measured by 
[CONTACT_875012] (3 doses for primary series + 1 dose as booster)  
• Percentage of subjects with serotype specific IgG concentration ≥ 0.35 µg/mL for each pneumococcal serotype included in the SP0202 formulations, as measured by [CONTACT_875013]3  
• Serotype specific IgG concentrations for all pneumococcal serotypes included in the SP0202 formulations, as measured by [CONTACT_875014]*, PD3, 
before Dose  4, and at PD4  
[COMPANY_011]  Pasteur PSK00008  
515 – PNEUMOPCV Protocol  Version  6.0 
 
Confidential/Proprietary Information  
Page 16 of 126 • Serotype specific IgG concentrations ratios (PD3/pre -dose 1* and PD4/pre -
dose 4) for ea ch pneumococcal serotype included in the SP0202 
formulations, as measured by [CONTACT_366469]  
* Not applicable from protocol Version 5.0  
Secondary Objectives  Immunogenicity of SP0202 or Prevnar  13: 
• To assess the immune response (serotype specific OPA titer) of the SP0202 
formulations and Prevnar  13 1 month after the administration of one dose in 
toddlers (Groups 1- 4) 
• To assess the immune response (serotype specific OPA titer) of the SP0202 formulations and Prevnar  13 1 month after the administration of 3 doses in a 
subset of infants (Groups 5 -8) 
• To assess the immune response (serotype specific OPA titer) of the SP0202 
formulations and Prevnar  13 1 month after administration of a 4- dose 
schedule in a subset of infants (Groups 5 -8) 
Immunogenicity of concomitant license d vaccines when co -administered with 
SP0202 or Prevnar13: 
Toddlers  
• To describe the Ab responses against Pentacel antigens before and 1  month 
following injection of Pentacel  
Infants  
• To describe the Ab responses against antigens of the routine pediatric 
vaccines (Pentacel, RotaTeq, ENGERIX -B, M -M-R
II, and VARIVAX) when 
administered concomitantly with either SP0202 or Prevnar  13 (at pre -
Dose 1* for RotaTeq, Diphteria, Tetanus and Pertussis antigens; at PD3 for 
ENGERIX -B†, RotaTeq, and Pentacel; at PD4 for M -M-R II and VARIVAX])  
* Not applicable from protocol Version 5.0  
† Immunogenicity to ENGERIX -B will be presented according to the number of 
doses received  
Secondary Endpoints:  Immunogenicity of SP0202 or Prevnar  13: 
Toddlers  
• Serotype specific OPA titers for all pneumococcal serotypes included in the SP0202 formulations, as determined by [CONTACT_875015] 
(MOPA), at baseline and [ADDRESS_1221913]- injection  
• Percentage of subjects with serotype specific OPA titers ≥ lower limit of 
quantitation ( LLOQ) for each pneumococcal serotype included in the SP0202 
formulations, as determined by [CONTACT_29491], at baseline and [ADDRESS_1221914]- injection  
• Serotype specific OPA titers ratio (post -/pre-injection) for each 
pneumococcal serotype included in the SP0202 formulati ons, as determined 
by [CONTACT_875016]  
• Serotype specific OPA titers for all pneumococcal serotypes included in the 
SP0202 formulations, as determined by [CONTACT_29491], at PD3, before Dose 4, and 
at PD4  
[COMPANY_011]  Pasteur PSK00008  
515 – PNEUMOPCV Protocol  Version  6.0 
 
Confidential/Proprietary Information  
Page 17 of 126 • Percentage of subjects with serotype specific OPA titers ≥ LLOQ for  each 
pneumococcal serotype included in the SP0202 formulations, as determined 
by [CONTACT_29491], at PD3, before Dose 4, and at PD4 post -injection  
• Serotype specific OPA titers ratio (PD4/pre -dose 4) for each pneumococcal 
serotype included in the SP0202 formulations,  as determined by [CONTACT_875017] -administered with 
SP0202 or Prevnar13: 
Toddlers  
Before vaccination (D0) in all subjects: 
• Anti-pertussis (PT [pertussis toxoid / toxin], filamentous hemagglutinin 
[FHA], pertactin [PRN], and fimbriae types 2 and 3 [FIM]) Ab 
concentrations  
• Anti-polyribosyl -ribitol phosphate [PRP] Ab concentrations  
• Anti-PRP Ab concentrations ≥ 0.15  μg/mL  
• Anti- diphtheria toxoid Ab concentrations  
• Anti- tetanus toxoid Ab concentrations  
• Anti-poliovirus (types 1, 2, and 3) Ab titers  
One month post -v accination (D30) in all subjects:  
• Anti-PRP Ab concentrations  
• Anti-PRP Ab concentrations ≥ 0.15 µg/mL and ≥ 1.0 µg/mL  
• Anti-poliovirus (types 1, 2, and 3) Ab titers  
• Anti-poliovirus (types 1, 2, and 3) Ab titers ≥ 1:8 
• Anti-pertussis (PT, FHA, PRN, and FIM) Ab concentrations  
• Anti-pertussis (PT, FHA, PRN, and FIM) vaccine response*  
* Pertussis vaccine response definition:  
• Pre-vaccination < LLOQ, then post -vaccination should be ≥ 4x the 
LLOQ 
• Pre-vaccination ≥ LLOQ but < 4x the LLOQ, then post -vaccination 
should achieve a 4 -fold rise (post - vaccination/pre -vaccination ≥ 4)  
• Pre-vaccination ≥ 4x the LLOQ, then post -vaccination shoul d achieve a 
2-fold response (post -vaccination/pre -vaccination ≥ 2)  
• Anti- diphtheria toxoid Ab concentrations  
• Anti-diphtheria toxoid Ab concentrations ≥ 0.1 IU/mL and ≥ 1.0  IU/mL  
• Anti- tetanus toxoid Ab concentrations  
• Anti-tetanus toxoid Ab concentrations ≥ 0.1 IU/mL and ≥ 1.0  IU/mL  
Infants  
Before first vaccination in all subjects (D0)*:  
• Anti-rotavirus serum immunoglobulin (Ig) A Ab concentrations  
• Anti-pertussis (PT, FHA, PRN, and FIM) Ab concentrations  
• Anti- diphtheria toxoid Ab concentrations  
• Anti- tetanus toxoid Ab concentrations  
* Not applicable from protocol Version 5.0  
[COMPANY_011]  Pasteur PSK00008  
515 – PNEUMOPCV Protocol  Version  6.0 
 
Confidential/Proprietary Information  
Page 18 of 126 One month after 6 MoA vaccination (D150) in all subjects:  
• IgG Abs against hepatitis B surface antigen concentration ≥ 10 mIU/mL and 
≥ 100 mIU/mL   
• Anti-PRP Ab concentration s 
• Anti-PRP Ab concentrations ≥ 0.15 µg/mL and ≥ 1.0 µg/mL  
• Anti-poliovirus (types 1, 2, and 3) Ab titers  
• Anti-rotavirus serum IgA Ab concentrations  
• Anti-rotavirus serum IgA Ab concentrations with ≥  3-fold rise over baseline*  
• Anti-pertussis (PT, FHA, PRN, and FIM) Ab concentrations  
• Anti- diphtheria toxoid Ab concentrations  
• Anti-diphtheria toxoid Ab concentrations ≥ 0.01  IU/mL and ≥ 0.1  IU/mL  
• Anti- tetanus toxoid Ab concentrations  
• Anti-tetanus toxoid Ab concentrations ≥ 0.01 IU/mL and ≥ 0.1  IU/mL  
* Not applicable from protocol Version 5.0  
One month after 12 -15  MoA vaccination (D330- D420) in all subjects: 
• Anti-measles Ab concentrations  
• Anti-measles Ab concentrations ≥ 255  mIU/mL  
• Anti-mumps Ab concentrations  
• Anti-mumps Ab concentrations ≥ 10  mumps Ab U/mL  
• Anti-rubella Ab concentrations  
• Anti-rubella Ab concentrations ≥ 10  IU/mL  
• Anti-varicella Ab concentrations  
• Anti-varicella Ab concentrations ≥ 5 glycoprotein enzyme -linked 
immunosorbent assay (gpELISA) units/mL  
Planned Sample Size:  A total of 840 subjects are planned to be enrolled, 140 toddlers and 700  infants.  
Stage I – Toddlers  
Groups  Number of subjects  Vaccine formulation / treatment 
Group 1 35 SP0202-IIb 
Group 2 35 SP0202-VI  
Group 3 35 SP0202-VII  
Group 4 35 Prevnar 13  
Stage II – Infants  
Groups  Number of subjects  Vaccine formulation /treatment 
Group 5 175 SP0202-IIb 
Group 6 175 SP0202-VI  
Group 7 175 SP0202-VII  
Group 8 175 Prevnar 13  
 
[COMPANY_011]  Pasteur PSK00008  
515 – PNEUMOPCV Protocol  Version  6.0 
 
Confidential/Proprietary Information  
Page 19 of 126 Duration of Participation 
in the Trial:  Toddlers  
The duration of each subject’s participation in the study will be approximately 
[ADDRESS_1221915]’s participation in the study will be approximately 16 to 19 months for subjects enrolled in Groups 5, 6, 7, and 8. 
Investigational Products:   
  Investigational Product 1:  SP0202- IIb – PCV; SK bioscience Co., Ltd.  
 Form:  Liquid, suspension  
 Composition:  Each 0.5  mL dose of vaccine will contain:  
Active ingredients: 
 Route:  Intramuscular (IM)  
 Batch Number:  TBD  
 Investigational Product 2:  SP0202- VI – PCV; SK bioscience Co., Ltd.  
 Form:  Liquid, suspension  
 Composition:  Each 0.5  mL dose of vaccine will contain:  
Active ingredients: 

[COMPANY_011]  Pasteur PSK00008  
515 – PNEUMOPCV Protocol  Version  6.0 
 
Confidential/Proprietary Information  
Page 20 of 126  Route:  IM 
 Batch Number:  TBD 
  Investigational Product 3:  SP0202- VII – PCV; SK bioscience Co., Ltd.  
 Form:  Liquid, suspension  
 Composition:  Each 0.5  mL dose of vaccine will contain:  
Active ingredients: 
 Route:  IM 
 Batch Number:   TBD 
Control Product:  Prevnar 13®, (Pneumococcal 13 -valent Conjugate Vaccine [Diphtheria 
CRM 197 Protein]); [COMPANY_007] Inc.  
 Form:  Liquid  
 Composition:  Each 0.5 mL dose of vaccine contains:  
Active ingredients: 
2.2 μg of polysaccharide from S. pneumoniae  serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 
18C, 19A, 19F, 23F, and 4.4 μg of polysaccharide for serotype 6B, individually 
conjugated to cross -reacting material 197 (CRM 197) 
approximately 34 μg of CRM 197 
Other ingredients: 
NaCl, succinic acid, polysorbate 80, water -for-injection  
Adjuvant:  
0.125 mg of aluminum  
 Route:  IM 
 Batch Number:  Commercial Lot  
Other Product 1:  Pentacel® (Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed, Inactivated Poliovirus and Haemophilus b Conjugate [Tetanus Toxoid Conjugate] 
vaccine); [COMPANY_011] Pasteur Ltd.  
Form:  DTaP -IPV Liquid used to reconstitute lyophilized PRP -T 

[COMPANY_011]  Pasteur PSK00008  
515 – PNEUMOPCV Protocol  Version  6.0 
 
Confidential/Proprietary Information  
Page 21 of 126 Composition:  Each 0.5  mL dose contains:  
Each 0.5  mL dose contains:  
Diphtheria toxoid  .............................................  15 Limit of Flocculation (Lf)  
Tetanus toxoid  .........................................................................................  5 Lf 
Acellular pertussis antigens:  
  Pertussis toxin (PT)  .............................................................................  20 µg 
  Filamentous hemagglutinin (FHA)  ...................................................... 20 µg 
  Pertactin (PRN) ......................................................................................  3 µg 
  Fimbriae Types 2 and 3 (FIM) ...............................................................  5 µg 
Inactivated polioviruses:  
  Type 1 (Mahoney)  .................................................  40 D- antigen units (DU)  
  Type 2 (MEF -1) ...................................................................................  8 DU  
  Type 3 (Saukett)  ................................................................................  32 DU  
H. influenzae  type b (PRP)  ....................................................................  10 µg 
Tetanus toxoid (PRP -T) .........................................................................  24 µg 
Adjuvant:  
0.33 mg of aluminum  
 
Route: IM 
Batch Number: Commercial Lot  
Other Product 2:  ENGERIX -B® (Hepatitis B Vaccine [Recombinant]); GlaxoSmithKline.  
Form:  Liquid  
Composition:  Each 0.5  mL dose contains 10  µg of hepatitis surface antigen  
Route:  IM 
Batch Number:  Commercial lot  
Other Product 3:  RotaTeq® (Rotavirus Vaccine, Live, Oral, Pentavalent); [COMPANY_006] & Co, Inc.  
Form:  Liquid  
Composition:  Each 2  mL dose contains:  
G1 serotype  .............................................................  2.2 x 106 infectious units  
G2 serotype  .............................................................  2.8 x 106 infectious units  
G3 serotype  .............................................................  2.2 x 106 infectious units  
G4 serotype  .............................................................  2.0 x 106 infectious units  
P1A(8) .....................................................................  2.3 x 106 infectious units  
The reassortants are suspended in a buffered stabilizer solution.  
Route: Oral 
Batch Number: Commercial Lot  
Other Product 4:  M-M-R® II vaccine (Measles, Mumps, and Rubella Virus Vaccine Live); [COMPANY_006] & 
Co, Inc.  
Form:  Liquid  
Composition:  Each 0.5  mL dose contains:  
Measles virus (derived from Ender’s Edmonston strain) 
propagated in chick embryo cell culture  not less than 
1000 TCID 50* 
Mumps virus (Jeryl Lynn™ [B level] strain) propagated in 
chick embryo cell culture  not less than 12 500 TCID
50* 
Rubella virus (Wistar RA 27/3 strain) propagated in WI -38 
human diploid lung fibroblasts  not less than 1000 TCID
50* 
*TCID 50 = tissue culture infectious doses 50%  
[COMPANY_011]  Pasteur PSK00008  
515 – PNEUMOPCV Protocol  Version  6.0 
 
Confidential/Proprietary Information  
Page 22 of 126 Route: Subcutaneous  
Batch Number:  Commercial Lot  
Other Product 5:  VARIVAX® (Varicella Virus Vaccine Live); [COMPANY_006] & Co, Inc.  
Form:  Liquid  
Composition:  Each 0.5  mL dose contains not less than 1350 plaque -forming units (PFU) of 
Oka/[COMPANY_006] varicella virus  
Route:  Subcutaneous  
Batch Number:  Commercial Lot  
Inclusion Criteria:  An individual must fulfill all of the following criteria to be eligible for study 
enrollment:  
Toddlers and infants  
1) Informed consent form has been signed and dated by [CONTACT_7071](s) or other 
guardian, and by [CONTACT_35308], if required by [CONTACT_427]  
2) Subject and parent/guar dian are able to attend all scheduled visits and to 
comply with all study procedures  
3) Born at full term of pregnancy (≥ 37 weeks) and/or with a birth weight ≥ 5.5 lbs or 2.5  kg 
4) Healthy toddlers / infants as determined by [CONTACT_9870], physical examinatio n, and judgment of the Investigator  
Specifically for toddlers  
5) Aged [ADDRESS_1221916] study visit
a 
6) Subject has received 3  doses of Prevnar  13 and 3  doses of diphteria, tetanus, 
acellular pertussis, poliovirus, and Haemophilus influenzae type b  antigens in 
infancy  
Specifically for infants  
7) Aged [ADDRESS_1221917] study visitb 
a “12 to 15 months” means from the 12th month after birth to the day before the 16th after  birth  
b “42 to 89 days” means the 42th day after birth to the day before the 90th day after birth  
Exclusion Criteria:  An individual fulfilling any of the following criteria is to be excluded from study 
enrollment:  
Toddlers and infants:  
1) Participation at the time of study enrollment (or in the [ADDRESS_1221918] study vaccination) or planned participation during the present study period in another clinical study investigating a vaccine, drug, medical device, 
or medical procedure  
2) Family history of congenital or hereditary immunodeficiency,  until the 
immune competence of the potential vaccine recipi[INVESTIGATOR_167466] 
3) Blood dyscrasias, leukemia, lymphoma of any type, or other malignant 
neoplasms affecting the bone marrow or lymphatic systems  
4) Active tuberculosis  
5) History of S. pneumoniae  infec tion or disease, confirmed either serologically 
or microbiologically  
6) History of any neurologic disorder, including any seizures and progressive neurologic disorders  
7) History of Guillain -Barré syndrome  
[COMPANY_011]  Pasteur PSK00008  
515 – PNEUMOPCV Protocol  Version  6.0 
 
Confidential/Proprietary Information  
Page 23 of 126 8) Known systemic hypersensitivity to any of the vaccine components, or 
history of a life -threatening reaction to the vaccines used in the study or to a 
vaccine containing any of the same substances  
9) Verbal report of thrombocytopenia contraindicating intramuscular 
vaccination in the Investigator’s opi[INVESTIGATOR_1649]  
10) Bleeding disorder, or receipt of anticoagulants in the 3 weeks preceding 
inclusion, contraindicating intramuscular vaccination in the Investigator's opi[INVESTIGATOR_1649].  
11) Receipt of oral or injectable antibiotic therapy within [ADDRESS_1221919] blood draw 
12) Chronic illness (including, but not limited to, cardiac disorders, congenital 
heart disease, chronic lung disease, renal disorders, auto -immune disorders, 
diabetes, psychomotor diseases, and know congenital or genetic diseases) that, in the opi[INVESTIGATOR_689], is at a stage where it might interfere 
with study conduct or completion  
13) Any condition which, in the opi[INVESTIGATOR_689], might interfere with 
the evaluation of the study objectives  
14) In an emergency setting, or hospi[INVESTIGATOR_29476]  
15) Moderate or severe acute illness/infection (according to Investigator judgment) on the day of vaccination or febrile illness (temperature ≥  38.0°C / 
≥ 100.4°F). A prospective subject should not be included in the study until the condition has resolved or until 3 days after the febrile event has resolved  
16) Identified as a natural or adopted child of the Investigator or employee with direct involvement in the proposed study  
Specifically for toddlers:  
17) Receipt of any vaccine in the [ADDRESS_1221920] blood sampling Visit (Visit 2), except for influenza vaccination, which may be 
received at least 2 weeks before or 2  weeks after any study vaccination. This 
exception incl udes monovalent pandemic influenza vaccines and multivalent 
influenza vaccines  
18) Receipt of immune globulins, blood or blood -derived products in the past 
3 months  
19) Known or suspected congenital or acquired immunodeficiency; or receipt of immunosuppressive the rapy, such as anti -cancer chemotherapy or radiation 
therapy, within the preceding 6 months; or long -term systemic corticosteroid 
therapy (prednisone or equivalent for more than [ADDRESS_1221921] 3 months)  
20) History of diphtheria, tetanus, pertussis, poliomyelitis, and/or H. influenzae  
type b infection or disease  
Specifically for infants:  
21) Receipt of any vaccine in the [ADDRESS_1221922] blood 
sampling Visit (Visit  6), except for influenza vaccination or COVID -[ADDRESS_1221923] 2 weeks before or 2  weeks after 
any study vaccination. This exception includes monovalent pandemic influenza vaccines and multivalent influenza vaccines, and COVID -19 
vaccines, as applicable per local recommendations  
22) Receipt of immune globulins, blood or blood -derived products since birth  
[COMPANY_011]  Pasteur PSK00008  
515 – PNEUMOPCV Protocol  Version  6.0 
 
Confidential/Proprietary Information  
Page 24 of 126 23) Known or suspected congenital or acquired immunodeficiency; or receipt of 
immunosuppressive therapy, such as anti -cancer  chemotherapy or radiation 
therapy; or long- term systemic corticosteroid therapy (prednisone or 
equivalent for more than 2 consecutive weeks) since birth  
24) Previous vaccination against S. pneumoniae  
25) Previous vaccination against the following antigens: diphte ria, tetanus, 
pertussis, H. influenzae  type b, poliovirus, rotavirus, measles, mumps, 
rubella, and varicella  
26) Receipt of more than 1 previous dose of hepatitis B vaccine 
27) History of diphtheria, tetanus, pertussis, poliomyelitis, hepatitis B, measles, mumps,  rubella, varicella, H. influenzae  type b, and/or rotavirus infection or 
disease  
28) History of intussusception  
Statistical Methods:  Statistical analyses will be performed on safety and immunogenicity data 
collected for each stage as follows:  
• 1 unblinded analysis on immunogenicity and safety data collected in toddlers 
(Stage I) up to V02 and including 6- month follow -up data if available at the 
time of V01 -V02 immunogenicity data release  
• 1 unblinded analysis on immunogenicity data (serotype specif ic IgG 
concentration) collected on the first 350 randomized infants (Stage II) up to [ADDRESS_1221924] dose of PCV
 
• 1 unblinded analysis on data collected in infants (Stage II) up to [ADDRESS_1221925] dose of PCV and including Stage I data of th e 6-month 
follow -up (if not done as part of first analysis). The analysis may be 
conducted in two steps depending on the duration of immunogenicity testing: 1 – an early analysis on safety and serotype specific IgG results (primary 
endpoints) of all subjec ts up to [ADDRESS_1221926] dose; 2 – an analysis 
on all results (primary and secondary endpoints) up to [ADDRESS_1221927] dose 
• 1 unblinded analysis on immunogenicity and safety collected in infants (Stage II) up to 1 month after the fourth dose  of PCV. The 6 -month safety 
follow -up data will be included, depending on the timing of this analysis.  
• 1 final analysis on complete Stage II data including the 6- month follow -up, if 
needed.  
Analyses  
All analyses will be descriptive; no hypotheses will be tested.  
The per -protocol population and the Full Analysis Set will be used for the 
immunogenicity analyses and the safety population will be used for the safety analyses.  
For the main parameters, 95% confidence intervals (CIs) of point estimates will be calculated using the normal approximation for quantitative data and the exact binomial distribution (Clopper -Pearson method) for proportions.  
CIs of the difference of proportions between 2 groups will be computed using the Wilson Score me thod without continuity correction.
 
CIs of ratio of geometric mean titers (GMTs) / GMCs between 2 groups will be computed from the difference in means of log10 transformed titers/concentrations between 2 groups with normal approximation.
 
[COMPANY_011]  Pasteur PSK00008  
515 – PNEUMOPCV Protocol  Version  6.0 
 
Confidential/Proprietary Information  
Page 25 of 126 Primary Objectives  
Safety  
Safety profile of each group will be described after each and any vaccination 
using counts and percentages. The 95% CIs may also be displayed.  
Immunogenicity – Stage I (toddlers)  
The point estimates and their 95% CI of the following parameters will be 
presented for each group before and [ADDRESS_1221928] -vaccination for each 
pneumococcal serotype specific IgG concentrations:  
• GM of serotype specific concentrations, GM of concentrations ratio (post - / 
pre-vaccination)  
 Immunogenicity – Stage II (infants)  
The point estimates and their 95% CI of the following parameters will be presented for each group and for each pneumococcal serotype specific IgG concentrations:  
• Percentage of subjects with a PD3 and PD4 serotype specific concentration  ≥ 0.35 µg/mL  
• GM of serotype specific concentrations (pre -dose 1*, PD3, pre -dose 4, PD4)  
• GM of serotype specific concentrations ratio (PD3/pre -dose 1* and PD4/pre -
dose 4)  
*
 Not applicable from protocol Version 5.0  
Further analyses may be described in the Statistical Analysis Plan (SAP).  
Secondary Objectives  
Immunogenicity – Stage I (toddlers)  
Immunogenicity of SP0202 or Prevnar 13:  
The point estimates and their 95% CI of the following parameters will be 
presented for each group before and [ADDRESS_1221929] -vaccination for pneumococcal 
serotype specific OPA titers:  
• GM of serotype specific titers, GM of titers ratio (post -/pre-vaccination)  
• Percentage of subjects with a post -vaccination serotype specific titers above 
or equal to LLOQ 
Immunogenicity of concomitant vaccines:  
The point estimates and their 95% CI of the following parameters will be presented for each group before and [ADDRESS_1221930] -vaccination for Pentacel 
antigens: 
• GM of concentratio ns / titers for all antigens  
• Percentage of subjects with concentration / titer above predefined threshold, 
including those defining seroprotection  
• Vaccine response for pertussis (PT, FHA, PRN, and FIM) antigens  

[COMPANY_011]  Pasteur PSK00008  
515 – PNEUMOPCV Protocol  Version  6.0 
 
Confidential/Proprietary Information  
Page 26 of 126 Immunogenicity – Stage II (infants)  
Immunogenicity of SP0202 or Prevnar 13:  
The point estimates and their 95% CI of the following parameters will be 
presented for each group in the random OPA subset for each pneumococcal serotype specific OPA titers:  
• Percentage of subjects with a PD3 and PD4 serotype  specific titers above or 
equal to LLOQ  
• GM of serotype specific titers (PD3, pre -dose 4, PD4)  
• GM of serotype specific titers ratio (PD4/pre -dose 4)  
Immunogenicity of concomitant vaccines:  
The point estimates and their 95% CI of the following parameters will be 
presented for each group for concomitant vaccines (Pentacel, ENGERIX -B, 
RotaTeq, M -M-R
II, and VARIVAX) antigens:  
• GM of concentrations / titers for all antigens (at pre -Dose  1* for RotaTeq, 
and diphtheria, tetanus, and Pertussis antigens;  at PD3 for ENGERIX -B†, 
RotaTeq, and Pentacel; at PD4 for M -M-R II and VARIVAX)  
• Percentage of subjects with concentrations / titers above predefined thresholds, including those defining seroprotection (at PD3 and PD4 as applicable)  
* Not applicable from pr otocol Version 5.0  
 † Immunogenicity to ENGERIX -B will be presented according to the number of 
doses received.  
For all analyses, RCDCs of individual concentrations / titers will be presented for all serotypes / antigens.  
 Sample size:  
The number of subjects is designed to provide immunogenicity and safety data on 
the 3 SP0202 formulations and on Prevnar  13 after each and any injection, as 
applicable in toddlers and infants.  
The sample size was set at 35  subjects per group (140 toddlers)  in Stage I and 
175 subjects per group (700 infants) in Stage II. Assuming a drop -out rate of 
approximatively 10% in the toddlers, 20% (PD3) and 30% (PD4) in infants, a 
total of 31, 140, and 122 evaluable subjects per group is anticipated for toddlers, 
infants at PD3, and infants at PD4, respectively.  
 

[COMPANY_011]  Pasteur PSK00008  
515 – PNEUMOPCV Protocol  Version  6.0 
 
Confidential/Proprietary Information  
Page 27 of 126 Table of Study Procedures 1 (Toddlers)   
Phase II Trial, [ADDRESS_1221931] 
Visit/Contact V01 PC1 V02 PC2 
6-month safety follow -up 
Trial timelines (approximate # of days [D]) D0 D8 D30 D180 
Visit intervals   V01 + 
8 D V01 + 
30 D V01 + 6 months  
Time windows (days)   +2 +14 +14 
Informed consent  X    
Inclusion/exclusion criteria  X    
Collection of demographic data  X    
Medical history  X    
Physical examination and temperature*  X  X  
Randomization/allocation of subject number  X    
Blood sampling (BL), approximately 6 mL†  BL0001  BL0002  
Injection (SP0202 or Prevnar  13) X    
Injection (pediatric vaccine [Pentacel])  X    
30-Minute observation period  X    
Diary card (DC) / electronic DC (eDC)  
 provided 
 collected   
DC1/eDC1  
 
  
DC1/eDC1  
Memory aid (MA)  
 provided 
 checked   
 X  
X 
Telephone contacts   X‡  X** 
Injection Site Reactions & Systemic Events 
Assessment§    X  
Collection of reportable concomitant medications  X  X  
Trial termination record    X  
Collection of SAEs and AESIs  To be reported at any time during the trial  
*  Mandatory at injection Visit (before injection). For V02: physical examination and temperature measurement 
will be performed if necessary, based on the health status of the subject.  
† BL0001 is to be collected prior to any injection (SP0202, Prevnar  13, and Pentacel).  
‡  During this call the staff will determine whether the subject experienced any SAE and AESI not yet reported. The site staff will remind subject's parent / guardian to continue using the DC / eDC.  
§ Solicited injection site and systemic reactions will be collected for 7 days after injection. Unsolicited AEs will be collected for 30 days after injection.  
** During this call the staff will review the M A with the subject’s parent / guardian and determine whether the 
subject experienced any SAE or AESI not yet reported.  
 
[COMPANY_011]  Pasteur PSK00008  
515 – PNEUMOPCV Protocol  Version  6.0 
 
Confidential/Proprietary Information  
Page 28 of 126 Table of Study Procedures 2 (Infants) (Applicable before protocol Version 5.0)   
Phase II Trial, 6 Visits, 5 Phone Calls, 4 doses of either one SP0202 formulation or 1 Prevnar 13, concomitant vaccine doses (Pentacel, ENGERIX- B, 
RotaTeq, M-M-R II, and VARIVAX [as per pediatric schedule]), [ADDRESS_1221932] 
Visit (V)  V01 PC1 V02 PC2 V03 PC3 V04 V05* PC4 V06 PC5 
6-month 
safety 
follow-up 
Trial timelines (approximate # of days 
[D]) D0 D8 D60 D68 D120 D128 D150 D300-390 D308 D330-420 D480-570 
Visit / Phone contact [CONTACT_437624]  V01 + 8  V01 + 60D  V02 + 8D  V02 + 60D  V03 + 8D  V03 + 30D  V03 + 180D*  V05 + 8D  V05 + 30D  V05 + 180D  
Time windows (days)   +2 ±14 +2 ±14 +2 +14 ±14 +2 +14 +14 
Approximate age of subjects (months)  2  4  6  7 12-15  13-16 18 - 21 
Informed consent  X           
Inclusion/exclusion criteria  X           
Collection of demographic data/body 
stature  X           
Medical history  X       X    
Physical examination and temperature†  X  X  X  X X  X  
IRT contact  X  X  X   X    
Randomization/allocation of subject 
number  X           
Blood sampling (BL)‡  
(approximate volume)  BL0001  
(3 mL)      BL0002  
(6 mL) BL0003  
(6 mL)  BL0004  
(6 mL)  
Injection (SP0202 or Prevnar  13) X  X  X   X    
Routine pediatric vaccines             
            Pentacel  X  X  X   -    
            ENGERIX-B§ X  X  X   -    
            RotaTeq  X  X  X   -    
            M-M-R II and Varivax  -  -  -   X    
[COMPANY_011]  Pasteur PSK00008  
515 – PNEUMOPCV Protocol  Version  6.0 
 
Confidential/Proprietary Information  
Page 29 of 126 Visit (V)  V01 PC1 V02 PC2 V03 PC3 V04 V05* PC4 V06 PC5 
6-month 
safety 
follow-up 
Trial timelines (approximate # of days 
[D]) D0 D8 D60 D68 D120 D128 D150 D300-390 D308 D330-420 D480-570 
Visit / Phone contact [CONTACT_437624]  V01 + 8  V01 + 60D  V02 + 8D  V02 + 60D  V03 + 8D  V03 + 30D  V03 + 180D*  V05 + 8D  V05 + 30D  V05 + 180D  
Time windows (days)   +2 ±14 +2 ±14 +2 +14 ±14 +2 +14 +14 
Approximate age of subjects (months)  2  4  6  7 12-15  13-16 18 - 21 
30-Minute observation period  X  X  X   X    
Telephone contacts   X**  X**  X**   X**  X†† 
Diary card (DC)  
 provided 
 collected   
DC1    
DC2  
DC1    
DC3  
DC2    
DC4  
DC3   
DC5  
DC4    
 
DC5   
Memory aid (MA)  
 provided 
 checked            
X  
 
X 
Injection Site Reactions & Systemic 
Events Assessment  Solicited injection site and systemic reactions: Day  0–7 after each injection  
Unsolicited adverse events: Day  0–[ADDRESS_1221933]        X   X  
Reporting of SAEs and AESIs  Throughout the trial  
* V05 can take place up until subject reaches 15  months. 
† Mandatory at injection Visit (before injection). For other visits: physical examination and temperature measurement will be  performed if necessary, based on the health status of the subject. 
‡ BL0001 and BL0003 are to be collected prior to injection of study and concomitant vaccines.  
§ First dose of hepatitis B vaccine must be given at least 28 days prior to study enrollment (US sites). Infants included in Canada will receive an additional dose of hepatitis B vaccine at V02.  
** During the phone calls the staff will determine whether the subject experienced any SAE or AESI not yet reported. The site staff will remind subject’s parent / guardian to continue using the DC. 
†† During this call the staff will review the MA with the subject’s parent / guardian and determine whether the subject experienced any SAE and AESI not yet reported.
[COMPANY_011]  Pasteur PSK00008  
515 – PNEUMOPCV Protocol  Version  6.0 
 
Confidential/Proprietary Information  
Page 30 of 126 Table of Study Procedures 2 (Infants) (applicable from protocol Version 5.0)   
Phase II Trial, 6 Visits, 5 Phone Calls, 4 doses of either one SP0202 formulation or 1 Prevnar 13, concomitant vaccine doses (Pentacel, ENGERIX- B, 
RotaTeq, M-M-R II, and VARIVAX [as per pediatric schedule]), [ADDRESS_1221934] 
Visit (V)  V01 PC1 V02 PC2 V03 PC3 V04 V05* PC4 V06 PC5 
6-month 
safety 
follow-up 
Trial timelines (approximate # of days 
[D]) D0 D8 D60 D68 D120 D128 D150 D300-390 D308 D330-420 D480-570 
Visit / Phone contact [CONTACT_437624]   V01 + 8  V01 + 60D  V02 + 8D  V02 + 60D  V03 + 8D  V03 + 30D  V03 + 180D*  V05 + 8D  V05 + 30D  V05 + 180D  
Time windows (days)   +2 ±14 +2 ±14 +2 +14 ±14 +2 +14 +14 
Approximate age of subjects (months)  2  4  6  7 12-15  13-16 18 - 21 
Informed consent  X           
Inclusion/exclusion criteria  X           
Collection of demographic data/body 
stature  X           
Medical history  X       X    
Vaccination history  X           
Physical examination and temperature†  X  X  X  X X  X  
IRT contact  X  X  X   X    
Randomization/allocation of subject 
number  X           
Blood sampling (BL)‡  
(approximate volume)        BL0002  
(6 mL) BL0003  
(6 mL)  BL0004  
(6 mL)  
Injection (SP0202 or Prevnar  13) X  X  X   X    
Routine pediatric vaccines             
            Pentacel  X  X  X   -    
            RotaTeq  X  X  X   -    
            M-M-R II and Varivax  -  -  -   X    
[COMPANY_011]  Pasteur PSK00008  
515 – PNEUMOPCV Protocol  Version  6.0 
 
Confidential/Proprietary Information  
Page 31 of 126 Visit (V)  V01 PC1 V02 PC2 V03 PC3 V04 V05* PC4 V06 PC5 
6-month 
safety 
follow-up 
Trial timelines (approximate # of days 
[D]) D0 D8 D60 D68 D120 D128 D150 D300-390 D308 D330-420 D480-570 
Visit / Phone contact [CONTACT_437624]   V01 + 8  V01 + 60D  V02 + 8D  V02 + 60D  V03 + 8D  V03 + 30D  V03 + 180D*  V05 + 8D  V05 + 30D  V05 + 180D  
Time windows (days)   +2 ±14 +2 ±14 +2 +14 ±14 +2 +14 +14 
Approximate age of subjects (months)  2  4  6  7 12-15  13-16 18 - 21 
Other pediatric vaccine  
            ENGERIX-B§ X  X  X   -    
30-Minute observation period  X  X  X   X    
Telephone contacts   X**  X**  X**   X**  X†† 
Diary card (DC)  
 provided 
 collected   
DC1    
DC2  
DC1    
DC3  
DC2    
DC4  
DC3   
DC5  
DC4    
 
DC5   
Memory aid (MA)  
 provided 
 checked            
X  
 
X 
Injection Site Reactions & Systemic 
Events Assessment  Solicited injection site and systemic reactions: Day  0–7 after each injection  
Unsolicited adverse events: Day  0–[ADDRESS_1221935]        X   X  
Reporting of SAEs and AESIs  Throughout the trial  
* V05 can take place up until subject reaches 15 months. 
† Mandatory at injection Visit (before injection). For other visits: physical examination and temperature measurement will be  performed if necessary, based on the health status of the subject. 
‡ BL0003 is to be collected prior to injection of study and concomitant vaccines. § Hepatitis B vaccination can be administered concomitantly with Pentacel and PCV doses at V01, V02, and V03. A first dose of hepatitis B vaccine can be given at least 28 days prior to study 
enrollment. 
** During the phone calls the staff will determine whether the subject experienced any SAE or AESI not yet reported. The site  staff will remind subject’s parent / guardian to continue using the DC.  
†† During this call the staff will review the MA with the subject’s parent / guardian and determine whether the subject experienced any SAE and AESI not yet reported. 
[COMPANY_011]  Pasteur PSK00008  
515 – PNEUMOPCV Protocol  Version  6.0 
 
Confidential/Proprietary Information  
Page [ADDRESS_1221936]  
Ag antigen  
AR adverse reaction  
BL blood sample  
CBER Center for Biologics Evaluation and Research  
CDM  Clinical Data Management  
CFL Clinical Franchise Leader  
CI confidence interval 
CQA  Clinical Quality Assessment  
CRA Clinical Research Associate 
CRB (electronic) case report book [all the case report forms for a subject]  
CRF (electronic) case report form  
CRM 197 cross-reacting material 197, a non -toxic mutant of diphtheria toxin  
CTA clinical trial agreement  
CTL Clinical Team Leader  
D day 
DC / eDC  diary card / electronic diary card  
dil dilution  
DMC  data monitoring committee  
DMF  N, N -dimethylformamide  
DOD  delta optical density 
DTaP  diphtheria, tetanus, and acellular pertussis 
DTP  diphtheria, tetanus, and pertussis  
ECL electro -chemiluminescence assay  
ELISA  enzyme-linked immunosorbent assay  
ESDR  early safety review  
EDC  electronic data capture  
EIA enzyme immunoassay  
EU endotoxin units  
FAS full analysis set  
FDA  Food and Drug Administration  
[COMPANY_011]  Pasteur PSK00008  
515 – PNEUMOPCV Protocol  Version  6.0 
 
Confidential/Proprietary Information  
Page [ADDRESS_1221937] 
GCI Global Clinical Immunology  
GCP  Good Clinical Practice  
GM geometric mean  
GMC  geometric mean concentration  
GMCR  geometric mean concentration ratio  
GMT  geometric mean titer  
gp glycoprotein  
GPV  Global Pharmacovigilance  
HB hepatitis B  
HBs hepatitis B surface  
Hib Haemophilus influenza b  
HIV human immunodeficiency virus  
IATA  International Air Transport Association  
ICF informed consent form  
ICH International Council for Harmonisation 
IDMC  Independent Data Monitoring Committee  
IEC Independent Ethics Committee  
IgA immunoglobulin type A  
IgG immunoglobulin type G  
IM intramuscular  
IME important medical event  
IND investigational new drug (application)  
IPD invasive pneumococcal disease  
IRB Institutional Review Board  
IRT interactive response technology  
IU international units  
JL135  Jeryl Lynn [ADDRESS_1221938] level term  
MA memory aid  
MedDRA  Medical Dictionary for Regulatory Activities  
mIU mili-international units  
mL milliliter  
[COMPANY_011]  Pasteur PSK00008  
515 – PNEUMOPCV Protocol  Version  6.0 
 
Confidential/Proprietary Information  
Page 34 of 126 M-M-R measles, mumps, rubella 
MMRV  measles, mumps, rubella & varicella  
MoA  months of age  
MOPA  multiplex opsonophagocytic activity 
MTL Medical Team Leader  
NSAID  non-steroidal anti-inflammatory drug  
OD optical density 
OPA  opsonophagocytic activity 
PCV  pneumococcal conjugate vaccine  
PD post-dose  
PFU plaque -forming unit  
PnPS  pneumococcal capsular polysaccharide  
PPAS per-protocol analysis set  
PRN pertactin  
PRP polyribosyl -ribitol phosphate  
PT pertussis toxoid / toxin  
RCDC reverse cumulative distribution curves  
RIA radioimmunoassay  
RLU relative light units  
RMO Responsible Medical Officer  
SAE  serious adverse event  
SafAS  safety analysis set  
SAP statistical analysis plan  
SC subcutaneous  
SCID Severe Combined Immunodeficiency Disease  
SK SK bioscience Co., Ltd.  
SMT Safety Management Team  
TCC tissue culture control  
TCID 50 tissue culture infectious doses 50%  
TMF trial master file 
TTxd  tetanus toxoid 
ULOQ  upper limit of quantification  
U units  
V visit 
VZv varicella-zoster virus 
WHO  World Health Organization  
WT wild type  
 
[COMPANY_011]  Pasteur PSK00008  
515 – PNEUMOPCV Protocol  Version  6.0 
 
Confidential/Proprietary Information  
Page 35 of 126 1 Introduction  
1.1 Background  
This is a Phase II study that will evaluate the safety and immunogenicity of different formulations 
of a multivalent pneumococcal conjugate vaccine (PCV) administered concomitantly with routine pediatric vaccines in healthy toddlers and infants. This vaccine (henceforth referred to as SP0202) is expected to be indicated for the prevention of invasive and non- invasive disease caused by 
[CONTACT_303244] (or pneumococcus), in all age groups. 
S. pneumoniae  (or pneumococcus) is a Gram -positive diplococcu s, encapsulated with a diverse 
range of polysaccharides. Based on the differences in the polysaccharide capsule, [ADDRESS_1221939] been described (1) (2) (3). The most common disease-causing 
serotypes observed in different countries and / or geographic regions are generally sim ilar; 
however, there may be large variations in relative serotype prevalence in these areas, particularly 
between developed and developi[INVESTIGATOR_14696]. 
The microorganism, through the asymptomatic colonization of the nasopharynx, is a major cause 
of a number of infections, including pneumonia, meningitis, bacteremia, sinusitis, and otitis media (3). Infections characterized by [CONTACT_29498] S. pneumoniae  from a normally sterile site, such as 
blood, cerebrospi[INVESTIGATOR_872], pleural fluid, or synovial fluid, are identified as occurrences of invasive pneumococcal disease (IPD).  
Pneumococcal conjugate vaccines (PCVs) have been shown to be effective in preventing pneumococcal pneumonia, IPD, and otitis media in children ( 4) (5) (6) (7) (8) (9). Ever since the 
introduction of a 7 -valent PCV in 2000
a, the overall number of IPD cases, especially the number 
of cases due to serotypes covered by [CONTACT_29500], has been declining ( 10) ( 11). Strengthening this 
trend, the introduction of a 10- valent PCV (2009)b and a 13-valent PCV (2010)c has confirmed 
the indirect benefit generated by [CONTACT_875018] (ie, herd immunity in unvaccinated population) and in antimicrobial res istance ( 11) (12) ( 13). PCVs have 
had an important impact on public health in developed countries, as well as worldwide, since global roll out (14).  
However, it is now acknowledged that serotypes covered by [CONTACT_875019] ( 15) (16). Less fit or emergent serotypes simply take 
advant age of an ecological niche left vacant ( 17). One of the mos t notable examples is serotype 
19A which emerged as a predominant serotype in several countries, in both children and adults, after the introduction of PCV7, as well as in other countries with no PCV7 vaccination programs (18). 
Currently, few strategies aiming to mitigate this phenomenon of serotype replacement are being developed. One possible solution would be to design a vaccine that combines 2 classes of 
 
a  Prevnar®. Pneumococcal 7 -valent Conjugate Vaccine (Diphtheria CRM 197 Protein), [COMPANY_007] Inc.  
b  SynflorixTM. Pneumococcal conjugate vaccine (Non -typeable Haemophilus influenzae [NTHi] protein D, 
diphtheria or tetanus toxoid conjugates) adsorbed; GlaxoSmithKline Biologicals S.A.  
c  Prevnar® 13. Pneumococcal 13 -valent Conjugate Vaccine [Diphtheria CRM 197 Protein]), [COMPANY_007] Inc. 
[COMPANY_011]  Pasteur PSK00008  
515 – PNEUMOPCV Protocol  Version  6.0 
 
Confidential/Proprietary Information  
Page 36 of 126 complementary antigens, one to prevent colonization (ie, pneumococcal polysaccharides) and 
another to limit virulence transition (ie, protein antigens that selectively target pneumococci virulence transition) ( 19). Another possible solution is to introduce a PCV that includes a higher 
number of serotypes to cover the emerging ones and hence to protect against a higher number of pneumococcal strains causing invasive disease.  
[COMPANY_011] Pasteur has decided to move forward with the latter approach, a next generation PCV comprising 21 serotypes (PCV21). Such a vaccine candidate has the potential to address important medical and public health needs by [CONTACT_29503].  
1.[ADDRESS_1221940]   
[COMPANY_011] Pasteur is developi[INVESTIGATOR_007] a PCV21 (internal vaccine name [CONTACT_875061]0202) that would extend the protection against pneumococcal disease to serotypes 8, 9N, 10A, 11A, 12F, 15B, 22F, and 33F, in addition to the 13 serotypes included in Prevnar 13 (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F).  
  
This vaccine is developed in partnership with SK bioscience Co., Ltd (South Korea) who has developed a 13- valent formulation comparable to Prevnar 13 vaccine in terms of serotypes 
composition and carrier protein (nontoxigenic variant of diphtheria toxin, referred to as CRM
197). 

[COMPANY_011]  Pasteur PSK00008  
515 – PNEUMOPCV Protocol  Version  6.0 
 
Confidential/Proprietary Information  
Page 37 of 126 Table  1.1: Specificities of the 4 formulations evaluated in Phase I study PSK00007   
Formulation name  [CONTACT_875062]0202 -I 
SP0202 -II 
SP0202-III 
SP0202-IV 
This study was carried out in healthy adults aged 19 to 49 years old in the US. No safety concerns 
were identified for any SP0202 formulations; the safety profile of the formulation SP0202- II 
containing 4 serotypes conjugated to tetanus toxoid was unremarkable compared to the 3 other SP0202 formulations.  
 
 
 
 

[COMPANY_011]  Pasteur PSK00008  
515 – PNEUMOPCV Protocol  Version  6.0 
 
Confidential/Proprietary Information  
Page 38 of 1 26 

[COMPANY_011]  Pasteur PSK00008  
515 – PNEUMOPCV Protocol  Version  6.0 
 
Confidential/Proprietary Information  
Page 39 of 126 1.3 Potential Benefits and Risks   
1.3.1 Potential Benefits to Subjects   
As mentioned previously, 4 formulations of SP0202 investigational vaccine were evaluated in 
Phase I clinical study (PSK00007) that was carried out in healthy adults aged [ADDRESS_1221941] the 21 serotypes (the 13 pneumococcal serotypes common with Prevnar 13 as well as the new 8 additional serotypes), although there is no guarantee. 
Subjects who will receive Prevnar [ADDRESS_1221942] pneumococcal disease due to 
13 serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F).  
Apart from protection against pneumococcal disease, infants will be vaccinated with routine 
licensed vaccines and will benefit from protection against different diseases: measles, mumps, rubella, varicella, rotavirus infection, hepatitis B, diphtheria, tetanus, pertussis, polio, and invasive disease caused by [CONTACT_875020] b bacteria.  
As with any vaccines, SP0202 formulations and Prevnar 13, as well as the concomitant routine vaccines administered during the study may not protect 100% of individuals against the disease they are designed to prevent.  
1.3.2 Potential Risks to Subjects   
Like other vaccines, SP0202, Prevnar 13, and other routine licensed vaccines included in this 
study may cause injection sites reactions such as pain, swelling, and erythema, or certain systemic events such as fever, irritability, drowsiness, loss of appetite, abnormal crying, decreased sleep, and vomiting when administered to infants/toddlers. 
No safety concerns were identified for any SP0202 formulations evaluated in the Phase I study; 
 
 
There may be a rare possibility of an allergic reactio n which could be severe. Prior to any vaccine 
injection, all known precautions should be taken to prevent hypersensitivity reactions. This 
includes a review of the subject’s prior vaccination history with respect to possible hypersensitivity to the vaccine or similar vaccines. Epi[INVESTIGATOR_156705] (1:1000) and other appropriate agents used for the control of immediate allergic reactions must be available to treat unexpected reactions (eg, anaphylaxis).  
There may be other risks for SP0202 which are not yet known.  

[COMPANY_011]  Pasteur PSK00008  
515 – PNEUMOPCV Protocol  Version  6.0 
 
Confidential/Proprietary Information  
Page 40 of 126 To this day, there is no adequate evidence to clearly demonstrate the causal relationship between 
TTxd -containing vaccines and Guillain -Barré syndrome ( 29). The Institute of Medicine found 
evidence in favor of a caus al relation between TTxd -containing vaccines and brachial neuritis 
(30). Arthus reactions are rarely reported after vaccination and can occur after TTxd -containing 
vaccines ( 31). 
The potential risks listed here are not exhaustive. Refer to the Investigator’s Brochure of the investigational vaccine and to the package inserts of Prevnar 13 ( 32) and concomitant licensed 
vaccines ( 33) (34) ( 35) ( 36) ( 37) for additional information regarding potential risks.   
1.[ADDRESS_1221943] pneumococcal serotypes. Compared to the licensed vaccine Prevnar 13, SP0202 investigational vaccine contains 21 serotypes with different content (13 serotypes common to those of Prevnar 13 and 8 additional serotypes) that are conjugated to [ADDRESS_1221944] T -cell independent 
antigens, thus, they respond poorly to pneumococcal polysaccharides vaccine which contains native pneumococcal polysaccharides only ( 38). Therefore, the conjugation technology using a 
carrier protein to polysaccharides has been used to increase immunogenicity in infants and toddlers. Prot ein carrier specific T -cells provide the signal needed for maturation of the B -cell 
response and generation of B-cell memory, and production of high-affinity antibodies. Two protein carriers are included in the PCV21 formulation, both with proven safety re cords.  
Based on PSK00007 results, [ADDRESS_1221945] been selected for further evaluation in the target populations and secure the identification of a lead formulation for Phase III studies. These 3 formulations will be evaluated in this Phase II study.  
The SP0202 investigational vaccine is designed for the immunization of infants/toddlers and 
el
derly against pneumococcal disease. Toddlers aged 12 -15 months, followed by [CONTACT_875021] 42 
to 89 days will be included in the current Phase II study (PSK00008). It is also planned to 
evaluate the same formulations in a Phase II study in adults aged 50 years and above (PSK00009). 
2 Study Objectives   
2.1 Primary Objectives   
Safety  
• To assess the safety profile of each SP0202 formulation and Prevnar 13 in toddlers and infants (after each and any injection) 
The endpoints for the safety objective are presented in Section  [IP_ADDRESS].  
 
[COMPANY_011]  Pasteur PSK00008  
515 – PNEUMOPCV Protocol  Version  6.0 
 
Confidential/Proprietary Information  
Page 41 of 126 Immunogenicity  
• To assess the immune response (serotype specific IgG concentration) of the SP0202 
formulations and Prevnar 13 1 month after the administration of one dose in toddlers (Groups 1 to 4) 
• To assess the immune response (serotype specific IgG concentration) of the SP0202 formulations and Prevnar 13 1 month after the administration of 3 doses in infants (Groups 5 to 8) 
• To assess the immune response (serotype specific IgG concentration ) of the SP0202 
formulations and Prevnar 13 1 month after administration of a 4-dose schedule in infants (Groups 5 to 8) 
The endpoints for the immunogenicity objectives are presented in Section  [IP_ADDRESS]. 
2.2 Secondary Objectives   
Immunogenicity of SP0202 or Prevnar 13 vaccines 
• To assess the immune response (serotype specific opso nophagocytic activity [OPA] titer) of 
the SP0202 formulations and Prevnar 13 1 month after the administration of one dose in 
toddlers (Groups 1 to 4) 
• To assess the immune response (serotype specific OPA titer) of the SP0202 formulations and Prevnar 13 1 month after the administration of 3 doses in a subset of infants (Groups 5 to 8) 
• To assess the immune response (serotype specific OPA titer) of the SP0202 formulations and 
Prevnar 13 1 month after administration of a 4- dose schedule in a subset of infants (G roups 5 
to 8) 
Immunogenicity of concomitant licensed vaccines when co -administered with SP0202 or 
Prevnar 13  
Toddlers  
• To describe the Ab responses against Pentacel® antigens before and 1 month following 
injection of Pentacel  
Infants  
• To describe the Ab responses against antigens of the routine pediatric vaccines (Pentacel, RotaTeq®, ENGERIX-B®, M-M-R
II®, and VARIVAX®) when administered concomitantly 
with either SP0202 or Prevnar 13 ( at pre -Dose  1a for RotaTeq, Diphteria, Tetanus, and 
Pertussis antigens; at post -dose 3 [PD3] for ENGERIX-Bb, RotaTeq, and Pentacel; at post-dose 
4 [PD4] for M -M-R II and VARIVAX])  
The endpoints for the secondary objectives are presented in Section  [IP_ADDRESS] 
 
a Not applicable from protocol Version 5.0  
b Immunogenicity to ENGERIX -B will be presented according to the number of doses received  
[COMPANY_011]  Pasteur PSK00008  
515 – PNEUMOPCV Protocol  Version  6.0 
 
Confidential/Proprietary Information  
Page 42 of 126 3 Investigators and Study Organization  
This study will be conducted in approximately 42 centers in [LOCATION_002], 8 centers in Canada 
and 2 centers in Honduras. The Principal Investigators and any sub- investigators at the individual 
sites will be coordinated by 1 Coordinating Investigator. Details of the study centers, the Investigators at  each center, and the Coordinating Investigators are provided in the “List of 
Investigators and Centers Involved in the Trial” document. 
An internal Safety Management Team (SMT) and a Data Monitoring Committee (DMC) will be 
implemented for this study.  
 
 
  
In parallel, the DMC will conduct a formal unblinded review of the safety and will endorse, or not, the recommendation from the SMT whether to continue, modify, or stop the study for Stage II . A 
DMC charter will be developed before study start . It is understood that this review will be based 
on preliminary data, ie, data that have not been subject to validation and database lock. 
The SMT may also review the data being generated from the study at regular intervals for any 
new safety signals or safety concerns. 
Biostatistics, data management, monitoring, and medical writing will be either subcontracted to a 
contract research organization (CRO) or performed in house by [CONTACT_1034]. 
The laboratories involved in this study will be:  
• [COMPANY_011] Pasteur Global Clinical Immunology (GCI), Swiftwater (PA), [LOCATION_003]: serotype specific 
immunoglobulin type G (IgG) concentrations for all pneumococcal serotypes, and anti-diphtheria antitoxin and anti- tetanus antitoxin concentrations  
• : serotype specific opsonophagocytic activity 
assay (OPA) titers for all pneumococcal serotypes as well as and anti -measles antibodies, 
anti-mumps antibodies, anti -rubella antibodies, and anti- varicella antibodies.  
•  
 [LOCATION_003]: anti-rotavirus serum immunoglobulin type A (IgA) antibody 
(Ab) concentrations  
The role of Responsible Medical Officer (RMO), ie, the person having the authority to sign this 
protocol and any amendments on behalf of the Sponsor, is held jointly by  
 
4 Independent Ethics Committee / Institutional Review Board  
Before the investigational product can be shipped to the investigational site and before the inclusion of the first subject, this protocol, the informed consent forms (ICFs), subject recruitment procedures, and any other written information to be provided to subjects must be approved by, 

[COMPANY_011]  Pasteur PSK00008  
515 – PNEUMOPCV Protocol  Version  6.0 
 
Confidential/Proprietary Information  
Page 43 of 126 and / or receive favorable opi[INVESTIGATOR_35269], the appropriate Independent Ethics Committees (IECs) or 
Institutional Review Boards (IRBs).  
In accordance with Good Clinical Practice (GCP) and local regulations, each Investigator and / or the Sponsor are responsible for obtaining this approval and / or favorable opi[INVESTIGATOR_874992]. If the protocol is subsequently amended, approval must be re-obtained for each substantial amendment. Copi[INVESTIGATOR_35271], along with information on the type, version number, and date of document, and the date of approval, must be forwarded by [CONTACT_35321] / IRB (the names and qualifications of the members attending and voting at the meetings).  
The Investigator or the Sponsor will submit written summaries of the status of the study to the IEC / IRB annually, or more frequently if requested. All serious adverse events (SAEs) occurring during the study that are related to the  product administered will be reported by [CONTACT_875022] / IRB, according to the IEC / IRB policy.  
5 Investigational Plan  
5.1 Description of the Overall Study Design and Plan  
5.1.1 Study Design  
This will be a Phase II, randomized, active-controlled, observer-blind, age de- escalating, 
multi-centered study to assess the safety and the immunogenicity of 3 different formulations of an investigational PCV in toddlers (12 to 15 months of age [MoA]), and infants (2 MoA). The vaccine is referred to as SP0202 in what follows. 
PSK00008 study is designed to evaluate the safety and immunogenicity of SP0202 formulations 
in a step -down approach and will involve 2 stages ( Table  5.1): 
• In Sta ge I, toddlers aged between 12 and 15 months, who previously received the 3- dose 
primary series of Prevnar 13 will receive 1  dose of either one SP0202 formulation (Group 1, 
2, and 3) or Prevnar 13 (Group 4), concomitantly administered with Pentacel 
• In Stag e II, infants aged 2 months will receive 3 doses of either one SP0202 formulation or 
Prevnar 13 at approximately at 2, 4, and 6 MoA and a 4th dose at 12 to 15 MoA (Groups 5, 6, 7, and 8), co- administered with pediatric vaccines recommended at this age  
A total of 140  toddlers (35  subjects per group) will be enrolled in Stage I and randomized in a 
1:1:1:1 ratio to receive a single dose of either one SP0202 formulation (Groups 1 to Group 3) or Prevnar 13 (Group 4).  
A total of 700 infants (175  subjects per  group) will be enrolled in Stage II and randomized in a 
1:1:1:1 ratio to be vaccinated with 1 of the 3 SP0202 formulations (Group 5 to Group 7) or with 
Prevnar 13 (Group 8) ( Table  5.1).  
[COMPANY_011]  Pasteur PSK00008  
515 – PNEUMOPCV Protocol  Version  6.0 
 
Confidential/Proprietary Information  
Page 44 of 126 Table  5.1: Study Design  
Stage I  
Toddlers (aged 12 to 15 months)  
[ADDRESS_1221946] received a 
3-dose primary series of 
Prevnar  13 and DTaP -IPV + Hib 
vaccines in infancy  35 subjects will receive 1 dose of SP0202 -IIb and 1 dose of 
Pentacel concomitantly (Group 1)  
35 subjects will receive 1 dose of SP0202 -VI and 1 dose of 
Pentacel concomitantly (Group 2)  
35 subjects will receive 1 dose of SP0202 -VII and 1 dose of 
Pentacel concomitantly (Group 3)  
35 subjects will receive 1 dose of Prevnar  13 and 1 dose of 
Pentacel concomitantly (Group 4)  
Stage II  
Infants (aged 2 months)  
525 subjects will be randomized to 
receive 4 doses of one SP0202 
formulation, along with routine pediatric vaccines, at 2, 4, 6, and 12-15 months of age  175 subjects will receive 4  doses of SP0202-IIb (Group 5)  
175 subjects will receive 4  doses of SP0202-VI (Group 6)  
175 subjects will receive 4  doses of SP0202-VII (Group 7)  
175 subjects will receive 3  doses 
of Prevnar  13, along with routine 
pediatric vaccines, at 2, 4, 6, and 
12-15 months of age  175 subjects will receive 4  doses of Prevnar  13 (Group 8)  
As a safety precaution, a stepwise approach for enrollment is proposed: toddlers (aged 12-
15 months) will be enrolled and vaccinated.  
. An 
acceptable review of safety data and an acceptable safety profile based on prospectively defined criteria will be required before proceed ing with the enrollment of infants (2  MoA).  
For both toddlers and infants, immediate unsolicited systemic adverse events (AEs) will be collected for 30 minutes following each injection. Solicited injection site reactions will be collected between D0 and D7 after each injection for both study and concomitant pediatric 
vaccines. Solicited systemic reactions will be collected between D0 –7 after each injection. 
Unsolicited AEs will be collected between D0 –[ADDRESS_1221947] injection.  
Following DMC recommendations after Stage I early safety data review (ESDR), any SP0202 formulation may be excluded from entering Stage II of the study if considered not adequate for further evaluation in infants. In such a case, the number of groups to entered Stage II will be adjusted accordingly and the planned sample size in each selected group will be kept. 
 
a  For both toddlers and infants, anaphylaxis/hypersensitivity, convulsions (including febrile convulsions), 
hypotonic -hyporesponsive epi[INVESTIGATOR_1865], and apnea will be considered as AESIs.  

[COMPANY_011]  Pasteur PSK00008  
515 – PNEUMOPCV Protocol  Version  6.0 
 
Confidential/Proprietary Information  
Page 45 of 126 An Interactive Respo nse Technology (IRT) will be used to assign subject numbers and study 
group at each clinical site.  
Over the study period of Stage I (Group 1 to 4), toddlers will attend 2 planned visits at D0 and 
D30. Two blood samples (BL) of 6 mL each will be collected for the assessment of the immunogenicity of the 3 SP0202 formulations, Prevnar 13 and Pentacel at each visit: before injection of PCV (BL0001) at D0 (Visit 1 [V01]) and 1 month after PCV injection (BL0002) at D30 (V02). 
Over the study period of Stage II (Group 5 to 8), infants will attend 6 planned visits at D0, D60, 
D120, D150, D300-390, and D330- 420. Overall, 3 or 4 BL will be collected for the assessment of 
the immunogenicity of the 3 SP0202 formulations, Prevnar 13 and pediatric vaccines: before injection of PCV (BL0001; 3 mL) at D0 (V01)
a, 1 month after PCV Dose 3 (BL0002; 6 mL) at 
D150 (V04), before PCV Dose 4 (BL0003; 6 mL) at D300 (V05), and 1 month after PCV Dose 4 (BL0004; 6 mL) at D330 (V06).  
The study vaccine- related immunogenicity assessments will involve both the measurement of 
serotype specific IgG concentrations and of OPA titers.  IgG concentrations for all pneumococcal 
serotypes included in each of the SP0202 formulations and Prevnar [ADDRESS_1221948] 
reference serum 007sp that includes assignment for all serotypes included in SP0202 ( 39). OPA 
will be measured on a s ubset of subjects.  
The immunogenicity of the pediatric vaccines administered concomitantly with the study vaccines, will be assessed using standard assays for the respective antigens.  
5.1.[ADDRESS_1221949] provinces of Canada, pneumococcal vaccination with 
PCV13 (Prevnar 13) is routinely recommended in infants as a s eries of 3 doses, one dose at each 
of the following ages: 2, 4, and [ADDRESS_1221950] this vaccination schedule, either one of the 3 SP0202 formulations or Prevnar will be administered concomitantly with routine pediatric vaccines in infants and toddlers in this study. Prevnar 13 has been selected as a comparator since this is the only marketed vaccine with 13 common serotypes with SP0202 investigational vaccine.  
Routine vaccines schedules differ between the US, Honduras and Canada. Hep B vaccine is 
usually administered at birth, 2 and 6 MoA in the US, at 2, 4, and 6 MoA in some provinces of Canada and from Grade 6 or 7 in others, and at birth, 2, 4 and 6 MoA in Honduras. In this study, infants may receive the Hep B vaccine concomitantly with study vaccines at V01, V02, and V03 (a first dose of Hep B vaccine can be given at least 28 days prior to study enrollment). Administration of ENGERIX -B during the study visits will be documented in the eCRF. 
 
a Not applicable from protocol Version 5.0  
[COMPANY_011]  Pasteur PSK00008  
515 – PNEUMOPCV Protocol  Version  6.0 
 
Confidential/Proprietary Information  
Page 46 of 126 Additionally, routine vaccines schedule differs between Canadian territories. Meningococcal C 
vaccine is recommended at 12 MoA in Canada except in 3 Canadian territories (North West, British, and Yukon territories) where the vaccin e should be administered at [ADDRESS_1221951] 4 weeks before the Dose 4 of study vaccines.  
In line with the ACIP recommendation the measles, mumps, rubella & varicella (MMRV) vaccine is proposed as [ADDRESS_1221952] time, PSK00008 study will involve 2 stages: a stage I in toddlers and after a review of the safety data of this stage, the stage II in infants will start.  
Due to differences in the appearance of SP0202 and Prevnar13 products, the study will have an observer-blinded design (double -blind across SP0202 formulations) to limit any bias in the 
assessment of safety.  
5.1.3 Study Plan  
Enrollment  
A total of approximately 140 subjects in Stage I and 700 subjec ts in Stage II will be enrolled. 
Eligible subjects will be identified and recruited, in accordance with inclusion / exclusion criteria. 
Each subject’s parent / guardian must sign and date the ICF before any procedure or treatment associated with the study is performed. A step-down approach to vaccine administration from Stage I to Stage II will be used: toddlers will first be vaccinated (Stage I) and after the safety data 
 from Stage I has been reviewed by [CONTACT_875023], the enrollment of infants will start. It is to be noted that after the Stage I data review, the DMC may recommend droppi[INVESTIGATOR_874993]0202 formulations before moving to Stage II . In 
any cases, the sample size of each group will remain unchanged (ie, around 175 infants per group) and ratio between groups will be balanced.  
Vaccination In Stage I, toddlers aged between 12 to 15 months, will receive one dose of either one formulation 
of SP0202 formulation or Prevnar 13, concomitantly administered with Pentacel. 
In Stage II, infants aged 2 months will receive 3 doses of either one SP0202 formulation or 
Prevnar 13 approximately at 2, 4, and 6 MoA and a 4th dose at 12 to 15 MoA (Groups 5, 6, 7, and 8), co- administered with pediatric vaccines recommended at this age.  
All infants will receive the following routine vaccines (summarized in Table  5.2): 
• Pentacel (DTaP -IPV//Hib) at 2, 4, [ADDRESS_1221953] study visit. The study personne l / Investigator will be responsible for 
administering this dose at the recommended age as per their standard practices  

[COMPANY_011]  Pasteur PSK00008  
515 – PNEUMOPCV Protocol  Version  6.0 
 
Confidential/Proprietary Information  
Page 47 of 126 • RotaTeq (pentavalent rotavirus vaccine [RV5]) at 2, 4, and 6 months of age 
• M-M-R II (measles, mumps, rubella [MMR] vaccine) at 12 to 15 months of age 
• VARIVAX (varicella vaccine) at 12 to 15 months of age 
In addition to routine vaccine mentioned above, hepatitis B vaccination (ENGERIX- B) can be 
administered concomitantly with Pentacel and PCV doses at V01, V02, and V03. A first dose of 
hepatitis B vaccine can be given at least 28 days prior to study enrollment. 
Table  5.2: Injection schedule for study and pediatric vaccines in infants   
Visit (V)  V01 V02 V03 V05 
Approximate age 
(months)  2 4 6 12 to 15 
PCV for Group 5, 6, and 7 SP0202 
(IIb, VI, or VII)  SP0202 
(IIb, VI, or VII)  SP0202 
(IIb, VI, or VII)  SP0202 
(IIb, VI, or VII)  
Group 8  Prevnar 13  Prevnar 13  Prevnar 13  Prevnar 13  
Concomitant pediatric vaccines  Pentacel*  
RotaTeq†  Pentacel*  
RotaTeq†  Pentacel*  
RotaTeq†  M-M-R II + VARIVAX§  
ENGERIX -B‡ ENGERIX -B‡ ENGERIX -B‡  
*    Pentacel (Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed, Inactivated Poliovirus and 
Haemophilus  b Conjugate [Tetanus Toxoid Conjugate]; [COMPANY_011] Pasteur Ltd)  
†   RotaTeq (Rotavirus Vaccine, Live, Oral, Pentavalent); [COMPANY_006] & Co, Inc.  
‡   ENGERIX -B (Purified Recombinant Hepatitis B Surface Antigen; GlaxoSmithKline Inc.). Hepatitis B vaccination 
can be administered concomitantly with Pentacel and PCV doses at V01, V02, and V03. A first dose of hepatitis B vaccine can be given at least 28 d ays prior to study enrollment.  
§    M-M-R
II (Measles, Mumps, and Rubella Virus Vaccine Live) and VARIVAX® (Varicella Virus Vaccine Live); 
[COMPANY_006] & Co, Inc.  

[COMPANY_011]  Pasteur PSK00008  
515 – PNEUMOPCV Protocol  Version  6.0 
 
Confidential/Proprietary Information  
Page 48 of 126 Blood sampling 
During Stage I, all toddlers will provide 2 BL of 6  mL each for the assessment of the 
immunogenicity of the 3 SP0202 formulations, Prevnar 13 and Pentacel: a first sample (BL0001) 
before injection at D0 (V01) and a second sample (BL0002) at D30 (+14 days) post-injection (V02). 
During Stage II, all infants will provide 3 or 4 blood samples for the assessment of the 
immunogenicity of the 3 SP0202 formulations, Prevnar 13 and pediatric vaccines: a sample before injection of PCV (BL0001; 3 mL) at D0 (V01)
a, a sample 1 month after PCV Dose 3 
(BL0002; 6 mL) at D150 (± 14 days; V04), before PCV Dose 4 (BL0003; 6 mL) at D300 -390 
(±14 days; V05), and 1 month after PCV Dose 4 (BL0004; 6 mL) at D330 -420 (+ 14 days; V06). 
Immunogenicity of pneumococcal antigens will be assessed in priority versus concomitants antigens (See Section  [IP_ADDRESS]) 
Details about study visits are provided in Section  5.1.[ADDRESS_1221954] any unsolicited systemic adverse events (AEs) occurring during that time as immediate 
unsolicited systemic AEs in the CRB.  
Subjects’ parents / guardians will record in the DC / eDC information about AEs (solicited and unsolicited), con comitant medications, and any medical visits or hospi[INVESTIGATOR_602].   
Solicited injection site and systemic reactions will be collected from D0 to D7 following injection. Unsolicited events will be collected from D0 to D30 following injection. SAEs and AESIs will be collected throughout the study (from D0 until the 6- month follow -up safety phone contact). 
For both toddlers and infants, anaphylaxis/hypersensitivity, convulsions (including febrile convulsions), hypotonic-hyporesponsive epi[INVESTIGATOR_1865], and apnea will b e considered as AESIs.  
5.1.4 Visit Procedures   
Toddlers 
Visit 1 (Day 0): Inclusion, Randomization, Blood Sample, and Vaccination  
1) Give the subject’s parent / guardian information about the study, answer any of her / his 
questions, obtain written informed consent, and give her / him a signed copy. 
2) Obtain significant medical history about the subject.  
3) Check vaccination history. 
 
a Not applicable from protocol Version 5.0  
[COMPANY_011]  Pasteur PSK00008  
515 – PNEUMOPCV Protocol  Version  6.0 
 
Confidential/Proprietary Information  
Page 49 of 126 4) Obtain demographic data.  
5) Check medications and record reportable medication ongoing at the time of inclusion.  
6) Check inclusion and exclusion criteria for eligibility.  
7) Conduct a physical examination, including, but not limited to, examination of the head (ear, 
nose, and throat), neck, heart, lungs, abdomen, and extremities. If a routine examination had 
been performed within the past week by a qualified health care provider, it does not need to be repeated unless there were changes in health status, in which case it may be limited to the affected area . 
8) Take the subject's temperature. If the temperature is ≥  38.0°C / ≥ 100.4°F, postpone 
vaccination until the condition is resolved.  
9) If the subject is eligible, contact [CONTACT_581622], to obtain a subject number, and 
vaccine allocation.  
10) Obtain th e first blood sample (BL0001 – 6 mL) for immunogenicity (see Section  7.1 for 
detailed instructions regarding the handling of blood samples).  
If the blood sample cannot be obtained, the parent/guardian should be given the opportunity 
to bring the subject back to the study site for another attempt, as long as the subject continues to remain eligible for the study. All attempts should be made to obtain a  blood sample; 
however, if the attempts are unsuccessful, the subject could continue in the study. 
11) Inject the following study vaccines. Each vaccine should be administered in an assigned 
location (see Operating Guidelines) and documented appropriately: 
• SP0202 or Prevnar 13: inject IM into the anterolateral area of the thigh, preferably the 
right thigh.  
• Pentacel: inject IM into the anterolateral area of the thigh, preferably the left thigh (ie, the 
opposite leg from that used for SP0202 or Prevnar). 
12) Keep the subject under observation for 30 minutes, and report any reaction / event in the 
source document. 
13) Record the date of injection, site, and side of injection, route of administration, as well as the 
dose number of the vaccine. 
14) Give the parent / guardian a DC / eDC to record any injection site and systemic AEs, together 
with instructions for its completion, including explanations on the definition and use of intensity scales for collection of AEs. Remind parents to carefully report any clinical signs / dia gnosis experienced at the same time as the fever epi[INVESTIGATOR_1865] > 39.5°C / 103.1°F. 
15) Give the parent / guardian a thermometer for rectal temperature measurements, and a ruler to 
measure the size of any injection site reactions, and go over the instructions for their use.  
[COMPANY_011]  Pasteur PSK00008  
515 – PNEUMOPCV Protocol  Version  6.0 
 
Confidential/Proprietary Information  
Page 50 of 126 16) Arrange an appointment for V02 (D30 + 14 days). Remind the parent / guardian to expect a 
telephone call 8  days after V01 and to bring back the DC / eDC when they return for V02 at 
a specified date and time.  
17) Remind the parent / guardian to notify the site in case of serious medical event occurs.  
18) Complete the source documents and relevant case report forms (CRFs) for this visit.  
Telephone Call 1 (8  [+2] days after Visit 1)  
Note : If D8 falls on a weekend or a holiday, the telephone call may be made on the following 
business day.  
1) Record relevant information concerning the subject’s health status on the telephone contact 
[CONTACT_982]. If an SAE occurred, follow the instructions in Section  10 for reporting it.  
2) Remind the parent / guardian to do the following: 
• Complete the Day 0 –7 pages of the DC / eDC  
• Complete the remaining pages of the diary card, and bring them to V02  
• Notify the site in case of an SAE  
Visit 2 (30 [+14] days after Visit 1): Collection of Safety Information and Blood Sample  
1) If the DC information from Day 0 –7 has not yet been obtained / information from D0 – D7 
not entered in eDC, obtain it at this time by [CONTACT_875024]. Review the pages of the DC / eDC with the parent / guardian, including any AEs, medications, or therapy that occurred since vaccination.  
2) Check medications and record reportable ongoing medications. Review temporary 
contraindications for blood sampling. Ensure the subject has not had any antibiotics within the previous 72 hours (3 days). 
3) Conduct a physical examination and take the subject’s temperature if necessary, based on the 
health status of the subject.  
4) Obtain the second blood sample (BL0002 – 6 mL) (see Section  7.1 for detailed instructions 
regarding the handling of blood samples).  
5) Complete the source document and the relevant CRFs for this visit. 
6) Complete the end of study CRF of the CRB. 
7) Provide the memory aid to the subject’s parent / gua rdian. 
Safety Follow -up Telephone Call (D180 + 14 days) 
The investigator or authorized designee will:  
[COMPANY_011]  Pasteur PSK00008  
515 – PNEUMOPCV Protocol  Version  6.0 
 
Confidential/Proprietary Information  
Page 51 of 126 1) Ask to the parent / guardian if the subject has experienced any SAE or AESI in the time since 
vaccination. 
2) Complete the relevant CRF for this phone contact. 
A follow -up visit can be arranged depending on the information recorded during the phone call. 
Infants  
Visit 1 (Day 0): Inclusion, Randomization, Blood Sample, and Vaccination  
1) Give the subject’s parent / guardian information about the study, answe r any of her / his 
questions, obtain written informed consent, and give her / him a signed copy. 
2) Obtain significant medical history about the subject.  
3) Check vaccination history. 
4) Obtain demographic data. 
5) Check medications and record reportable medication ongoing at the time of inclusion.  
6) Check inclusion and exclusion criteria for eligibility.  
7) Conduct a physical examination, including, but not limited to, examination of the head (ear, 
nose, and throat), neck, heart, lungs, abdomen, and extremities. If a routine examination had been performed within the past week by a qualified health care provider, it does not need to be repeated unless there were changes in health status, in which case it may be limited to the 
affected area.   
8) Take the subject's temperature. If the temperature is ≥  38.0°C / ≥ 100.4°F, postpone 
vaccination until the condition is resolved.  
9) If the subject is eligible, contact [CONTACT_581622], to obtain a subject number, and 
vaccine allocation.  
10) Administer the follow ing study vaccines. Each vaccine should be administered in an assigned 
location (see Operating Guidelines) and documented appropriately: 
[COMPANY_011]  Pasteur PSK00008  
515 – PNEUMOPCV Protocol  Version  6.0 
 
Confidential/Proprietary Information  
Page 52 of 126 Table  5.3: Vaccinations and route of administration at V01, V02, and V03  
Vaccine   Route of administration  
SP0202 or Prevnar [ADDRESS_1221955] IM into the anterolateral area of the thigh , preferably the left thigh 
(ie, the opposite leg from that used for SP0202 or Prevnar)  
ENGERIX -B Open -label  Inject IM into the anterolateral area of the thigh , preferably the left thigh 
(ie, the opposite leg from that used for SP0202 or Prevnar)  
RotaTeq  Open -label  Administer orally per instructions in the package insert  
When multiple vaccines are administered at a single visit, each vaccine should be 
administered at a different anatomic site. If vaccines are given in the same limb, the injection sites should be separated by 1 inch / 2.5 cm or more, so that any local reactions can be differentiated ( 40). 
Pentacel and ENGERIX -B (as applicable) should be given in the same thigh. They should 
not be administered in the same thigh as SP0202 or Prevnar. For details see Operating Guidelines. 
Failure to administer vaccines in the designated limb will not constitute a protocol deviation, 
but should be recorded as a comment in the vaccination form of the eCRF. If the vaccines are not administered in the recommended limb(s), this should be corrected for subsequent injections.  
11) Keep the subject under observation for 30 minutes and report any reaction / event in the 
source document. 
12) Record the date of injection, site of injection, route of administration, as well as the dose 
number of the vaccine.  
13) Give the parent / guardian a DC1 to record any injection site and systemic AEs, together with 
instructions for its completion, including explanations on the definition and use of intensity scales for collection of AEs. Remind parents to carefully report any clinical signs / diagnosis experienced at the same time as the fever epi[INVESTIGATOR_1865] > 39.5°C / 103.1°F. 
14) Give the parent / guardian a thermometer for rectal temperature measurements, and a ruler to 
measure the size of any injection site reactions, and go over the instruction s for their use.  
15) Arrange an appointment for V02 (D60 ± 14 days). Remind the parent / guardian to expect a 
telephone call 8  days after V01 and to bring back the DC1 when they return for V02 at a 
specified date and time.  
16) Remind the parent / guardian to notif y the site in case of a serious medical event occurs.  
17) Complete the source document and relevant CRFs for this visit.  
[COMPANY_011]  Pasteur PSK00008  
515 – PNEUMOPCV Protocol  Version  6.0 
 
Confidential/Proprietary Information  
Page 53 of 126 Telephone Call 1 (8  [+2] days after Visit 1)  
Note : If D8 falls on a weekend or a holiday, the telephone call may be made on the following 
business day.  
1) Record relevant information concerning the subject’s health status on the telephone contact 
[CONTACT_982]. If an SAE occurred, follow the instructions in Section  10 for reporting it.  
2) Remind the parent / guardian to do the following: 
• Complete the Day 0 –7 pages of the DC1 
• Complete the remaining pages of the DC1, and bring them to V02 
• Notify the site in cas e of an SAE 
Visit 2 (60 [±14] days after Visit 1): Collection of Safety Information and Vaccination  
1) If the DC1 information from Day 0 –7 has not yet been obtained, obtain it at this time by 
[CONTACT_875024]. Review the pages of the DC1 with the parent / guardian, including any AEs, medications, or therapy that occurred since vaccination.  
2) Check medications and record reportable ongoing medications.  
3) Conduct a physical examination, including, but not limited to, examination of the head (ear, nose, and throat), neck, heart, lungs, abdomen, and extremities. If a routine examination had been performed within the past week by a qualified health care provider, it does not need to be repeated unless there were changes in health status, in which case it may be limited to the affected area.  
4) Take the subject's temperature. If the temperature is ≥  38.0°C / ≥ 100.4°F, postpone 
vaccination until the condition is resolved.  
5) Contact [CONTACT_875025].  
6) Inject the following study vaccines. Each vaccine should be administered in an assigned location (see Operating Guidelines) and documented appropriately. Refer to Table  5.3 for 
details on vaccinations and route of administration at V01, V02, and V03. 
When multiple vaccines are administered at a single visit, each vaccine should be administered at a different anatomic site. If vaccines are given in the same limb, the injection sites should be separ ated by 1 inch / 2.5 cm or more, so that any local reactions can be 
differentiated ( 40).  
Pentacel and ENGERIX -B (as applicable) should be given in the same thigh. They should not 
be administered in the same thigh as SP0202 or Prevnar. For details see Operating Guidelines. 
Failure to administer vaccines in the designated limb will not constitute a protocol deviation, 
but should be recorded as a comment in the vaccination form of the eCRF. If the vaccines are not administered in the recommended limb(s), this should be corrected for subsequent injections.  
[COMPANY_011]  Pasteur PSK00008  
515 – PNEUMOPCV Protocol  Version  6.0 
 
Confidential/Proprietary Information  
Page 54 of 126 7) Keep the subject under observation for [ADDRESS_1221956] any adverse reaction in the 
source document. 
8) Give the parent / guardian a DC2. Remind parents to carefully report any clinical signs / diagnosis experienced at the same time as the fever epi[INVESTIGATOR_1865] > 39.5°C / 103.1°F. 
9) Arrange an appointment for V03 (D120 ± 14 days). Remind the parent / guardian to expect a telephone call 8 days after V02 and to bring back the DC2 when they return for V03 at a specified date and time.  
10) Remind the parent / guardian to notify the site in case of a serious medical event occurs.  
11) Complete the source document and the relevant CRFs for this visit. 
Telephone Call 2 (8  
 [+2] days after Visit 2)  
Note : If D8 falls on a weekend or a holiday, the telephone call may be made on the following 
business day.  
1) Record relevant information concernin g the subject’s health status on the telephone contact 
[CONTACT_982]. If an SAE occurred, follow the instructions in Section  10 for reporting it.  
2) Remind the parent / guardian to do the following: 
• Complete the Day 0 –7 pages of the DC2 
• Complete the remaining pages of the DC2, and bring them to V03 
• Notify the site in case of an SAE  
Visit 3 (60 [±14] days after Visit 2): Collection of Safety Information and Vaccin at ion 
1) If the DC2 information from Day 0 –7 has not yet been obtained obtain it at this time by 
[CONTACT_875024]. Review the pages of the DC2 with the parent / guardian, including any AEs, medications, or therapy that occurred since vaccination.  
2) Check med ications and record reportable ongoing medications.  
3) Conduct a physical examination, including, but not limited to, examination of the head (ear, nose, and throat), neck, heart, lungs, abdomen, and extremities. If a routine examination had been performed within the past week by a qualified health care provider, it does not need to be repeated unless there were changes in health status, in which case it may be limited to the affected area.  
4) Take the subject's temperature. If the temperature is ≥  38.0°C / ≥ 100.4°F, postpone 
vaccination until the condition is resolved.  
5) Contact [CONTACT_875025].  
[COMPANY_011]  Pasteur PSK00008  
515 – PNEUMOPCV Protocol  Version  6.0 
 
Confidential/Proprietary Information  
Page 55 of 126 6) Inject the following study vaccines. Each vaccine should be administered in an assigned 
location (see Operating Guidelines) and documented appropriately. Refer to Table  5.3 for 
details on vaccinations and route of administration at V01, V02, and V03.  
When multiple vaccines are administered at a single visit, each vaccine should be 
administered at a different anatomic site. If vaccines are given in the same limb, the injection sites should be separated by 1 inch / 2.5 cm or more, so that any local reactions can be differentiated (40).  
Pentacel and ENGERIX -B (as applicable) should be given in the same thigh. They should not 
be administered in the same thigh as SP0202 or Prevnar. For details see Operating Guidelines. 
Failure to administer vaccines in the d esignated limb will not constitute a protocol deviation, 
but should be recorded as a comment in the vaccination form of the eCRF. If the vaccines are 
not administered in the recommended limb(s), this should be corrected for subsequent injections.  
7) Keep the subject under observation for [ADDRESS_1221957] any adverse reaction in the source document. 
8) Give the parent / guardian a DC3. Remind parents to carefully report any clinical signs / diagnosis experienced at the same time as the fever epi[INVESTIGATOR_1865] > 39.5°C / 103.1°F. 
9) Arrange an appointment for V04 (D150 + 14 days). Remind the parent / guardian to expect a telephone call 8 days after V03 and to bring back the DC3 when they return for V04 at a specified date and time.  
10) Remind the parent / guardian to notify the site in case of a serious medical event occurs.  
11) Complete the source document and the relevant CRFs for this visit. 
Telephone Call 3 (8  
 [+2] days after Visit 3)  
Note : If D8 falls on a weekend or a holiday, the telephone call may be made on the following 
business day.  
1) Record relevant information concerning the subject’s health status on the telephone contact [CONTACT_982]. If an SAE occurred, follow the instructions in Section  10 for reporting it.  
2) Remind the parent / guardian to do the following: 
• Complete the Day 0 –7 pages of the DC3 
• Complete the remaining pages of the DC3, and bring them to V04 
• Notify the site in case of an SAE  
Visit 4 (30 [+14] days after Visit 3): Collection of Safety Information and Blood Sample  
1) If the DC3 information from Day 0 –7 has not yet been obtained, obtain it at this time by 
[CONTACT_875024]. Review the pages of the DC3 / eDC3 with the parent / guardian, including any AEs, medications, or therapy that occurred since vaccination.  
[COMPANY_011]  Pasteur PSK00008  
515 – PNEUMOPCV Protocol  Version  6.0 
 
Confidential/Proprietary Information  
Page 56 of 126 2) Check medications and record reportable ongoing medications. Review temporary 
contraindications for blood sampling. Ensure the subject has not had any antibiotics within the previous 72 hours  (3 days). 
3) Conduct a physical examination and take subject’s temperature if necessary, based on the health status of the subject.  
4) Obtain the blood sample (BL0002 – 6 mL) (see Section  7.1 for detailed instructions regarding 
the handling of blood samples).  
If the blood sample cannot be obtained, the parent/guardian should be given the opportunity to 
bring the subject back to the study site for another attempt, as long as the subject continues to remain eligible for the study. All attempts should be made to obtain a blood sample; however, if the attempts are unsuccessful, the subject could continue in the study with all the study procedures including vaccination. 
5) Give the parent / guardian a DC4. 
6) Arrange an appointment for V05 (D300–390 ± 14 days). Remind the parent / guardian to bring back the DC4 when they return for V05 at a specified date and time. 
7) Complete the end of study phase CRF of the CR B. 
8) Complete the source document and the relevant CRFs for this visit. 
Visit 5 (180 [±14] days after Visit 3): Collection of Safety Information, Blood Sample, and 
Vaccination  
Note : V05 can take place up from the day subject turns to 12 months until 15 months of agea. 
1) If the DC4 information from Day 0 –7 has not yet been obtained, obtain it at this time by 
[CONTACT_875026]. Collet and review the pages of the DC4 with the parent / guardian. 
2) Obtain significant medical history about the subject.  
3) Check medications and record reportable ongoing medications. Review temporary contraindications for blood sampling. Ensure the subject has not had any antibiotics within the previous 72 hours (3 days). 
4) Conduct a physical examination, including, but not limited to, examination of the head (ear, nose, and throat), neck, heart, lungs, abdomen, and extremities. If a routine examination had been performed within the past week by a qualified health care provider, it does not need to be repeated unless there were changes in health status, in which case it may be limited to the affected area.   
5) Take the subject's temperature. If the temperature is ≥  38.0°C / ≥ 100.4°F, postpone 
vaccination until the condition is resolved.  
6) Contact [CONTACT_875025].  
 
a “15 months” means the day before the 16th after birth  
[COMPANY_011]  Pasteur PSK00008  
515 – PNEUMOPCV Protocol  Version  6.0 
 
Confidential/Proprietary Information  
Page 57 of 126 7) Obtain the blood sample (BL0003 – 6 mL) (see Section  7.1 for detailed instructions regarding 
the handling of blood samples).  
If the blood sample can not be obtained, the parent/guardian should be given the opportunity to 
bring the subject back to the study site for another attempt, as long as the subject continues to 
remain eligible for the study. All attempts should be made to obtain a blood sample; however, if the attempts are unsuccessful, the subject could continue in the study with all the study procedures including vaccination. 
8) Inject the following study vaccines. Each vaccine should be administered in an assigned location (see Operating Guidelines) and documented appropriately: 
Table  5.4: Vaccinations and route of administration at V05   
Vaccine   Route of administration  
SP0202 or Prevnar 
[ADDRESS_1221958] SC into the anterolateral area of the thigh (preferably the left 
thigh, ie, the opposite thigh from that used for SP0202 or Prevnar 13) 
or the outer aspect of the upper left arm  
VARIVAX  Open -label  Inject SC into the anterolateral area of the thigh (preferably the left 
thigh, ie, the opposite thigh from that used for SP0202 or Prevnar 13) 
or the outer aspect of the upper right arm (ie, the opposite arm from 
that used for M -M-RII) 
When multiple vaccines are administered at a single visit, each vaccine should be administered at a different anatomic site. If vaccines are given in the same limb, the injection sites should be separated by 1 inch / 2.5 cm or more, so that any local reactions can be differentiated ( 40). 
Failure to administer vaccines in the designated limb will not constitute a protocol deviation, but should be recorded as a comment in the vaccination form of the eCRF. 
9) Keep the subject under observation for [ADDRESS_1221959] any adverse reaction in the source document. 
10) Give the parent / guardian a DC5. Remind parents to carefully report any clinical signs / diagnosis experienced at the s ame time as the fever epi[INVESTIGATOR_1865] > 39.5°C / 103.1°F. 
11) Arrange an appointment for V06 (D330-420 + 14  days). Remind the parent / guardian to 
expect a telephone call 8 days after V05 and to bring back the DC5 when they return for V06 at a specified date and time.  
12) Remind the parent / guardian to notify the site in case of a serious medical event occurs.  
13) Complete the source document and the relevant CRFs for this visit. 
[COMPANY_011]  Pasteur PSK00008  
515 – PNEUMOPCV Protocol  Version  6.0 
 
Confidential/Proprietary Information  
Page 58 of 126 Telephone Call 4 (8  [+2] days after Visit 5)  
Note : If D8 falls on a weekend or a holiday, the telephone call may be made on the following 
business day.  
1) Record relevant information concerning the subject’s health status on the telephone contact 
[CONTACT_982]. If an SAE occurred, follow the instructions in Section  10 for reporting it.  
2) Remind the parent / guardian to do the following: 
• Complete the Day 0 –7 pages of the DC5 
• Complete the remaining pages of the DC5, and bring them to V06 
• Notify the site in case of an SAE  
Visit 6 (30 [+14] days after Visit 5): Collection of Safety Information and Blood Sample  
1) If the DC5 information from Day 0 –7 has not yet been obtained, obtain it at this time by 
[CONTACT_875024]. Review the pages of the DC5 with the parent / guardian, including any AEs, medications, or therapy that occurred since vaccination.  
2) Check medications and record reportable ongoing medications. Review temporary contraindications for blood sampling. Ensure the subject has not had any antibiotics wi thin the 
previous 72 hours (3 days). 
3) Conduct a physical examination and take subject’s temperature if necessary, based on the health status of the subject.  
4) Obtain the blood sample (BL0004 – 6 mL) (see Section  7.1 for detailed instructions regarding 
the handling of blood samples).  
5) Record the study termination.  
6) Complete the source document and the relevant CRFs for this visit. 
7) Complete the end of study CRF of the CRB.  
8) Provide the memory aid (MA) to the subject’s parent / guardian  
Safety Follow -up Telephone Call (D 480 - 570 + 14 days) 
The investigator or authorized designee will:  
1) Ask the parent / guardian if the subject has experienced any SAE or A ESI in the time since 
vaccination 
2) Complete the relevant CRF for this phone contact. 
A follow -up visit can be arranged depending on the information recorded during the phone call. 
[COMPANY_011]  Pasteur PSK00008  
515 – PNEUMOPCV Protocol  Version  6.0 
 
Confidential/Proprietary Information  
Page 59 of 126 Follow-up of subjects with Related AEs or with AEs That Led to Study/Vaccinat ion 
Discontinuation:  
Unless a subject or subject’s parent/guardian refuses further contact, each subject who 
experiences an AE (whether serious or non -serious) during the study must be followed until the 
condition resolves, becomes stable, or becomes chronic (even after the end of the subject’s participation in the study) if either  of the following is true:  
• The AE is considered by [CONTACT_35326]. 
• The AE caused the discontinuation of the subject from the study or f rom vaccination.  
5.1.[ADDRESS_1221960] been obtained. 
Planned study period - FVFS (first visit, first subject) to LCLS (last contact, last subject):  
• Toddlers: May 2020 to September 2021  
• Infants: April 2021 to May 2023 
Planned inclusion period - FVFS to FVLS (f irst visit, last subject):  
• Toddlers: May 2020 to March 2021 
• Infants: April 2021 to November 2021 
Planned vaccination period for toddlers: May 2020 to March 2021 
Planned primary vaccination period (V01- V02-V03) for infants: April 2021 to March 2022 
Planned booster vaccination period for infants: February 2022 to December 2022 Planned end of study: June 2023 Planned date of final clinical study report: Q4 [ADDRESS_1221961]:  

[COMPANY_011]  Pasteur PSK00008  
515 – PNEUMOPCV Protocol  Version  6.0 
 
Confidential/Proprietary Information  
Page 60 of 126 • Immediate unsolicited systemic AEs  
• Solicited injection site and systemic reactions  
• Unsolicited AEs reported as related by [CONTACT_737] 
• SAEs  
• AESIs  
Enrollment of infants will not begin until the end of the review. In addition, the data will be 
examined for the following: 
• Any deaths, regardless of causality  
• Any vaccine- related SAEs 
• AESIs  
• Any signs of injection site necrosis or exfoliative dermatitis  
• Grade 3 fever reported in more than 10% of subjects; presence of concurrent infectious 
disease will be documented.   
If any of the above criteria are met, a decision based on the SMT and DMC recommendations will be made as to whether enrollment of infants will be allowed to begin or whether any adjus tments 
ought to be done (eg, an SP0202 formulation should not enter Stage II of the study).  
The DMC will review the unblinded data by [CONTACT_875027]0202 formulation and Prevnar 13 for each safety cri terion and overall safety 
profile. The DMC may recommend removing 1 or more SP0202 formulation from Stage II. 
Moreover, the option of partial or full unblinding can be available to the Sponsor through an 
independent statistician, if required, for a further in -depth review of the data.  
The Sponsor’s SMT is empowered to recommend a pause in recruitment while it investigates any potential signal or concern. The clinical team and SMT will review the data being generated from the study at regular intervals for a ny new safety signals or safety concerns.  
5.2 Enrollment and Retention of Study Population  
5.2.1 Recruitment Procedures  
Before the start of the study, the Investigator and / or study staff will determine the recruitment strategy to be used for this study (eg, advertising, database, direct mail, word of mouth referral). Using the relevant methods they will contact [CONTACT_875028] / guardians and invite them to participate in the study. The site will ensure that any advertisements or materials used to recruit subjects (eg, letters, pamphlets, posters, etc.) have been submitted to [COMPANY_011] Paste ur for review prior to submission to the IEC/IRB for approval.  
In addition, a parent / guardian who brings a child to the study site for a routine visit will be invited to enroll the subject in the study, if eligible. Subjects may also be recruited from th e 
general population. 
[COMPANY_011]  Pasteur PSK00008  
515 – PNEUMOPCV Protocol  Version  6.0 
 
Confidential/Proprietary Information  
Page [ADDRESS_1221962]’s parent(s) / guardian voluntarily confirms his 
or her willingness to allow the child to participate in a particular study. Informed consent must be obtained before any study procedures are performed. The process is documented by [CONTACT_3553] a written, signed, and dated ICF. 
In accordance with GCP, prior to signing and dating the consent form, the subject ’s parents / 
guardian must be informed by [CONTACT_875029], and must have sufficient time and opportunity to ask any questions. 
The actual ICF used at each center may differ, depending on local regulations and IEC / IRB 
requirements. However, all versions must contain the standard information found in the sample ICF provided by [CONTACT_1034]. Any change to the content of the ICF must be approved by [CONTACT_29540] / IRB prior to the form being used.  
If new information becomes available that may be relevant to the subject’s parent / guardian’s willingness to continue participation in the study, this will be communicated to him / her in a timely manner. Such information will be provided via a revised ICF or an addendum to the original ICF.  
ICFs will be provided in duplicate, or a photocopy of the signed consent will be made. The original will be kept by [CONTACT_737], and the copy will be kept by [CONTACT_423]’s parent / guardian. 
Documentation of the consent process should be recorded in the source documents. 
5.2.[ADDRESS_1221963] fulfill all  of the following criteria to be eligible for study enrollment:  
Toddlers and infants 
1) Informed consent form has been signed and dated by [CONTACT_7071](s) or other guardian, and by 
[CONTACT_35308], if required by [CONTACT_427] 
2) Subject and parent/guardian are able to attend all scheduled visits and to comply with all study procedures 
3) Born at full term of pregnancy (≥ 37 weeks) and/or with a birth weight ≥ 5.5 lbs or 2.5 kg 
4) Healthy toddlers / infants as determined by [CONTACT_9870], physical examination, and judgment of the Investigator  
[COMPANY_011]  Pasteur PSK00008  
515 – PNEUMOPCV Protocol  Version  6.0 
 
Confidential/Proprietary Information  
Page 62 of 126 Specifically for toddlers  
5) Aged [ADDRESS_1221964] study visita  
6) Subject has received 3 doses of Prevnar 13 and 3 doses of diphteria, tetanus, acellular 
pertussis, poliovirus and Haemophilus influenzae  type b antigens in infancy 
Specifically for infants  
7) Aged [ADDRESS_1221965] study visitb 
5.2.5 Exclusion Criteria   
An individual fulfilling any of the following criteria is to be excluded from study enrollment:  
Toddlers and infants 
1) Participation at the time of study enrollment (or in the [ADDRESS_1221966] study 
vaccination) or planned participation during the present study period in another clinical study investigating a vaccine, drug, medical device, or medical procedure 
2) Family history of congenital or hereditary immunodeficiency, until the immune competence of the potential vaccine recipi[INVESTIGATOR_167466]  
3) Blood dyscrasias, leukemia, lymphoma of any type, or other malignant neoplasms affecting the bone marrow or lymphatic systems 
4) Active tuberculosis  
5) History of S. pneumoniae  infection or disease, confirmed either serologically or 
microbiologically  
6) History of any neurologic disorder, including any seizures and progressive neurologic disorders 
7) History of Guillain -Barré syndrome 
8) Known systemic hypersensitivity to any of the vaccine components, or history of a life-threatening reaction to the vaccines used in the study or to a vaccine contai ning any of the 
same substances  
9) Verbal report of thrombocytopenia contraindicating intramuscular (IM) vaccination in the Investigator’s opi[INVESTIGATOR_1649] 
10) Bleeding disorder, or receipt of anticoagulants in the 3 weeks preceding inclusion, contraindicating IM vaccinat ion in the Investigator's opi[INVESTIGATOR_1649]  
11) Receipt of oral or injectable antibiotic therapy within [ADDRESS_1221967] blood draw  
12) Chronic illness (including, but not limited to, cardiac disorders, congenital heart disease, chronic lung disease, renal disor ders, auto -immune disorders, diabetes, psychomotor diseases, 
and know congenital or genetic diseases) that, in the opi[INVESTIGATOR_689], is at a stage where it might interfere with study conduct or completion  
 
a “12 to 15 months” means from the 12th month after birth to the day before the 16th after  birth  
b “42 to 89 days” means the 42th day after birth to the day before the 90th day after birth  
[COMPANY_011]  Pasteur PSK00008  
515 – PNEUMOPCV Protocol  Version  6.0 
 
Confidential/Proprietary Information  
Page 63 of 126 13) Any condition which, in the opi[INVESTIGATOR_1101] t he Investigator, might interfere with the evaluation of 
the study objectives 
14) In an emergency setting, or hospi[INVESTIGATOR_29476]. 
15) Moderate or severe acute illness/infection (according to Investigator judgment) on the day of 
vaccination or febrile illnes s (temperature ≥ 38.0°C / ≥ 100.4°F). A prospective subject should 
not be included in the study until the condition has resolved or until 3 days after the febrile event has resolved  
16) Identified as a natural or adopted child of the Investigator or employee w ith direct 
involvement in the proposed study 
Specifically for toddlers 
17) Receipt of any vaccine in the [ADDRESS_1221968] blood sampling Visit (Visit 2), except for influenza vaccination, which may be received at least 2 weeks before or 2  weeks after any 
study vaccination. This exception includes monovalent pandemic influenza vaccines and multivalent influenza vaccines  
18) Receipt of immune globulins , blood or blood-derived products in the past 3 months 
19) Known or suspected congenital or acquired immunodeficiency; or receipt of 
immunosuppressive therapy, such as anti-cancer chemotherapy or radiation therapy, within 
the preceding 6 months; or long- term systemic cor ticosteroid therapy (prednisone or 
equivalent for more than [ADDRESS_1221969] 3 months) 
20) History of diphtheria, tetanus, pertussis, poliomyelitis, and/or H. influenzae  type b infection 
or disease  
Specifically for infants  
21) Receipt of any vaccine in the [ADDRESS_1221970] blood sampling Visit (Visit 6), except for influenza vaccination or COVID [ADDRESS_1221971] 2 weeks before o r 2 weeks after any study vaccination. This exception includes monovalent pandemic 
influenza vaccines and multivalent influenza vaccines, and COVID- 19 vaccines, as 
applicable per local recommendations.  
22) Receipt of immune  globulins, blood or blood-derived products since birth. 
23) Known or suspected congenital or acquired immunodeficiency; or receipt of immunosuppressive therapy, such as anti-cancer chemotherapy or radiation therapy; or long-term systemic corticosteroid therapy (prednisone or equivalent for more than 2 consecutive 
weeks) since birth  
24) Previous vaccination against  S. pneumoniae  
25) Previous vaccination against the following antigens: diphtheria, tetanus, pertussis , 
H. influenzae  type b, poliovirus, rotavirus, measles, mumps, rubella, and varicella  
26) Receip t of more than 1 previous dose of hepatitis B vaccine 
[COMPANY_011]  Pasteur PSK00008  
515 – PNEUMOPCV Protocol  Version  6.0 
 
Confidential/Proprietary Information  
Page 64 of 126 27) History of diphtheria, tetanus, pertussis, poliomyelitis, hepatitis B, measles, mumps, rubella, 
varicella, H. influenzae type b, and/or rotavirus infection or disease 
28) History of intussusception  
If the s ubject has a primary physician who is not the Investigator, the site should contact [CONTACT_357276] / guardian’s consent to inform him / her of the subject’s participation in the study. In addition, the site should ask this primary physician to verify exclusion criteria relating to previous therapi[INVESTIGATOR_014], such as receipt of blood products or previous vaccines. 
5.2.[ADDRESS_1221972] 
and ongoing. Any such conditions will be documented in the source document. Significant 
(clinically relevant) medical history (reported as diagnosis) including conditions/illnesses for 
which the subje ct is or has been followed by a physician or conditions/illnesses that could resume 
during the course of the study or lead to an SAE or to a repetitive outpatient care will be collected in the case report book (CRB). The significant medical history section of the CRB contains a core list of body systems and disorders that could be used to prompt comprehensive reporting, as well as space for the reporting of specific conditions and illnesses.  
For each condition, the data collected will be limited to:  
• Diagnos is (this is preferable to reporting signs and symptoms) 
• Presence or absence of the condition at enrollment  
The reporting of signs and symptoms in lieu of a diagnosis is strongly discouraged. 
Dates, medications, and body systems are not to be recorded, and the information collected will not  
be coded. Its purpose is to assist in the later interpretation of safety data collected during the 
study. 
5.2.7 Contraindications for Subsequent Vaccinations   
[IP_ADDRESS] Temporary Contraindications  
Toddlers 
Not applicable. 
Infants  
Should an infant experiences one of the conditions listed below, the Investigator will postpone 
further vaccination until the condition is resolved. Postponement must still be within the timeframe for vaccination indicated in the Table of Study Procedures. 
1) Febrile illness (temperature ≥  38.0°C [≥  100.4°F]) or moderate or severe acute illness / 
infection on the day of vaccination, according to Investigator judgment  
2) Receipt of any vaccine (other than the study vaccine[s]) in the [ADDRESS_1221973] study Visit in 
[COMPANY_011]  Pasteur PSK00008  
515 – PNEUMOPCV Protocol  Version  6.0 
 
Confidential/Proprietary Information  
Page 65 of 126 which SP0202 or Prevnar 13 is injected (V05), except for influenza vaccination or COVID -
[ADDRESS_1221974] 2 weeks before or 2  weeks aft er any study 
vaccination. This exception includes monovalent pandemic influenza vaccines and 
multivalent influenza vaccines, and COVID- 19 vaccines, as applicable per local 
recommendation. 
3) Long- term systemic corticosteroid therapy (prednisone or equivalent for more than [ADDRESS_1221975] 3 months preceding the study vaccination) 
[IP_ADDRESS] Definitive Contraindications   
Toddlers 
Not applicable. 
Infants  
Should a subject experie nce 1 of the conditions listed below, the Investigator will discontinue 
vaccination:  
1) An anaphylactic or other significant allergic reaction to the previous dose of vaccine  
2) Receipt of immunosuppressive therapy, such as anti-cancer chemotherapy or radiation 
therapy 
3) Ongoing clinical AE related to the previous study vaccination, and in the Investigator’s 
opi[INVESTIGATOR_1649], contraindicating further vaccination 
4) SAE related to the study vaccine following the previous study vaccination 
Subjects with a definitive contraindic ation will continue to be followed up for the study -defined 
safety and immunogenicity assessments, as applicable.  
In the event of a local or national immunization program with a pandemic influenza vaccine or a 
COVID- [ADDRESS_1221976] is not to receive any additional study vaccines but should continue in the study and be followed up for safety only, as per protocol. Only the vaccine which has a related SAE or a definite contraindication will be stopped wherever it is possible to identify the vaccine that caused the event.  
Prevnar  
1) Hypersensitivity to the active substances, to any of the excipi[INVESTIGATOR_840], to diphtheria toxoid, or to a previous dose of Prevnar 13 
[COMPANY_011]  Pasteur PSK00008  
515 – PNEUMOPCV Protocol  Version  6.0 
 
Confidential/Proprietary Information  
Page 66 of 126 Pentacel  
1) Severe allergic reaction (eg, anaphylaxis) after a previous dose of Pentacel, any ingredient of 
Pentacel, or any other diphtheria toxoid, tetanus toxoid, pertussis-containing vaccine, inactivated poliovirus vaccine or H. influenzae  type b vaccine 
2) Encephalopathy within 7 days of a previous pertussis-containing vaccine with no other identifiable cause  
3) Progressive neurologic disorder including infantile spasms, uncontrolled epi[INVESTIGATOR_002], or progressive encephalopathy until a treatment regimen has been established and the condition has stabilized  
ENGERIX-B 
1) Severe allergic reaction (eg, anaphylaxis) a previous dose of any hepatitis B-containing 
vaccine, or to any component of ENGERIX-B, including yeast 
RotaTeq  
1) Demonstrated history of hypersensitivity to the rotavirus vaccine or any component of the vaccine  
2) History of Severe Combined Immunodeficiency Disease (SCID) 
3) Epi[INVESTIGATOR_167476] 
M-M-R
II 
1) Hypersensitivity to any component of the vaccine, including gelatin 
2) Anaphylactic or anaphylactoid reactions to neomycin 
3) Febrile respi[INVESTIGATOR_874994]  
4) Patients receiving immunosuppressive therapy. This contraindication does not apply to patients who are receiving corticosteroids as replacement therapy, eg, f or Addison’s disease  
5) Individuals with blood dyscrasias, leukemia, lymphomas of any type, or other malignant neoplasms affecting the bone marrow or lymphatic systems  
6) Primary and acquired immunodeficiency states, including patients who are immunosuppressed i n association with acquired immune deficiency syndrome (AIDS) or 
other clinical manifestations of infection with human immunodeficiency viruses; cellular immune deficiencies; and hypogammaglobulinemic and dysgammaglobulinemic states  
7) Individuals with a family history of congenital or hereditary immunodeficiency, until the immune competence of the potential vaccine recipi[INVESTIGATOR_874995] 
1) History of severe allergic reaction to any component of the vaccine (including neomycin and 
gelatin) or to a pre vious dose of varicella vaccine 
2) History of primary or acquired immunodeficiency states, leukemia, lymphoma or other malignant neoplasms affecting the bone marrow or lymphatic system, AIDS, or other clinical manifestations of infection with HIV  
[COMPANY_011]  Pasteur PSK00008  
515 – PNEUMOPCV Protocol  Version  6.0 
 
Confidential/Proprietary Information  
Page 67 of 126 3) Individuals receiving immunosuppressive therapy, including individuals receiving 
immunosuppressive doses of corticosteroids 
4) Any febrile illness or active infection, including untreated tuberculosis  
5.2.8 Contraindication for Subsequent blood draw   
The following is a temporary contraindication to blood draws for toddlers (BL0002 at V02) and for infants (BL0002 at V04 and BL004 at V06): 
1) Receipt of oral or injectable antibiotic therapy with in 72 hours prior blood draw.  
Note : If a subject receives oral or injectable antibiotic therapy within [ADDRESS_1221977] still be within the timeframe for blood draw. If postponement would result in the sample collection falling outside of this timeframe, the blood sample should be collected without postponement, and it should be documented appropriately (in source documents and CRB) that the sample was taken less than 3  days after stoppi[INVESTIGATOR_29479].  
5.2.9 Coronavirus Disease 2019 (COVID-19) Vaccine  
Should COVID-19 vaccination campaign be implemented during the course of the study for the pediatric population eligible to participate or participating to the study, applicable country 
recommendations will be implemented. When possible and unless recommended otherwise, a 2 -
week interval between any study vaccine dose and the COVID vaccine dose is desirable.  
If a COVID-19 vaccine dose is received during one study vaccine solicited reactogenicity period 
it would not be possible to differentiate systemic re actions between them. Likewise, if the 
COVID-19 vaccine is received between a study vaccine dose and the collection of blood, it will not be possible (at this point) to rule out an immunogenicity interaction. Therefore, in any of the two situations it is recommended that the subject will be pulled out of the per protocol (PP) population but should continue in the study within the full analysis set (FAS). 
The type of COVID- 19 vaccine received (including tradename) and the date of its 
administration(s) should  be documented in the concomitant medications CRF. 
Wherever possible the site of injection of study vaccines should be in the limb separate from the 
limb in which COVID -19 vaccine is administered (if it has already been administered). Likewise, 
and if on the control of the study site, any COVID- [ADDRESS_1221978] 1 inch / 2.5  cm should be maintained between the two administration 
sites.  
5.2.10 Conditions for Withdrawal  
Parents / Guardians will be informe d that they have the right to withdraw their child from the 
study at any time. A subject may be withdrawn from the study: 
[COMPANY_011]  Pasteur PSK00008  
515 – PNEUMOPCV Protocol  Version  6.0 
 
Confidential/Proprietary Information  
Page 68 of 126 • At the discretion of the Investigator or Sponsor due to safety concerns or significant 
non-compliance with the protocol (based on the Investigator’s judgment), without the subject’s permission (withdrawal)  
• At the request of the parent / guardian (dropout) 
The reason for a withdrawal or dropout should be clearly documented in the source documents and in the CRB.  
The Investigator must det ermine whether voluntary withdrawal is due to safety concerns (in 
which case, the reason for discontinuation will be noted as “Adverse Event”) or for another 
reason.  
Withdrawn subjects will not be replaced.  
5.2.[ADDRESS_1221979] to Follow- up Procedures   
In the case of subjects who fail to return for a follow-up examination, documented reasonable effort (ie, documented telephone calls and certified mail) should be undertaken to locate or recall them, or at least to determine their health status while fully respecting their rights. These efforts should be documented in the source documents. 
5.2.[ADDRESS_1221980] significant (refer to the CRF completion instructions for additional details and examples):  
[COMPANY_011]  Pasteur PSK00008  
515 – PNEUMOPCV Protocol  Version  6.0 
 
Confidential/Proprietary Information  
Page [ADDRESS_1221981] is permanently terminated from the study because of an 
AE (including an SAE), as defined in Section  [IP_ADDRESS] . 
This category also applies if the subject experiences a definitive contraindication that 
is an SAE or AE.  
Lost to Follow-
up To be used when t he subject cannot be found or contact[CONTACT_35331][INVESTIGATOR_874996] s to 
locate him/her before the date of his/her planned last visit, as outlined in 
Section  5.2.11. The certified letter was sent by [CONTACT_875030], and the subject or parent/guardian  did not give any other news and 
did not come to any following visit.  
Protocol 
Deviation  To be used:  
• In case of significant noncompliance with the protocol (eg,, deviation of the Inclusion / Exclusion criteria, non-compliance with time windows, blood sampling or vaccination refusal, missed injection/treatment, or error in the vaccine/treatment administration).  
• If the subject experiences a definitive contraindication that is not an SAE or AE.  
• The subject
 or the parent/guardian  signed the certified letter sent by [CONTACT_875031]. 
Withdrawal by [CONTACT_85189] / 
Guardian  To be used: 
• When the subject or parent/guardian  indicated unwillingness to continue 
in the study 
• When th e subject or parent/guardian  made the decision to discontinue 
participation in the study for any personal reason other than an SAE/AE ( eg,, 
subject is relocating, inform consent withdrawal, etc.) 
5.2.[ADDRESS_1221982]’s status at the end of the  study is “Withdrawal by [CONTACT_85189] / Guardian”, the site will 
attempt to contact [CONTACT_35336] 6 -month follow-up except if they specified that they do not want to 
be contact[CONTACT_29524]. 
5.3 Safety Emergency Call   
If, as per the Investigator's judgment, a subject experiences a medical emergency, the Investigator may contact [CONTACT_1034]'s RMO for advice on how to address any study related medical question or problem. If the RMO is not available, then the Investigator may contact [CONTACT_29555]—available 24  hours a day, 7 days a week —that will forward all safety emergency calls to the 
[COMPANY_011]  Pasteur PSK00008  
515 – PNEUMOPCV Protocol  Version  6.0 
 
Confidential/Proprietary Information  
Page [ADDRESS_1221983] the need to report an SAE. The Investigator is still required to 
follow the protocol-defined process for reporting SAEs to the GPV De partment (please refer to 
Section  10). 
In case of emergency code-breaking, the Investigator is required to follow the code-breaking procedures des cribed in Section  6.4. 
5.[ADDRESS_1221984] the earlier version. All substantial amendments (eg, those that affect the conduct of the study or the safety of subjects) require IEC / IRB approval, and must also be forwarded to regulatory authorities.  
An administrative / non- substantial amendment to a protocol is one that modifies some 
administrative, logistical, or other aspect of the study but does not affect its scientific quality or have an impact on the subjects’ safety. The IECs / IRB s will be notified by [CONTACT_875032] / non -substantial amendment is made.   
The Investigator is responsible for ensuring that changes to an approved study, during the period for which IEC / IRB approval has already been given, are not initiated without IEC / IRB review 
and approval, except to eliminate apparent immediate hazards to subjects.  
5.[ADDRESS_1221985] resulting from this or any other studies become available; or for administrative reasons; or on advice of the Sponsor, the Investigators, the IECs/IRBs, or the governing regulatory authorities in the countries where the study is taking place.  
If the study is prematurely terminated or suspended, the Sponsor shall promptly inform the Investigators, the IECs/IRBs, the regulatory authorities, and any contract research organization(s) used in the study of the reason for termination or suspension, as specified by [CONTACT_25435]. The Investigator shall promptly inform the study subjects’ parents/guardians and should assure appropriate subject therapy and/or follow-up. 
[COMPANY_011]  Pasteur PSK00008  
515 – PNEUMOPCV Protocol  Version  6.0 
 
Confidential/Proprietary Information  
Page [ADDRESS_1221986] 1   
SP0202- IIb: Pneumococcal Conjugate Vaccine ([PCV], SK bioscience Co., Ltd.)  
Form:    Liquid 
Dose:     0.5 mL  
Route:    IM 
Batch Number:  TBD  
[IP_ADDRESS] Composition   
Each 0.5 mL dose of vaccine contains the following components: 
Active ingredients  
[IP_ADDRESS] Pr
eparation and Administration  
Prior to administration, all study products must be inspected visually for cracks, broken seals, 
correct label content (see Section  6.3.1), and extraneous particulate matter and / or discoloration, 
whenever solution and container permit. If any of these conditions exists, the vaccine must not be administered. A replacement dose is to b e used, and the event is to be reported to the Sponsor. 
The product is a liquid preparation that does not require diluting. Since this product is a suspension containing an adjuvant, white particulate matter and transparent supernatant may be observed during storage of the product;  it has to be shaken vigorously immediately prior to use to 
obtain a homogenous, white suspension. Do not use the vaccine if it cannot be resuspended. 

[COMPANY_011]  Pasteur PSK00008  
515 – PNEUMOPCV Protocol  Version  6.0 
 
Confidential/Proprietary Information  
Page [ADDRESS_1221987] be kept under observation for 30 minutes after vaccination to ensure their safety, 
and any reactions during this period will be documented in the CRB. Appropriate medical equipment and emergency medications, including epi[INVESTIGATOR_238] (1:1000), must be available on site in the event of an anaphylactic, vasovagal, or other immediate allergic reaction.  
[IP_ADDRESS] Dose Selection and Timing   
Subjects in Group 1 (toddlers) will receive one dose of PCV, formulation SP0202-IIb, at D0 (V01). 
Subjects in Group 5 (infants) will receive one dose of PCV, formulation SP0202- IIb, at D0 
(V01), D60 (V02), D120 (V03), and D300-390 (V05). 
6.1.[ADDRESS_1221988] 2   
SP0202- VI: Pneumococcal Conjugate Vaccine ([PCV], SK bioscience Co., Ltd.)  
Form:    Liquid 
Dose:     0.5 mL  
Route:    IM 
Batch Number:  TBD  
[IP_ADDRESS] Composition   
Each 0.5 mL dose of vaccine contains the following components: 
Active ingredients  

[COMPANY_011]  Pasteur PSK00008  
515 – PNEUMOPCV Protocol  Version  6.0 
 
Confidential/Proprietary Information  
Page 73 of 126 [IP_ADDRESS] Preparation and Administration  
The procedures for preparing and administering the control product a re the same as those 
described for the study product in Section  [IP_ADDRESS] . 
[IP_ADDRESS] Dose Selection and Timing   
Subjects in Group 2 (toddlers) will receive one dose of PCV, formulation SP0202- VI, at D0 
(V01). 
Subjects in Group 6 (infants) will receive one dose of PCV, formulation SP0202-VI, at D0 (V01), 
D60 (V02), D120 (V03), and D300-390 (V05). 
6.1.[ADDRESS_1221989] 3   
SP0202- VII: Pneumococcal Conjugate Vaccine ([PCV], SK bioscience Co., Ltd.)  
Form:    Liquid 
Dose:     0.5 mL  
Route:    IM 
Batch Number:  TBD  
[IP_ADDRESS] Composition   
Each 0.5 mL dose of vaccine contains the following components: 
Active ingredients  
[IP_ADDRESS] Pr
eparation and Administration  
The procedures for preparing and administering the control product are the same as those 
described for the study product in Section  [IP_ADDRESS] . 

[COMPANY_011]  Pasteur PSK00008  
515 – PNEUMOPCV Protocol  Version  6.0 
 
Confidential/Proprietary Information  
Page 74 of 126 [IP_ADDRESS] Dose S election and Timing   
Subjects in Group 3 (toddlers) will receive one dose of PCV, formulation SP0202- VII, at D0 
(V01). 
Subjects in Group 7 (infants) will receive one dose of PCV, formulation SP0202- VII, at D0 
(V01), D60 (V02), D120 (V03), and D300-390 (V05). 
6.1.[ADDRESS_1221990]   
Prevnar 13: Pneumococcal 13- valent Conjugate Vaccine [Diphtheria CRM1 97 Protein] (Wyeth 
Pharmaceuticals, Inc., a subsidiary of [COMPANY_007] Inc, Philadelphia, PA, [LOCATION_003]) 
Form:    Liquid 
Dose:     0.5 mL  
Route:    IM 
Batch Number:  Commercial Lot 
[IP_ADDRESS] Composition   
Each 0.5 mL dose of vaccine contains the following components: 
Streptococcus pneumoniae  serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 23F 
saccharides  .............................................................................. approximately 2.2 μg of each  
6B saccharides ............................................................................................................. 4.4 μg 
CRM 197 carrier protein  ................................................................................................. 34 μg 
Polysorbate 80 ............................................................................................................ 100 μg 
Succinate buffer  .......................................................................................................... 295 μg 
Aluminum as aluminum phosphate adjuvant  ............................................................. 125 μg 
 
[IP_ADDRESS] Preparation and Administration  
Prevnar [ADDRESS_1221991] in Section  [IP_ADDRESS] . 
[IP_ADDRESS] Dose Selection and Timing   
Subjects in Group 4 (toddlers) will receive one dose of Prevnar 13, at D0. 
Subjects in Group 8 (infants) will receive one dose of Prevnar 13, at D0 (V01), D60 (V02), D120 
(V03), and D300-390 (V05). 
[COMPANY_011]  Pasteur PSK00008  
515 – PNEUMOPCV Protocol  Version  6.0 
 
Confidential/Proprietary Information  
Page [ADDRESS_1221992] 1   
Pentacel (Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed, Inactivated 
Poliovirus and Haemophilus b Conjugate (Tetanus Toxoid Conjugate); [COMPANY_011] Pasteur Ltd, 
Toronto, Ontario, Canada  
Form:    Liquid 
Dose:     0.5 mL  
Route:    IM 
Batch Number:  Commercial Lot 
[IP_ADDRESS] Composition   
Each 0.5 mL dose contains: 
Diphtheria toxoid .................................................................... 15 Limit of Flocculation (Lf)  
Tetanus toxoid ................................................................................................................ 5 Lf 
Acellular pertussis antigens:  
Pertussis toxin (PT)  ................................................................................................ 20 µg 
Filamentous hemagglutinin (FHA) ......................................................................... 20 µg Pertactin (PRN) ........................................................................................................ 3 µg 
Fimbriae Types 2 and 3 (FIM) ................................................................................. 5 µg 
Inactivated polioviruses:  
Type 1 (Mahoney) .................................................................... 40 D-antigen units (DU) Type 2 (MEF-1) ...................................................................................................... 8 DU  
Type 3 (Saukett) ................................................................................................... 32 DU 
H. influenzae  type b (PRP) ........................................................................................... 10 µg 
Tetanus toxoid (PRP- T) ................................................................................................ 24 µg 
Excipi[INVESTIGATOR_840]:  
Aluminum phosphate (0.33 mg aluminum) (adjuvant) .............................................. 1.5 mg Polysorbate 80 ............................. approximately 10 parts per million (ppm) by [CONTACT_875033] ..................................................................................................................... 42.5 mg Residual formaldehyde  ............................................................................................... ≤ 5 µg 
Residual glutaraldehyde ............................................................................................ < 50 ng 
Residual bovine serum albumin  ................................................................................. ≤ 50ng 
2-phenoxyethanol ..................................................................................... 3.3 mg (0.6% v/v) Neomycin ................................................................................................. < 4 pi[INVESTIGATOR_167465] (pg) Polymyxin B sulfate  .................................................................................................... < 4 pg 
[COMPANY_011]  Pasteur PSK00008  
515 – PNEUMOPCV Protocol  Version  6.0 
 
Confidential/Proprietary Information  
Page 76 of 126 [IP_ADDRESS] Preparation and Administration  
The general precautions of use are the same as those described for the study product in 
Section  [IP_ADDRESS] 
Pentacel will be supplied as a liquid vaccine component that is combined through recons titution 
with a lyophilized vaccine component, both in single dose vials. 
One dose (0.5 mL) is to be injected in the anterolateral aspect of thigh. After gently swirl the vial, 
the suspension should be cloudy, uniform and white to off-white (yellow tinge). 
Subjects must be kept under observation for 30 minutes after vaccination to ensure their safety, 
and any reactions during this period will be documented in the CRB. Appropriate medical equipment and emergency medications, including epi[INVESTIGATOR_238] (1:1000), m ust be available on site 
in the event of an anaphylactic, vasovagal, or other immediate allergic reaction.  
The procedures for preparing and administering Pentacel are detailed in the package insert (33). 
[IP_ADDRESS] Dose Selection and Timing   
Subjects in Groups 1, 2, 3, and 4 will receive one dose of Pentacel at D0 (V01). 
Subjects in Groups 5, 6, 7, and 8 (infants) will receive one dose of Pentacel at D0 (V01), D60 
(V02), and D120 (V03). 
6.2.[ADDRESS_1221993] 2   
ENGERIX- B (Hepatitis B Vaccine [Recombinant]); GlaxoSmithKline  
Form:    Liquid 
Dose:     0.5 mL  
Route:    IM 
Batch Number:  Commercial Lot  
[IP_ADDRESS] Composition   
Each 0.5 mL pediatric/adolescent dose contains 10 µg of hepatitis B virus surface antigen 
(HBsAg) adsorbed on 0.25 mg aluminum as aluminum hydroxide. 
Excipi[INVESTIGATOR_841] s: 
Sodium chloride ...................................................................................................... 9 mg/mL  
Disodium phosphate dihydrate .......................................................................... 0.98 mg/mL 
Sodium dihydrogen phosphate dihydrate .......................................................... 0.71 mg/mL 
[IP_ADDRESS] Preparation and Administration  
The general precautions of use are the same as those described for the study product in 
Section  [IP_ADDRESS] 
ENGERIX-B will be supplied as 0.5 mL prefilled syringes.  
[COMPANY_011]  Pasteur PSK00008  
515 – PNEUMOPCV Protocol  Version  6.0 
 
Confidential/Proprietary Information  
Page 77 of 126 One dose (0.5 mL) is to be injected in the anterolateral aspect of the thigh for infants. The content, 
upon storage may present a fine white deposit with a clear colorless supernatant. Once shaken, the vaccine is slightly opaque. 
Subjects must be kept under observation for 30 minutes after vaccination to ensure their safety, 
and any reactions during this period will be documented in the CRB. Appropriate medical equipment and emergency medications, including epi[INVESTIGATOR_238] (1:1000), must be available on site in the event of an anaphylactic, vasovagal, or other immediate allergic reaction.  
The procedures for preparing and administering ENGERIX -B are detailed in the package insert 
(34). 
[IP_ADDRESS] Dose Selection and Timing   
Subjects can receive one dose of ENGERIX -B at D0 (V01), D60 (V02), and D120 (V03). Of 
note, a first dose of hepatitis B vaccine can be given at least [ADDRESS_1221994] 3   
RotaTeq: Rotavirus Vaccine, Live, Oral, Pentavalent ([COMPANY_006] Sharp & Dohme Corp., a subsidiary 
of [COMPANY_006] & Co., Inc ., Whitehouse Station, NJ, [LOCATION_003])  
Form:    Liquid 
Dose:     2 mL  
Route:    Oral 
Batch Number:  Commercial Lot 
[IP_ADDRESS] Composition   
Each 2  mL dose contains 
the following 5 live reassortant rotaviruses : 
G1 serotype ............................................................................ 2.2 x 106 infectious units (IU)  
G2 serotype ........................................................................................................ 2.8 x 106 IU 
G3 serotype ........................................................................................................ 2.2 x 106 IU 
G4 serotype ........................................................................................................ 2.0 x 106 IU 
P1A(8) ............................................................................................................... 2.3 x 106 IU 
The reassortants are suspended in a buffered stabilizer solution.  
Each 2  mL vaccine dose also contains sucrose, sodium citrate, sodium phosphate monobasic 
monohydrate, sodium hydroxide, polysorbate 80, cell culture media, and trace amounts of fetal bovine serum. 
[IP_ADDRESS] Preparation and Administration  
The general precautions of use are the same as those described for the study product in 
Section  [IP_ADDRESS] 
[COMPANY_011]  Pasteur PSK00008  
515 – PNEUMOPCV Protocol  Version  6.0 
 
Confidential/Proprietary Information  
Page [ADDRESS_1221995] oral administration.  
One dose (2 mL) of RotaTeq is to be administered by [CONTACT_875034]’s mouth toward the inner cheek until dosing tube is empty. A residual drop may remain in the tip of the tube. 
Subjects must be kept under observation for 30 minutes aft er vaccination to ensure their safety, 
and any reactions during this period will be documented in the CRB. Appropriate medical 
equipment and emergency medications, including epi[INVESTIGATOR_238] (1:1000), must be available on site in the event of an anaphylactic, vasovagal, or other immediate allergic reaction.  
The procedures for preparing and administering RotaTeq are detailed in the package insert ( 35). 
[IP_ADDRESS] Dose Selection and Timing   
Subjects in Groups 5, 6, 7 and 8 (infants) will receive one dose of RotaTeq at D0 (V01), D60 (V02), and D120 (V03). 
6.2.[ADDRESS_1221996] 4   
M-M-R
II: Measles, Mumps, and Rubella Virus Vaccine Live ([COMPANY_006] Sharp & Dohme Corp., a 
subsidiary of [COMPANY_006] & Co., Inc., Whitehouse Station, NJ, [LOCATION_003])  
Form:    Liquid 
Dose:     0.5 mL  
Route:    SC 
Batch Number:  Commercial Lot 
[IP_ADDRESS] Composition   
Each 0.5 mL dose contains: 
Measles virus (derived from Ender’s Edmonston 
strain) propagated in chick embryo cell culture  not less than 1000 TCID
50* 
Mumps virus (Jeryl Lynn ™ [B level] strain) 
propagated in chick embryo cell culture not less than 
12 500 TCID
50* 
Rubella virus (Wistar RA 27/3 strain) propagated 
in WI-38 human diploid lung fibroblasts not less than 1000 TCID
50* 
*TCID 50 = tissue culture infectious doses 50%  
Other ingredients  
• sucrose, sodium citrate, sodium phosphate monobasic monohydrate, sodium hydroxide, 
polysorbate 80, cell culture media, trace amounts of fetal bovine serum 
[COMPANY_011]  Pasteur PSK00008  
515 – PNEUMOPCV Protocol  Version  6.0 
 
Confidential/Proprietary Information  
Page 79 of 126 [IP_ADDRESS] Preparation and Administration  
The general precautions of use are the same as those described for the study product in 
Section  [IP_ADDRESS] 
M-M-R II will be supplied as a vial of lyophilized vaccine and a vial of diluent for reconstitution to 
prepare a single dose (0.5  mL).  
One dose (0.5 mL) of M -M-R II is to be administered SC in the anterolateral area of the thigh or 
the outer aspect of the upper ar m. The site of injection is to be documented. The site of injection is 
to be prepared with a suitable antiseptic. After administration of the vaccine, the used syringe and needle are to be disposed of in accordance with currently established guidelines.  
Subjects must be kept under observation for 30 minutes after vaccination to ensure their safety, 
and any reactions during this period will be documented in the CRB. Appropriate medical equipment and emergency medications, including epi[INVESTIGATOR_238] (1:1000), must be available on site in the event of an anaphylactic, vasovagal, or other immediate allergic reaction.  
The procedures for preparing and administering M-M-R
II are detailed in the package insert (36). 
[IP_ADDRESS] Dose Selection and Timing   
Subjects in Groups 5, 6, 7 and 8 (infants) will receive one dose of M-M-R II at D300-390 (V05). 
6.2.[ADDRESS_1221997] 5   
VARIVAX: Varicella Virus Vaccine Live ([COMPANY_006] Sharp  & Dohme Corp., a subsidiary of [COMPANY_006] 
& Co., Inc., Whitehouse Station, NJ, [LOCATION_003])  
Form:    Liquid 
Dose:     0.5 mL  
Route:    SC 
Batch Number:  Commercial Lot 
[IP_ADDRESS] Composition   
Each approximately 0.5 mL dose contains: 
Live, attenuated Oka/[COMPANY_006] varicella virus  ........ at least 1350 plaque-forming units (PFU) 
Excipi[INVESTIGATOR_840]:  
Sucrose ........................................................................................................................ 25 mg Hydrolyzed gelatin  ................................................................................................... 12.5 mg 
Sodium chloride .......................................................................................................... 3.2 mg 
Monosodium L- glutamate  .......................................................................................... 0.5 mg 
Sodium phosphate dibasic ........................................................................................ 0.45 mg  
Potassium phosphate monobasic  .............................................................................. 0.08 mg 
Potassium chloride  .................................................................................................... 0.08 mg 
[COMPANY_011]  Pasteur PSK00008  
515 – PNEUMOPCV Protocol  Version  6.0 
 
Confidential/Proprietary Information  
Page 80 of 126 The vaccine contains residual components of MRC -5 cells including DNA and protein and trace 
quantities of sodium phosphate monobasic, EDTA, neomycin, and fetal bovine serum. The 
vaccine co ntains no preservative. 
[IP_ADDRESS] Preparation and Administration  
The general precautions of use are the same as those described for the study product in Section  [IP_ADDRESS] 
VARIVAX will be supplied as a vial of lyophilized vaccine and a vial of diluent for reconstitution to prepare a single dose (0.5 mL).  
One dose (0.5 mL) of VARIVAX is to be administered SC into the anterolateral area of the thigh or the outer aspect of the upper arm. The site of injection is to be documented. The site of injection will be prepared with a suitable antiseptic. After administration of the vaccine, the used syringe and needle were to be disposed of in accordance with currently established guidelines. 
Subjects must be kept under observation for 30 minutes after vaccination to ensure their safety, 
and any reactions during this period will be documented in the C RB. Appropriate medical 
equipment and emergency medications, including epi[INVESTIGATOR_238] (1:1000), must be available on site in the event of an anaphylactic, vasovagal, or other immediate allergic reaction.  
The procedures for preparing and administering VARIVAX are detailed in the package insert 
(37). 
[IP_ADDRESS] Dose Selection and Timing   
Subjects in Groups 5, 6, 7 and 8 (infants) will receive one dose of VARIVAX at D300-390 (V05). 
6.[ADDRESS_1221998], according to the applicable national regulation. Applicable local regulatory text will be included 
on the label for each country. 
The comparator vaccine (Prevnar  13) will be supplied as per the standard commercial packaging: 
the syr inge will retain the original commercial label and the carton will have a clinical label with a 
dose number and a detachable label.  Commercial lots of the routine pediatric vaccines (Pentacel, ENGERIX -B, RotaTeq, M-M-R
II, 
and VARIVAX) will be supplied by [CONTACT_35346], Inc. 
[COMPANY_011]  Pasteur PSK00008  
515 – PNEUMOPCV Protocol  Version  6.0 
 
Confidential/Proprietary Information  
Page [ADDRESS_1221999] Shipment, Storage, and Accountability   
[IP_ADDRESS] Product Shipment   
The Clinical Logistics Coordinator or designee will contact [CONTACT_29517] a designee to 
determine the dates and times of delivery of products.  
Each vaccine shipment will include a temperature- monitoring device to verify maintenance of the 
cold chain during transit. On delivery of the product to the site, the person in charge of product receipt will follow the instructions given in the Operating Guidelines, including checking that the cold chain was maintained during shipment (ie,, verification of the temperature reco rders). If there 
is an indication that the cold chain was broken, this person should immediately quarantine the product, alert the [COMPANY_011] Pasteur representative, and request authorization from [COMPANY_011] Pasteur to use the product. 
[IP_ADDRESS] Product Storage   
The Investigator will be personally responsible for product management or will designate a staff 
member to assume this responsibility.  
At the site, products must be kept in a secure place with restricted access. Vaccines will be stored in a refrigerator / freezer at a temperature ranging from:  
• +2°C to +8°C for Prevnar 13, SP0202, Pentacel, Hepatitis B, and RotaTeq 
• –50°C to +8°C for M-M-R
II 
• –50°C to –15°C or +2°C to + 8°C for VARIVAX (depending on locally approved monograph) 
They  should be protected from light. All vaccines but M -M-R II and VARIVAX, must not be 
frozen. The temperature must be monitored and documented (see the Operating Guidelines) for the entire time that the vaccine is at the study site. In case of accidental freezing or disruption of the cold chain, vaccines must not be administered and must be quarantined, and the Investigator or authorized designee should contact [CONTACT_875035]. 
[IP_ADDRESS] Product Accountability   
As the study is observer -blinded, the “unblinded study personnel” will be in charge of product 
management at the site and will maintain records of product delivery to the study site, product 
inventory at the site, the dose given to each subject, and the disposal of or return to the Sponsor of unused doses.  
The necessary information on the product labels is to be entered into the source document and the 
CRB. If  applicable, information may also be entered into the subject’s vaccination card. 
The Sponsor’s monitoring staff will verify the study site’s product accountability records against the record of administered doses in the CRBs and the communication from the IRT (if applicable).  
[COMPANY_011]  Pasteur PSK00008  
515 – PNEUMOPCV Protocol  Version  6.0 
 
Confidential/Proprietary Information  
Page [ADDRESS_1222000] during the study, the Investigator or an 
authorized designee should alert the [COMPANY_011] Pasteur representative as soon as possible, so that a shipment of extra doses can be arranged. 
6.3.3 Replacement Doses  
If a replacement dose is required (eg, because the syringe broke or particulate matter was 
observed in the syringe), the unblinded site personnel must either contact [CONTACT_875036], or follow the instructions given in the Operating Guidelines. 
6.3.[ADDRESS_1222001] accountability will be verified throughout the study period. 
6.3.5 Recall of Products   
If the Sponsor makes a decision to launch a retrieval procedure, the Investigator(s) will be 
informed of what needs to be done. 
6.4 Blinding and Code -breaking Procedures   
The study will be performed in an observer-blind fashion: 
• Investigators and study staff who conduct the safety assessment and the subject will not know 
which vaccine is administered  
• Only the study staff who prepare and administer  the vaccine and are not involved with the 
safety evaluation will know which vaccine is administered  
This study will be observer-blinded between any SP0202 formulation and Prevnar [ADDRESS_1222002] where only she / he has access.  
It is to be noted that the vaccinator will know whether the injected product is Prevnar 13 or one of 
the SP0202 formulations. However, she / he will not be able to tell the SP0202 formulations apart. 
The code may be broken in the event of an AE only when the identification of the vaccine 
received could influenc e the treatment of the subject. Code-breaking should be limited to the 
subject(s) experiencing the AE.  
The blind can be broken by [CONTACT_29517] a delegate through the IRT system, as explained in the code-breaking procedures described in the Operating Guidelines. Once the emergency has 
[COMPANY_011]  Pasteur PSK00008  
515 – PNEUMOPCV Protocol  Version  6.0 
 
Confidential/Proprietary Information  
Page [ADDRESS_1222003]’s code was broken. All contact [CONTACT_875037], and the code breaking CRF is to be completed. 
A request for the code to be broken may also be made:  
• By [CONTACT_875038] E2A. In this case, the code will be broken only for the subject(s) in question. The information resulting from code- breaking (ie, the subject’s vaccine 
or group assignment) will not be communicated to either the Investigator or the immediate team working on the study, except for the GPV representative.  
• By [CONTACT_875039].  
The IEC / IRB must be notified of the code-breaking. All documentation pertaining to the event must be retained in the site’s study records and in the [COMPANY_011] Pasteur files. Any intentional or unintentional code-breaking must be reported, documented, and explained, and the name [CONTACT_29562]. 
 
 An unblinded independent 
statistician will share unblinded outputs with the DMC members. The information will not be communicated to either the Investigator or the Sponsor study te am before the end of the Stage I 
and database lock. 
The detailed information related to DMC activities, including the planned frequency and scope of 
the meetings and reviews are described in the charter.  
If during the internal SMT review a further in -depth  review of the data and partial or full 
unblinding is required by [CONTACT_1034], it will be done by [CONTACT_875040]. 

[COMPANY_011]  Pasteur PSK00008  
515 – PNEUMOPCV Protocol  Version  6.0 
 
Confidential/Proprietary Information  
Page 84 of 126 6.5 Randomization and Allocation Procedures   
On the day of enrollment, subjects who meet the inclusion/exclusion criteria and sign the ICF will 
be randomly assigned to Groups  1 through 4 in a 1:1:1:[ADDRESS_1222004] approximatively 140 
subjects (35 subjects in each treatment group) for toddlers subjects (Stage I) or to Group 5 through 8 in a 1:1:1:[ADDRESS_1222005] approximatively 700 subjects (175 subjects in each treatment 
group) for infants subjects (Stage II). Stage II randomization will be at least stratified by [CONTACT_1606].  
Following DMC assessment, in case one or more of the SP0202 formulations may not be included in the stage II, the randomization list will match with the selected groups for stage  II; the sample 
size of each group will remain unchanged (175 subjects by [CONTACT_19313]) and the ratio between groups will be balanced.  
Site staff will connect to the IRT, enter the identification and security information, and confirm a 
minimal amount of data in response to IRT prompts. The IRT will randomize the subjects and 
then provide the vaccine assignment and have the site staff confirm it. The full detailed 
procedures for group allocation are described in the Operating Guidelines. If the subject is not eligible to participate in the study, then the information will only be recorded on the subject recruitment log.  
IRT will also be used to randomly allocate subject to the OPA subset in Stage II (around 125 infants by [CONTACT_19313]). This allocation has no impact on the study conduct on site; the list of selected subjects will be communicated to the laboratory personnel. 
Subject numbers that are assigned by [CONTACT_29515] a 12-digit string (a 3-digit country 
identifier, a [ADDRESS_1222006] identifier). The first digit of the 
subject identifier will be ‘1’ for tod dlers subjects randomized into Stage 1 and ‘2’ for infants 
subjects randomized into Stage 2. For example, Subject [ADDRESS_1222007] enrolled in Center Number 1 in the US in stage I (840 being the US country code), and Subject [ADDRESS_1222008] enrolled in Center Number 1 in the US (840 being the US country code). 

[COMPANY_011]  Pasteur PSK00008  
515 – PNEUMOPCV Protocol  Version  6.0 
 
Confidential/Proprietary Information  
Page 85 of 126 6.6 Treatment Compliance   
The following measures will ensure that the vaccine doses administered comply with those planned, 
and that any non- compliance is documented so that it can be accounted for in the data analyses:  
• All vaccinations will be administered by [CONTACT_9260] 
• The person in charge of product management at the site will maintain accountability records 
of product delivery to the study site, product inventory at the site, dose(s) given to each 
subject, and the disposal of unused or wasted doses 
6.7 Concomitan t Medications and Other Therapi[INVESTIGATOR_874997], ongoing medications and other therapi[INVESTIGATOR_014] (eg, blood products) should be recorded in the source document as well as new  medications prescribed for new medical 
conditions / AEs during study participation.  
Documentation in the CRB of ongoing concomitant medication(s) will be limited to specific 
categories of medication(s) of interest beginning on the day of first vaccinatio n. This may include 
medications of interest that were started prior to the day of vaccination.  
Reportable medications will be collected in the CRB from the day of each vaccination to the end of the solicited and unsolicited follow-up period.  
Reportable me dications include medications that impact or may impact the consistency of the safety 
information collected after any vaccination and/or the immune response to vaccination. Three 
standard categories of reportable medications are defined:  
• Category 1: medica tions impacting or that may have an impact on the evaluation of the safety 
(eg, antipyretics, analgesics, and non- steroidal anti- inflammatory drugs [NSAIDs], 
steroids/corticosteroids [therapy duration for less than 2 consecutive weeks])  
Note: Topi[INVESTIGATOR_441498] (Inhaled, otic, ophthalmic, nasal etc.) should not be captured or reported. 
 
• Category 2: medications impacting or that may have an impact on the immune response (eg, other vaccines [including influenza vaccine in the 2  weeks [14 days) preceding or following 
any study vaccination], blood products, antibiotic classes taken within 3 days [72 hours] prior to blood draw that may interfere with bioassays used by [CONTACT_875041], immune -suppressors, immune-modulators with immunosuppressive properties, 
anti-proliferative drugs such as DNA synthesis inhibitors, immune globulins preceding in the 3 months preceding any vaccination for infants) 
Note: Topi[INVESTIGATOR_8163] (Inhaled, otic, ophthalmic, nasal, etc.) should not be captured or reported.  
• Category 3: medic ations impacting or that may have an impact on both the safety and the 
immune response (eg, long- term systemic corticosteroid therapy [prednisone or equivalent for 
more than 2 consecutive weeks])  
Note: Topi[INVESTIGATOR_8826] (Inhaled, otic, ophthalmic, nasal etc.) should not be captured or reported. 
[COMPANY_011]  Pasteur PSK00008  
515 – PNEUMOPCV Protocol  Version  6.0 
 
Confidential/Proprietary Information  
Page 86 of 126 The information reported in the CRB for each reported medication will be limited to: 
• Trade name [INVESTIGATOR_8178] a medication composed of several molecules OR international nonproprietary 
name (INN) for a medication composed of one single molecule  
• Origin of prescription: prophylaxis Yes/No. Medication(s) prescribed for AE prophylaxis will be recorded in the Action Taken of the AE collection tables. 
• Medication category (1, 2, or 3) 
• Start and stop dates  
Dosage and administration route, homeopathic medication, topi[INVESTIGATOR_211251], as well as topi[INVESTIGATOR_2855], ophthalmic, and ear treatments will not be recorded. Topi[INVESTIGATOR_874998]; however, if they are applie d inadvertently to the vaccination site, 
they should be recorded as a Category 1 medication in this specific instance.  
Medications given in response to an AE will be captured in the “Action Taken” section of the AE CRF only. No details will be recorded in the concomitant medication CRF unless  the medication(s) 
received belongs to one of the prelisted categories. Medications will not be coded . 
7 Management of Samples   
Blood samples for the assessment of antibody responses will be collected at V01 and V02 for toddlers; at V01
a, V04, V05, and V06 for infants. See the Table of Study Procedures and 
Section  5.1.3 for details of the sampling schedule. 
7.1 Sample Collection   
At Visits that include a blood draw, 6  mL (at V01 and V02 for toddlers and at V04, V05 and V06 
for infants) and 3  mL (at V01 for infantsa) of blood will be collected in tubes provided by [CONTACT_875042]. Immediately prior to the blood draw, the staff member performing the procedure will verify the subject’s identity as well as the assigned subject’s number and sampling stage on the pre-printed label, and will attach the label to the tube. When vaccination and blood sample collection occur at the same visit and vaccine is given only in one of the arms, blood is to be taken from the limb opposite to the one that will be used for vaccination, if possible. 
Optional blood collection for routine screening tests (not part of study) for the US sites only  
The American Academy of Pediatrics (AAP) recommends blood lead screening as part of routine 
health supervision for children at 9 to 12 MoA and, if possible, again at 24 months of age. Further, the AAP recommends universal screening for anemia at approximately 12  MoA with 
determination of hemoglobin concentration and an assessment of risk factors associated with iron deficiency and iron deficient anemia ( 41). Children enrolled in this study will undergo routine 
screening outside of the study. Collection of blood for lead and anemia screening could be done at the same time as blood is drawn for the study immunologic assessment via the same venipuncture. This collection should be done in sample tubes which are not part of the study, and as per standard 
 
a Not applicable from protocol Version 5.0  
[COMPANY_011]  Pasteur PSK00008  
515 – PNEUMOPCV Protocol  Version  6.0 
 
Confidential/Proprietary Information  
Page 87 of 126 of care. The results of these tests will not be part of the study report. Blood collection for these 
screening tests could be done at any visit in the 2nd year of life, once for complete blood count (CBC) (1  mL) and twice for lead blood levels ([ADDRESS_1222009]).  
7.2 Sample Preparation  
Detailed instructions on how to prepare blood samples for assessment of immune response are contained in the Operating Guidelines provided to the site. An overview of the procedures is provided here. 
7.3 Sample Storage and Shipment   
During storage, serum tubes are to be kept in a freezer whose temperature is set and maintained at -20°C or below. The temperature will be monitored and documented on the appropriate form during the entire study. If it rises above -10°C for any period of time, the Clinical Logistics Coordinator must b e notified. See the Operating Guidelines for further details.  
Shipments to the laboratories will be made only after appropriate monitoring, and following notification of the Clinical Logistics Coordinator. Sera will be shipped frozen, using dry ice to main tain them in a frozen state, in the packaging container provided by [CONTACT_21440]. Again, 
temperatures will be monitored. Shipments must be compliant with the United Nations (UN) Class 6.2 specifications and the International Air Transport Association (IATA) 602 packaging instructions.  
Samples will be shipped to Global Clinical Immunology (GCI) at [COMPANY_011] Pasteur. The address is provided in the Operating Guidelines.  
Blood samples will be aliquoted at GCI.  
 
 
 

[COMPANY_011]  Pasteur PSK00008  
515 – PNEUMOPCV Protocol  Version  6.0 
 
Confidential/Proprietary Information  
Page 88 of 126 7.4 Future Use of Stored Biological Samples for Research   
Any unused part of the serum samples will be securely stored at the [COMPANY_011] Pasteur serology 
laboratory (GCI) for up to [ADDRESS_1222010]’s licensure and the potential revalidation of the study results. 
In addition, Subjects’ parents / guardians will be asked to indicate in the ICF whether they will 
permit the future use of any unused stored serum samples for other tests. If they refuse permission, the samples will not be used  for any testing other than that directly related to this 
study. If they agree to this use, they will not be paid for giving permission. Anonymity of samples will be ensured. The aim of any possible future research is unknown today, and may not be related to this particular study. It may be to improve the knowledge of vaccines or infectious diseases, or to improve existing tests or develop new tests to assess vaccines. Human genetic tests will never be performed on these samples without specific individual informed consent.  
8 Clinical Supplies   
[COMPANY_011] Pasteur will supply the study sites with protocols, ICFs, CRBs, SAE reporting forms, DCs/eDCs, MAs/eMAs, and other study documents, as well as with the following study materials: all study vaccines, blood collection tubes, cryotubes, cryotube storage boxes, cryotube labels, temperature recorders, shippi[INVESTIGATOR_35275], rulers, and digital thermometers.  
The means for performing Electronic Data Capture (EDC) will be defined by [CONTACT_35346]. If a computer is provided by [CONTACT_35346], it will be retrieved at the end of the study. 
The Investigator will supply all vaccination supplies, phlebotomy, and centrifugation equipment, 
including biohazard and / or safety supplies. The biohazard and safety supplies include needles and syringes, examination gloves, laboratory coats, sharps disposal containers, and absorbent countertop paper. The site will ensure that all biohazard wastes are autoclaved and disposed of in accordance with local practices. The Investigator will also supply appropriate space in a temperature -monitored refrigerator for the storage of the products and for the blood samples, and 
appropriate space in a temperature -monitored freezer for serum aliquots.  
In the event that additional supplies are required, study staff must contact [CONTACT_35346], indicating the quantity required. Contact [CONTACT_35347].  
[COMPANY_011]  Pasteur PSK00008  
515 – PNEUMOPCV Protocol  Version  6.0 
 
Confidential/Proprietary Information  
Page 89 of 126 9 Endpoints and Assessment Methods   
9.1 Primary Endpoints and Assessment Methods   
9.1.1 Safety   
[IP_ADDRESS] Safety Definitions   
The following definitions are taken from the ICH E2A Guideline for Clinical Safety Data 
Management: Definitions and Standards for Expedited Reporting.  
Adverse Event (AE):  
An AE is any untoward medical occurrence in a patient or in a clinical investigation subject administered a medicinal product and which does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product.  
Therefore an AE may be:  
• A new illness  
• The worsening of a pre- existing condition  
• An effect of the vaccination, including the comparator 
• A combination of the above 
All AEs include serious and non- serious AEs.  
Surgical procedures are not AEs; they are the actions taken to treat a medical condition. It is the 
condition leading to the action taken that is the AE (if it occurs during the study period). Pre-existing medical conditions are not to be reported as AEs. However, if a pre- existing medical 
condition worsens following study interventions in frequency or intensity, or if according to the 
Investigator there is a change in its clinical significance, this change should be reported as an AE (exacerbation). This applies equally to recurring epi[INVESTIGATOR_35276]-existing conditions (eg, asthma) if the frequency or intensity increases post -vaccination. 
Serious Adverse Event (SAE):  
Serious  and severe are not synonymous. The term severe is often used to describe the intensity of 
a specific event as corresponding to Grade 3. This is not the same as serious,  which is ba sed on 
subject / event outcome or action criteria usually associated with events that pose a threat to a subject’s life or functioning. Seriousness, not severity, serves as a guide for defining regulatory reporting obligations. 
An SAE is any untoward medical occurrence that at any dose  
• Results in death  
[COMPANY_011]  Pasteur PSK00008  
515 – PNEUMOPCV Protocol  Version  6.0 
 
Confidential/Proprietary Information  
Page 90 of 126 • Is life -threateninga 
• Requires inpatient hospi[INVESTIGATOR_35277] 
• Results in persistent or significant disability / incapacityc 
• Is a congenital anomaly / birth defect  
• Is an important medical event (IME)  
Medical and scientific judgment should be exercised in deciding whether expedited reporting 
is appropriate in other situations, such as IMEs that may not be immediately life -threatening 
or result in death or hospi[INVESTIGATOR_35278]. These IMEs should also usually be considered serious. Examples of such events include allergic bronchospasm requ iring intensive treatment in an emergency room or at home, blood 
dyscrasias or convulsions that do not result in inpatient hospi[INVESTIGATOR_059], or the development of drug dependency or drug abuse, new onset diabetes, or autoimmune disease. 
Adverse Reaction:  
All noxious and unintended responses to a medicinal product related to any dose should be 
considered adverse reactions (AR).  
(The phrase “responses to a medicinal product” means that a causal relationship between a medicinal product and an AE is at least a r easonable possibility) 
The following additional definitions are used by [CONTACT_35346]: 
Immediate Event/Reaction:  
Immediate events are recorded to capture medically relevant unsolicited systemic AEs (including 
those related to the product administered) that occur within the first 30 minutes after vaccination.  
Solicited Reaction:  
A solicited reaction is an “expected” adverse reaction (sign or symptom) observed and reported under the conditions (nature and onset) prelisted in the protocol and CRB (eg, injection site pain or headache occurring between D0 and D7 post- vaccination).  
By [CONTACT_108], solicited reactions are to be considered as being related to the product administered.  
For injectable vaccines, solicited reactions can either be solic ited injection site reactions or 
solicited systemic reactions.  
 
a  The term “life -threatening” refers to an event in which the subject was at risk of death at the time of the event; it 
does not refer to an event which hypothetically might have caused death if it were more severe.  
b  All medical events leading to hospi[INVESTIGATOR_167480], with the exception of: 
hospi[INVESTIGATOR_874999].  
c  “Persistent or significant disability or incapacity” means that there is a substantial disruption of a person’s ability 
to carry out normal life functions.  
[COMPANY_011]  Pasteur PSK00008  
515 – PNEUMOPCV Protocol  Version  6.0 
 
Confidential/Proprietary Information  
Page 91 of 126 Unsolicited AE / AR:  
An unsolicited AE is an observed AE that does not fulfill the conditions prelisted in the CRB in 
terms of diagnosis and/or onset window post-vaccination. For example, if he adache between D0 
and D7 is a solicited reaction (ie, prelisted in the protocol and CRB), then a headache starting on D7 is a solicited reaction, whereas headache starting on D8 post-vaccination is an unsolicited AE. Unsolicited AEs includes both serious (SAEs) and non- serious unsolicited AEs.  
Injection Site Reaction:  
An injection site reaction is an AR at and around the injection site. Injection site reactions are commonly inflammatory reactions. They are considered to be related to the product administere d. 
Systemic AE:  
Systemic AEs are all AEs that are not injection or administration site reactions. They therefore include systemic manifestations such as headache, fever, as well as localized or topi[INVESTIGATOR_29480] (eg, erythema that is localized but that is not occurring at the injection site).  
Adverse Event of Special Interest (AESI):  
An adverse event of special interest is one of scientific and medical concern specific to the Sponsor’s product or program, for which ongoing monitoring and rapid communication by [CONTACT_875043]. Such an event might warrant further investigation in order to characterize and understand it. Depending on the nature of the event, rapid communication by [CONTACT_29546] (eg,, regulators) might also be warranted. 
[IP_ADDRESS] Safety Endpoints   
The primary endpoints for the evaluation of safet y are:  
• Occurrence of any unsolicited systemic AEs reported in the 30 minutes after each and any 
injection of a SP0202 formulation or Prevnar 13, as applicable  
• Occurrence of solicited (ie, pre -listed in the subject’s DC / eDC and in the CRB) injection site 
reactions occurring up to D7 after each and any injection of a SP0202 formulation, 
Prevnar 13, or a concomitant pediatric vaccine, as applicable 
• Occurrence of solicited systematic reactions occurring up to D7 after each and any injection of a SP0202 formulation or Prevnar 13, as applicable  
• Occurrence of unsolicited (spontaneously reported) AEs up to 30 days after each and any 
injection of a SP0202 formulation or Prevnar 13, as applicable  
• Occurrence of SAEs and AESIs, throughout the study period 
Other endpoi nts will be recorded or derived as described in the statistical analysis plan. 
Depending on the item, these could include: nature (Medical Dictionary for Regulatory Activity 
[MedDRA] preferred term), time of onset, duration, number of days of occurrence, Grade of severity, relationship to vaccine, action taken, whether the AE led to early termination from the study, seriousness, or outcome. 
[COMPANY_011]  Pasteur PSK00008  
515 – PNEUMOPCV Protocol  Version  6.0 
 
Confidential/Proprietary Information  
Page 92 of 126 [IP_ADDRESS] Safety Assessment Methods  
At each visit,  the Investigator or a delegate will perform a clinical or medically -driven physical 
examination, and will ask the parent / guardian about any solicited reactions and unsolicited AEs 
recorded in the DC / eDC,, as well as about any other AEs that may have occurred since the previous visit. All relevant data will be transcribed into the CRB according to the instructions provided by [CONTACT_1034]. 
[IP_ADDRESS].[ADDRESS_1222011] -vaccination observation should be documented in the source document. Any AE 
that occurs during this period will be noted on the source document and recorded in the CRB, as follows:  
• Unsolicited systemic AEs will be recorded as immediate AEs in the CRB (presence marked as “yes” and details collected).  
• Solicited and unsolicited injection site reactions and solicited systemic reactions will be recorded in the CRB in the same way as any reactions starting on the day of vaccination.  
• SAEs will be recorded in the CRB and reported to the Sponsor in the same way as any other SAEs, according to the procedures described in Section  10. 
[IP_ADDRESS].2 Reacto genicity (Solicited Reactions From Day  0 to Day 7 After Each 
Vaccination)  
After each vaccination, subjects parents / guardians will be provided with a DC / eDC, a digital thermom eter, and a flexible ruler, and will be instructed how to use them. The following items 
will be recorded by [CONTACT_35349] 7 days (ie,, Day 0 through Day 7) until resolution: 
• Daily temperature, with the route by [CONTACT_35350] 
• Daily measurement or intensity grade of all other solicited injection site and systemic 
reactions  
• Action taken for each event (eg, medication) 
The action(s) taken by [CONTACT_875044]/or manage any solicited reactions  
will be classified in the CRB using the following list (all applicable items should be checked):  
• None 
• Medication  
• Health care provider contact  
• Hospi[INVESTIGATOR_057]  
• Discontinuation of study vaccination  
 
[COMPANY_011]  Pasteur PSK00008  
515 – PNEUMOPCV Protocol  Version  6.0 
 
Confidential/Proprietary Information  
Page 93 of 126 Subjects’ parents / guardians will be contact[CONTACT_5143] [ADDRESS_1222012] all safety information in the DC / eDC.  
If the timing of the telephone call should fall on a weekend or a holiday, the call should be made on the next business day. If contact [CONTACT_875045], study staff will continue calling until contact [CONTACT_58661]. Every telephone attempt and its outcome will be documented in the source document. 
Table  9.1 and Table  9.2 present, respectively, the injection site reactions and systemic reactions 
that are prelisted in the DC / eDC, and CRB, together with the intensity scales.  
[COMPANY_011]  Pasteur PSK00008  
515 – PNEUMOPCV Protocol  Version  6.0 
 
Confidential/Proprietary Information  
Page 94 of 126 Table  9.1: Sol icited injection site reactions: terminology, definitions, and intensity scales   
CRB term  
(MedDRA lowest 
level term [LLT])  Injection site tenderness  Injection site erythema  Injection site swelling  
Diary card term  Tenderness  Redness  Swelling  
Definition  Pain when the injection site is touched or injected limb mobilized Presence of a redness including the approximate point of needle entry Swelling at or near the injection site  
Swelling or edema is caused by a fluid infiltration in tissue or cavity and, depending on the space available for the fluid to disperse, swelling may be either soft 
(typi[INVESTIGATOR_897]) or firm (less typi[INVESTIGATOR_2855]) to touch and 
thus can be best described b y looking at the 
size of the swelling  
Intensity scale*  
 Grade 1: Minor reaction when injection site 
is touched  
Grade 2: Cries or protests when injection site 
is touched  
Grade 3 (CRB): Cries when injected limb is 
mobilized, or the movement of the injected limb is reduced  
Grade 3 (DC / eDC): Cries when injected 
limb is moved or the movement of the injected limb is reduced  Grade 1: > 0 to <  25 mm  
Grade 2: ≥ 25 to <  50 mm  
Grade 3: ≥ 50 mm Grade 1: > 0 to <  25 mm  
Grade 2: ≥ 25 to <  50 mm  
Grade 3: ≥ 50 mm 
*  For the subjective reaction of tenderness, parents /guardians will record the intensity level (Grade  1, 2, or 3) in the diary card. For the measurable reactions of redness and swelling, 
they will record just the size of the reaction, and the classif ication as Grade  1, 2, or 3 will be assigned at the time of the statistical analysis.  
 
[COMPANY_011]  Pasteur PSK00008  
515 – PNEUMOPCV Protocol  Version  6.0 
 
Confidential/Proprietary Information  
Page 95 of 126 Table  9.2: Solicited systemic reactions: terminology, definitions, and intensity scales   
CRB term 
(MedDRA lowest level term [LLT])
 Fever  
 Vomiting  Crying abnormal  Drowsiness  Appetite lost  Irritability 
Electronic diary card 
term  Temperature  Vomiting  Abnormal crying  Drowsiness  Loss of appetite  Irritability  
Definition  Elevation of 
temperature to ≥°38.0°C (≥ 100.4°F)  Vomiting does not include spi[INVESTIGATOR_875000] a determined reason  Reduced interest in surroundings, or increased sleepi[INVESTIGATOR_35282]: increased 
fussiness, whining, and 
fretfulness despi[INVESTIGATOR_875001]*  Grade  1:  
≥ 38.0°C to ≤  38.5°C  
or ≥ 100.4°F to ≤  101.3°F  Grade  1: 1 epi[INVESTIGATOR_35267] 
24 hours  Grade  1: < 1 hour Grade  1: Sleepi[INVESTIGATOR_654746]  1: Eating less 
than normal  Grade  1: Easily 
consolable  
 Grade  2: 
> 38.5°C to ≤  39.5°C  
or > 101.3°F to ≤ 103.1°F  Grade  2: 2–5 epi[INVESTIGATOR_11644] 24  hours  Grade  2: 1–3 hours  Grade  2: Not interested 
in surroundings or did 
not wake up for a feed / 
meal  Grade  2: Missed 1 or 2 
feeds / meals completely  Grade  2: Requiring 
increased attention  
 Grade  3: > 39.5°C  
or > 103.1°F  Grade  3: ≥ 6 epi[INVESTIGATOR_11644] 24  hours or 
requiring parenteral hydration Grade  3: > 3 hours  Grade  3: Sleepi[INVESTIGATOR_35285]  3: Refuses ≥ 3 
feeds / meals or refuses most feeds / meals  Grade  3: Inconsolable  
*  For all reactions but fever, parents /guardians will record the intensity level (Grade  1, 2, or 3) in the diary card. For fever, they will record the body temperature, and the 
classification as Grade  1, 2, or 3 will be assigned at the time of the statistical a nalysis based on the unit used to measure the temperature and the intensity scale.  
[COMPANY_011]  Pasteur PSK00008  
515 – PNEUMOPCV Protocol  Version  6.0 
 
Confidential/Proprietary Information  
Page 96 of 126 Important notes for the accurate assessment of temperature:  
Parents / guardians are to measure body temperature once per day, preferably always at the same 
time. The optimal time for measurement is the evening, when body temperature is the highest. Temperature is also to be measured at the time of any apparent fever. The observed daily temperature and the route of measurement are  to be recorded in the DC / eDC, and the highest 
temperature will be recorded by [CONTACT_35358]. The preferred route for this study is rectal. Pre-vaccination temperature is also systematically collected by [CONTACT_167540]. Tym panic thermometers must not be used. 
[IP_ADDRESS].3 Unsolicited Adverse Events  
In addition to recording solicited reactions, parents / guardians will be instructed to record any other medical e vents that may occur during the 30- day period after vaccination for toddlers / 
between the vaccination and the next visit for infants to be taken as per the study design. Space will be provided in the diary card for this purpose.  
Information on SAEs will be collected and assessed throughout the study, from inclusion (D0) 
until [ADDRESS_1222013] vaccination. Any SAE occurring at any time during the study will be reported by [CONTACT_35359]; this includes checking the “Serious” box on the AE CRF and completing the appropriate 
Safety Complementary Information CRFs. All information concerning the SAE is to be reported 
either as part of the initial reporting or during follow -up re porting if relevant information became 
available later (eg, outcome, medical history, results of investigations, copy of hospi[INVESTIGATOR_35286]). In case a subject experiences febrile convulsion (neurological event associating fever and seizure), the assessment will be performed according to the “Guideline for definition and collection of cases of febrile convulsion”, and this event will be considered an SAE. See Section  10 for further details on SAE reporting.  
For each unsolicited AE (whether serious or non-serious), the following information is to be recorded:  
• Start and stop dates
a  
• Intensity of the event: 
For measurable unsolicited AEs that are part of the list of solicited reactions, the  size of the 
AE as well as the temperature for fever will be collected and analyzed based on the 
corresponding scale used for solicited reactions (see Table  9.1 and Table  9.2).  
All other unsolicited AEs will be classified according to the following intensity scale:  
 
 
 
a  The stop date of all related AEs will  be actively solicited. For other events, the investigator will provide the stop 
date when it becomes available. AEs for which no stop date was obtained during the course of the study will be 
considered as ongoing at the end of the study. 
[COMPANY_011]  Pasteur PSK00008  
515 – PNEUMOPCV Protocol  Version  6.0 
 
Confidential/Proprietary Information  
Page 97 of 126 • Grade  1  
CRB: A type of adverse event that is usually transient and may require only minimal 
treatment or therapeutic intervention. The event does not generally  interfere with usual 
activities of daily living.  
DC / eDC: No interference with usual activities.  
• Grade  2  
CRB: A type of adverse event that is usually alleviated with additional therapeutic intervention. The event interferes with usual activities of daily living, causing discomfort but poses no significant or permanent risk of harm to the research participant.  
DC / eDC: Some interference with usual activities.  
• Grade  3 
CRB: A type of adverse event that interrupts usual activities of daily living, or significantly affects clinical status, or may require intensive therapeutic intervention.  
DC / eDC: Significant; prevents usual activities.  
• Whether the AE was related to the investigational product (for unsolicited systemic AEs) 
The Investigator will assess the causal relationship between the AE and the investigational product as either “Not related” or “Related”, as described in Section  [IP_ADDRESS].5. 
• Action taken for each AE (eg, medication)  
The action(s) taken by [CONTACT_875044]/or manage any unsolicited AEs will be classified in the CRB using the following list (all a pplicable items should be checked): 
• None 
• Medication  
• Health care provider contact  
• Hospi[INVESTIGATOR_057]  
• Discontinuation of study vaccination 
• Whether the AE was serious 
For each SAE, the Investigator will complete all seriousness criteria that apply (outcome, 
elapsed time, and relationship to study procedures) 
• Whether the AE caused study discontinuation 
[IP_ADDRESS].[ADDRESS_1222014] be done. The following AE will be captured as AESI throughout the study: 
• Anaphylaxis defined as per the Brighton collaboration case definition ( 42) 
• Convulsions including febrile convulsions 
• Hypotonic-hyporesponsive epi[INVESTIGATOR_1865] 
• Apnea 
[COMPANY_011]  Pasteur PSK00008  
515 – PNEUMOPCV Protocol  Version  6.0 
 
Confidential/Proprietary Information  
Page 98 of 126 Because of its medical importance and to ensure expedited communication to the Sponsor, these 
AESI are to be collected with the same level of information as SAE and reported to the Sponsor according to the procedure described in Section  10. Further instructions on the data collection for 
this event and the relevant definition will be provided in the Operating Guidelines.  
[IP_ADDRESS].[ADDRESS_1222015] administered as either not related  or related , based on the following 
definitions:  
Not related – The AE is clearly / most probably caused by [CONTACT_29549], therapeutic intervention, or concomitant therapy; or the delay between vaccination and the onset of the AE is incompatible with a causal relationship; or the AE started before the first vaccination (screening phase, if applicable)  
Related – There is a “reasonable possibility” that the AE was caused by [CONTACT_875046], meaning that there is evidence or arguments to suggest a causal relationship  
Note: By [CONTACT_559], all AEs reported at the injection site (whether solicited or unsolicited) and all solicited systemic AEs are considered to be related to the administered product and therefore 
are referred to as reactions and do not require the Investigator’s opi[INVESTIGATOR_125611]. 
Adverse events likely to be related to the product, whether serious or not, that persist at the end of 
the study will be followed up by [CONTACT_125630]’s condition. The Investigator will inform the Sponsor of the date of final disappearance of the event or the date of “chronicity” establishment.  
9.1.2 Immunogenicity   
[IP_ADDRESS] Immunogenicity Endpoints   
The primary endpoint(s) for the evaluation of immunogenicity are: 
Toddlers (1 dose)  
• Serotype specific IgG concentrations for all pneumococcal serotypes i ncluded in the SP0202 
formulations, as measured by [CONTACT_29492] -chemiluminescence assay (ECL) at baseline and [ADDRESS_1222016]- injection  
• Serotype specific IgG concentrations ratios (post -/pre-injection) for each pneumococcal 
serotype included in the SP0202 formulat ions, as measured by [CONTACT_875047] (3 doses for primary series + 1 dose as booster)  
• Percentage of subjects with serotype specific IgG concentration ≥ 0.35 µg/mL for each 
pneumococcal serotype included in the SP0202 formulations, as measured by [CONTACT_875013]3 
[COMPANY_011]  Pasteur PSK00008  
515 – PNEUMOPCV Protocol  Version  6.0 
 
Confidential/Proprietary Information  
Page 99 of 126 • Serotype specific IgG concentrations for all pneumococcal serotypes included in the SP0202 
formulations, as measured by [CONTACT_875048], PD3, before Dose 4, and at PD4 
• Serotype specific IgG concentrations ratios (PD3/pre -dose 1a and PD4/pre- dose 4) for each 
pneumococcal serotype included in the SP0202 formulations, as measured by [CONTACT_366469] 
[IP_ADDRESS] Immunogenicity Assessment Methods   
Pneumococcal capsular polysaccharide – electro -chemiluminescent assay (PnPS- ECL)  
This method will be performed on BL0001 and BL0002 collected from toddlers, and on BL0001a, 
BL0002, BL0003, and BL0004 collected from infants (See Table  9.3 and Table  9.4).  
9.1.3 Efficacy   
No clinical efficacy data will be obtained in the study.  
9.2 Secondary Endpoints and Assessment Methods   
9.2.1 Safety   
There are no secondary objectives for safety.  
 
a Not applicable from protocol Version 5.0  

[COMPANY_011]  Pasteur PSK00008  
515 – PNEUMOPCV Protocol  Version  6.0 
 
Confidential/Proprietary Information  
Page 100  of 126 9.2.2 Immunogenicity   
[IP_ADDRESS] Immunogenicity Endpoints   
[IP_ADDRESS].1 Immunogenicity of SP0202 or Prevnar 13  
Toddlers  
• Serotype specific OPA titers for all pneumococcal serotypes included in the SP0202 
formulations, as determined by [CONTACT_29490] (MOPA), at baseline, and [ADDRESS_1222017]- injection  
• Percentag e of subjects with serotype specific OPA titers ≥ lower limit of quantitation (LLOQ) 
for each pneumococcal serotype included in the SP0202 formulations, as determined by [CONTACT_29491], at baseline, and [ADDRESS_1222018]- injection  
• Serotype specific OPA titers ratio (post- /pre-injection) for each pneumococcal serotype 
included in the SP0202 formulations, as determined by [CONTACT_875016]  
• Serotype specific OPA titers for all pneumococcal serotypes included in the SP0202 formulations, as determined by [CONTACT_29491], at PD3, before Dose 4, and at PD4 
• Percentage of subjects with serotype specific OPA titers ≥ LLOQ for each pneumococcal serotype included in the SP0202 formulations, as determined by [CONTACT_29491], at PD3, before Dose 4, and at PD4 post- injection  
• Serotype specific OPA titers ratio (PD4/pre -dose 4) for each pneumococcal serotype included 
in the SP0202 formulations, as determined by [CONTACT_29491] 
[IP_ADDRESS].2 Immunogenicity of Concomitant Licensed Vaccines When Co -administered With 
SP0202 or Prevnar 13  
Toddlers 
Before vaccination (D0) in all subjects: 
• Anti-pertussis (pertussis toxoid / toxin [PT], filamentous hemagglutinin (FHA), pertactin 
[PRN], and fimbriae types 2 and 3[FIM]) Ab concentrations  
• Anti-polyribosyl- ribitol phosphate [PRP] Ab concentrations  
• Anti-PRP Ab concentrations ≥ 0.15 μg/mL  
• Anti- diphtheria toxoid Ab concentrations  
• Anti- tetanus toxoid Ab concentrations 
• Anti-poliovirus (types 1, 2, and 3) Ab titers 
One month post - vaccination (D30) in all subjects: 
• Anti-PRP A b concentrations 
[COMPANY_011]  Pasteur PSK00008  
515 – PNEUMOPCV Protocol  Version  6.0 
 
Confidential/Proprietary Information  
Page 101  of 126 • Anti-PRP Ab concentrations ≥ 0.15 µg/mL and ≥ 1.0 µg/mL  
• Anti-poliovirus (types 1, 2, and 3) Ab titers 
• Anti-poliovirus (types 1, 2, and 3) Ab titers ≥  1:8 
• Anti-pertussis (PT, FHA, PRN, and FIM) Ab concentrations  
• Anti-pertussis (PT, FHA, PRN, and FIM) vaccine response*  
* Pertussis vaccine response definition:  
• Pre-vaccination < LLOQ, then post- vaccination should be ≥  4x the LLOQ  
• Pre-vaccination ≥ LLOQ but < 4x the LLOQ, then post -vaccination should achieve a 
4-fold rise (post - vaccination/pre -vaccination ≥ 4)  
• Pre-vaccination ≥ 4x the LLOQ, then post -vaccination should achieve a 2 -fold response 
(post- vaccination/pre -vaccination ≥ 2) 
• Anti- diphtheria toxoid Ab concentrations  
• Anti-diphtheria toxoid Ab concentrations ≥ 0.1 IU/mL and ≥ 1.0 IU/mL  
• Anti- tetanus toxoid Ab concentrations 
• Anti-tetanus toxoid Ab concentrations ≥ 0.1 IU/mL and ≥ 1.0 IU/mL  
Infants  
Before first vaccination in al l subjects (D0)a: 
• Anti-rotavirus serum immunoglobulin (Ig) A Ab concentrations 
• Anti-pertussis (PT, FHA, PRN, and FIM) Ab concentrations 
• Anti- diphtheria toxoid Ab concentrations  
• Anti- tetanus toxoid Ab concentrations 
One month after 6  MoA vaccination (D150) in all subjects:  
• IgG Abs against hepatitis B surface antigen concentration ≥ 10 mIU/mL and ≥  100 mIU/mL  
• Anti-PRP Ab concentrations 
• Anti-PRP Ab concentrations ≥ 0.15 µg/mL and ≥ 1.0 µ g/mL  
• Anti-poliovirus (types 1, 2, and 3) Ab titers 
• Anti-rotavirus seru m IgA Ab concentrations 
• Anti-rotavirus serum IgA Ab concentrations with ≥  3-fold rise over baselinea 
• Anti-pertussis (PT, FHA, PRN, and FIM) Ab concentrations  
• Anti- diphtheria toxoid Ab concentrations  
• Anti-diphtheria toxoid Ab concentrations  ≥ 0.01 IU/mL and ≥ 0.1 IU/mL  
• Anti- tetanus toxoid Ab concentrations 
• Anti-tetanus toxoid Ab concentrations  ≥ 0.01 IU/mL and ≥ 0.1 IU/mL  
 
a Not applicable from protocol Version 5.0  
[COMPANY_011]  Pasteur PSK00008  
515 – PNEUMOPCV Protocol  Version  6.0 
 
Confidential/Proprietary Information  
Page 102  of 126 One month after 12- 15 MoA vaccination (D330-D420) in all subjects: 
• Anti-measles Ab concentrations  
• Anti-measles Ab concentration s ≥ 255 mIU/mL  
• Anti-mumps Ab concentrations 
• Anti-mumps Ab concentrations ≥ 10 mumps Ab U/mL  
• Anti-rubella Ab concentrations 
• Anti-rubella Ab concentrations ≥ 10 IU/mL  
• Anti-varicella Ab concentrations 
• Anti-varicella Ab concentrations ≥ 5 glycoprotein enzyme -linked immunosorbent assay 
(gpELISA) units/mL  
[IP_ADDRESS] Immunogenicity Assessment Methods   
A summary of the tests conducted per time point for toddlers and for infants is provided in 
Table  9.[ADDRESS_1222019] carried out for primary endpoints 
(ie, PnPS- ECL).  
The tests are presented by [CONTACT_875049] (from highest to lowest).  
Table  9.3: Summary of tests per time point in toddlers   
Tests  BL0001  BL0002  
PnPS -ECL  X X 
MOPA  X X 
Anti-Diphtheria, Tetanus, and Pertussis Antibodies  X X 
Anti-Haemophilus influenza  type b (Anti -PRP) Antibodies  X X 
Anti-Polio (types 1, 2, and 3) Antibodies  X X 
Table  9.4: Summary of tests per time point in infants   
Tests  BL0001*  BL0002  BL0003  BL0004  
PnPS -ECL  X X X X 
MOPA   X X X 
Anti-Diphtheria, Tetanus, and Pertussis Antibodies  X X   
Anti-Haemophilus influenza type b (Anti -PRP) 
Antibodies   X   
Anti-Polio (types 1, 2, and 3) Antibodies   X   
Anti-HB antibodies   X   
Anti-Rotavirus IgA Antibodies  X X   
Anti-Measles Antibodies     X 
Anti-Mumps Antibodies     X 
Anti-Rubella Antibodies     X 
Anti-Varicella Antibodies     X 
* Not applicable from protocol Version 5.0  
[COMPANY_011]  Pasteur PSK00008  
515 – PNEUMOPCV Protocol  Version  6.0 
 
Confidential/Proprietary Information  
Page 103  of 126 Multiplexed opsonophagocytic killing assay (MOPA) 
 
This method will be performed on BL0001 and BL0002 collected from toddlers, and on BL0002, 
BL0003 and BL0004 collected from a subset of infants.  
Anti-Diphtheria, Tetanus, and Pertussis Antibodies  
This method will be performed on BL0001 and BL0002 collected from both toddlers and infants.  
Anti-Haemophilus influenza type b (Anti- PRP) Antibodies  

[COMPANY_011]  Pasteur PSK00008  
515 – PNEUMOPCV Protocol  Version  6.0 
 
Confidential/Proprietary Information  
Page 104  of 126 Thi
s method will be performed on BL0001 and BL0002 collected from toddlers and on BL0002 
from infants.  
Anti-Polio (types 1, 2, and 3) Antibodies 
Thi
s method will be performed on BL0001 and BL0002 collected from toddlers and on BL0002 
from infants.  
Anti-Rotavirus IgA Antibodies 
This method will be performed on BL0001 and BL0002 collected from infants. 
Anti-Hepatitis B Antibodies  
The assay for measuring anti -HB antibodies will be performed at GCI, [COMPANY_011] Pasteur, 
Swiftwater, PA, [LOCATION_003].  

[COMPANY_011]  Pasteur PSK00008  
515 – PNEUMOPCV Protocol  Version  6.0 
 
Confidential/Proprietary Information  
Page 105  of 126 Thi
s method will be performed on BL0002 collected from infants. 
Anti-Measles Antibodies  
This method will be performed on BL0004 collected from infants. 
Anti-Mumps Antibodies  

[COMPANY_011]  Pasteur PSK00008  
515 – PNEUMOPCV Protocol  Version  6.0 
 
Confidential/Proprietary Information  
Page 106  of 126 Thi
s method will be performed on BL0004 collected from infants. 
Anti-Rubella Antibodies 
T
his method will be performed on BL0004 collected from infants. 
Anti-Varicella Antibodies 
This method will be performed on BL0004 collected from infants. 

[COMPANY_011]  Pasteur PSK00008  
515 – PNEUMOPCV Protocol  Version  6.0 
 
Confidential/Proprietary Information  
Page [ADDRESS_1222020] 
document all SAEs regardless of causal relationship, and notify the Sponsor and the Clinical 
Research Associate (CRA) within the notification timelines stated in the following sections. The Investigator will give access and provide the Sponsor and the CRA with all necessary information to allow the Sponsor to conduct a detailed analysis of the safety of the investigational product(s). It is the responsibility of the Investigator to request all necessary documentation (eg, medical records, disch arge summary) in order to provide comprehensive safety information. All relevant 
information must then be transcribed onto the AE CRF and the appropriate Safety Complementary Information CRFs.  
10.[ADDRESS_1222021]’s participation in the study or experiment must be reported within 24 hours to the Sponsor’s GPV Department and to the CRA. Every SAE must be reported, e ven if the Investigator considers that it is not related to the vaccine. The Investigator 
(licensed physician [M.D. or D.O.]) must validate the information entered on the AE CRF by [CONTACT_167543].  
The Investigator must indicate on the AE CRF that the event was serious and must complete the 
relevant SAE section of this form as well as the appropriate Safety Complementary Information CRFs. An e -mail alert will automatically be sent by [CONTACT_167544], the 
CRA, an d the RMO  with relevant SAE information details.  
If the EDC system is unavailable, the site must notify the Sponsor, using the paper version of the CRB, as described in the operating guidelines. 
The Investigator must complete the paper copi[INVESTIGATOR_875002] <one of> the following 
means:  
• By [CONTACT_6791], to the following number: [PHONE_425] 
• In PDF format to the following e -mail address, using a method of transmission that 
includes password protection: [EMAIL_16606] 
[COMPANY_011]  Pasteur PSK00008  
515 – PNEUMOPCV Protocol  Version  6.0 
 
Confidential/Proprietary Information  
Page 108  of 126 • By [CONTACT_29554], to the following address:  
[COMPANY_011] Pasteur Inc.  
Reception and Triage – Case Management  
Global PharmacoVigilance Mail Drop: 45D38 Discovery Drive Swiftwater, PA [ADDRESS_1222022] be updated within 24 hours after the Investigator has become aware of any new relevant information concerning the SAE (eg, outcom e, precise 
description of medical history, results of the investigation). All relevant information must be included directly in the AE CRF and the appropriate Safety Complementary Information CRFs . 
An e -mail alert will be sent automatically to the GPV Depa rtment and to the CRA. Copi[INVESTIGATOR_167488] (eg, medical records, discharge summary, autopsy) may be requested by [CONTACT_167545].  
The anonymity of the subject must always be respected when forwarding this information. 
10.[ADDRESS_1222023](s), other products (eg, a benefit vaccine), or to the experiment must also be reported as soon as possible. In such a case, the reporting procedure to be followed is identical to that described in Section  10.1. 
10.[ADDRESS_1222024] administered will be 
evaluated by [CONTACT_344223]  [IP_ADDRESS].5. 
Following this, the Sponsor’s Global Safety Officer will also assess the causal relationship to the product, based on the available information and current medical knowledge. 
The causal relationship to study procedures will be also assessed in the CRB. The decision to modify or discontinue the study may be made after mutual agreement between the 
Sponsor and the Investigator(s).  
[COMPANY_011]  Pasteur PSK00008  
515 – PNEUMOPCV Protocol  Version  6.0 
 
Confidential/Proprietary Information  
Page 109  of 126 10.5 Reporting SAEs to Health Authorities and IECs / IRBs   
The Sponsor will inform the relevant health authorities of any reportable SAEs according to the 
local regulatory requirements. Reporting to the health authorities will be according to the Sponsor’s standard operating procedures. 
The Sponsor will notify the Investigators in writing of the occurrence of any reportable SAEs. 
The Investigators will be responsible for informing the IECs or IRBs that reviewed the study protocol. 
11 Data Collection and Management   
11.1 Data Collection and CRB Completion   
Individual DCs/eDCs, specifically designed for this study by [CONTACT_654778], will be given to study participants for the recording of daily safety information as described in Section  [IP_ADDRESS]. These DCs/eDCs will include prelisted terms and intensity scales 
(see Table  9.1 and Table  9.2) as well as areas for free text to capture additional safety informat ion 
or other relevant details. Parents or guardians will also be provided with rulers for measuring the size of injection site reactions, and with standard digital thermometers for measuring daily temperatures. To ensure consistency of reporting, the study sites will instruct parents / guardians on how to correctly use these tools.  
The 6 -month follow-up will be done by [CONTACT_35372]’ parent / guardian either during a 
visit or over the telephone using a questionnaire to capture SAEs and AESIs, if applicable. A 
memory aid may be provided to the subjects’ parent / guardian at the preceding visit to help them record information on events occurring between this visit and the 6- month follow -up. 
Relevant information will be transcribed into the AE CRF. Any SAEs captured during the 6-month follow -up period will be reported and followed- up as per the normal process for 
reporting SAEs. 
At specified intervals, the Investigator or an authorized designee will interview the parents / 
guardians to collect the information recorded in the DC / eDC, and will attempt to clarify anything that is incomplete or unclear. All clinical study information gathered by [CONTACT_875050] a web- based CRB.  (Any 
information that was not documented in the DC / eDC will first be captured in the source document and then reported electronically.) The CRB has been designed specifically for this study under the responsibility of the Sponsor, using a validated Elec tronic Records / Electronic 
Signature- compliant platform (21 CFR Part 11).  
To ensure the correct and consistent completion of the CRBs, the Sponsor or authorized representative will provide all necessary tools, instructions, and training to all site staff involved in data entry prior to study start. Additional instructional documents such as training manuals and completion instructions will be provided to assist with data entry during the course of the study. 
[COMPANY_011]  Pasteur PSK00008  
515 – PNEUMOPCV Protocol  Version  6.0 
 
Confidential/Proprietary Information  
Page [ADDRESS_1222025]; the username [CONTACT_35395] a previous user may not be reissued. If any study personnel leave the study, the Investigator is responsible for informing the Sponsor immediately so that their access is deactivated. An audit trail will be initiated in the EDC system at the time of the first data entry to track all modifications and ensure database integrity. 
The Investigator is responsible for the timeliness, completeness, and accuracy of the information 
in the CRBs; must provide explanations for all missing information; and must sign the CRB using an e- signature.  
11.2 Data M anagement   
Management of SAE Data 
During the study, SAE data (reported on the AE, Death, and Safety Complementary Information 
CRFs) will be integrated into the Sponsor’s centraliz ed GPV database upon receipt of these forms 
and after a duplicate check. Each case will be assigned a case identification number. Each case will be assessed by [CONTACT_35375]. The assessment of related cases will be done in collaboration with the Global Safety Officer and the RMO. Follow -up information concerning a completed case 
will be entered into the GPV database, and a new version of the case will be created.  
The information from the GPV database cases will be reconciled with that in the clinical database.  
Management of Clinical and Laboratory Data 
Clinical data, defined as all data reported in the CRB, and laboratory data will be handled by [CONTACT_429]’s Clinical Data Management (CDM) platform or authorized representative.  
During the study, clinical data reported in the CRBs will be integrated into the clinical database under the responsibility of the [COMPANY_011] Pasteur CDM platform. Data monitoring at the sites and 
quality control in the form of computerized logic and / or consistency checks will be 
systematically applied to detect errors or omissions. In addition, data reviews may be performed several times by [CONTACT_1034]’s staff in the course of the study. Any questions pertaining to the reported clinical data will be submitted to the Investigator for resolution using the EDC system. Each step of this process will be monitored through the implementation of individual passwords to maintain appropriate data base access and to ensure database integrity.  
The validation of the immunogenicity data will be performed at the laboratory level following the laboratory’s procedures. Information from the laboratory will be checked for consistency before integration into the clinical Datawarehouse.  
After integration of all corrections in the complete set of data, and after the SAE information available from CDM and the GPV Department has been reconciled, the database will be released for statistical analysis.  
[COMPANY_011]  Pasteur PSK00008  
515 – PNEUMOPCV Protocol  Version  6.0 
 
Confidential/Proprietary Information  
Page [ADDRESS_1222026] 
will be performed, the goal of which is to allow for a cautious, ste pwise approach to vaccine 
administration prior to proceeding to Stage II.  
A blinded review of the data is anticipated through the data review process led by [CONTACT_875051].   
12 Statistical Methods and Determination of Sample Size   
12.1 Statistical Methods   
For immunogenicity data, assuming that log10 transformation of the titers / concentrations and titers / concentrations ratio follows a normal distribution, first, the mean and 95% confidence intervals (CIs) will be calculated on log10 (titers / concentrations; titers / concentrations ratio) using the usual calculation for normal distribution, then antilog transformations will be applied to the results of calculations, to compute geometric mean titers / concentrations (GMTs / GMCs) and geometric mean of the individual titer / concentration ratios (GMTRs / GMCRs) and their 95% CIs.  
The 95% CIs of point estimates will be calculated using the exact binomial distribution (Clopper-Pearson method ( 43)) for proportions.  
12.1.1 Hypotheses and Statistical Methods for Primary Objective(s)  
[IP_ADDRESS] Hypotheses   
All analyses will be descriptive; no hypothesis will be tested.  
[IP_ADDRESS] Statistical Methods   
Safety  
Safety results will be analyzed for subjects in the safety analysis set (SafAS) who at least received one of the vaccines. The main parameters will be described with 95% CI. At least the following parameters will be presented by [CONTACT_875052]/any vaccination(s) as applicable:  
• Immediate unsolicited systemic AEs  
• Solicited injection site reactions and solicited systemic reactions occurring within 7 days after 
the day of injection (D0 to D7) according to occurrence, time to onset, intensity (Grade 1, 
Grade 2, or Grade 3), number of days of occurrence and action taken  

[COMPANY_011]  Pasteur PSK00008  
515 – PNEUMOPCV Protocol  Version  6.0 
 
Confidential/Proprietary Information  
Page 112  of 126 • Unsolicited AEs occurring within 30 days after injection by [CONTACT_9313] (SOC) and PT, 
relationship, intensity, time to onset, and duration 
• All SAEs that occur throughout the study by [CONTACT_3592], relationship and seriousness criteria 
• All AESIs rep orted throughout the study by [CONTACT_875053] - Stage I toddlers  
The point estimates and their 95% CI of the following parameters will be presented for each group before and 1-month post- vaccination for each pneumococcal serotype specific IgG 
concentrations:  
• GM of serotype specific concentrations 
• GM of concentrations ratio (post- / pre-vaccination) 
Immunogenicity – Stage II infants  
The point estimates and their 95% CI of the following parameters will be presented for each group before and 1-month post- vaccination for each pneumococcal serotype specific IgG 
concentrations:  
• Percentage of subjects with a PD3 and PD4 serotype specific IgG concentrations 
≥ 0.35 µg/mL  
• GM of serotype specific concentrations / titers (pre-dose 1
a, PD3, pre-dose 4, PD4) 
• GM of serotype specific concentrations / titers ratio (PD3/pre -dose 1a, PD4/pre- dose 4)  
In addition, difference between any SP0202 formulations and Prevnar 13 groups, in term of 
percentages of subjects with serotype specific IgG concentration ≥ 0.35 µg/mL and 95%CI at PD3, as well of GM ratio between groups and 95%CI at PD3 and PD4, may be also presented.  
CIs of the difference of proportions between 2 groups will be computed using the Wilson Score 
method without continuity correction. CIs of ratio of GMTs / GMCs between 2 groups will be computed from the difference in means of log10 transformed titers/concentrations between 2 groups with normal approximation. 
RCDCs of individual concentrations / titers will be presented for all serotyp es. Further analyses 
may be described in the Statistical Analysis Plan (SAP).  
 
a Not applicable from protocol Version 5.0  
[COMPANY_011]  Pasteur PSK00008  
515 – PNEUMOPCV Protocol  Version  6.0 
 
Confidential/Proprietary Information  
Page 113  of 126 12.1.2 Hypotheses and Statistical Methods for Secondary Objective(s)   
[IP_ADDRESS] Hypotheses   
[IP_ADDRESS] Statistical Methods   
[IP_ADDRESS].1 Stage I toddlers  
Immunogenici ty of SP0202 or Prevnar 13  
The point estimates and their 95% CI of the following parameters will be presented for each 
group before and 1-month post- vaccination for pneumococcal serotype specific OPA titers:  
• GM of serotype specific titers, GM of titers ra tio (post - / pre-vaccination) 
• Percentage of subjects with a serotype specific titers above or equal to LLOQ  
Immunogenicity of concomitant vaccine  
The point estimates and their 95% CI of the following parameters will be presented for each group before and 1-month post- vaccination for Pentacel antigens:  
• GM of concentrations / titers for all antigens  
• Percentage of subjects with concentration / titer above predefined threshold, including those defining seroprotection 
• Vaccine response for pertussis (PT, FHA, PRN, and FIM) antigens 
[IP_ADDRESS].2 Stage II infants   
Immunogenicity of SP0202 or Prevnar 13 
The point estimates and their 95% CI of the following parameters will be presented for each 
group in the OPA subset and for each pneumococcal serotype specific OPA titers: 
• Percentage of subjects with a PD3 and PD4 serotype specific titers above or equal to LLOQ 
• GM of serotype specific titers (PD3, pre- dose 4, PD4)  
• GM of serotype specific titers rat io (PD4/pre-dose 4) 
Immunogenicity of concomitant vaccines:  
The point estimates and their 95% CI of the following parameters will be presented for each 
group for concomitant vaccines (Pentacel, ENGERIX -B, RotaTeq, M-M- RII, and VARIVAX) 
antigens:  
[COMPANY_011]  Pasteur PSK00008  
515 – PNEUMOPCV Protocol  Version  6.0 
 
Confidential/Proprietary Information  
Page 114  of 126 • GM of concentrations / titers for all antigens (at pre -Dose  1a for RotaTeq and diphteria, 
tetanus, and Pertussis antigens, at PD3 for ENGERIX-Bb, RotaTeq, and Pentacel; at PD4 for 
M-M- RII and VARIVAX)  
• Percentage of subjects with concentrations / titers above predefined thresholds, including 
those defining seroprotection (at PD3 and PD4 as applicable) 
For all immunogenicity analyses, RCDCs of individual concentrations / titers will be presented for all serotypes / antigens.  
Further analyses may be described in the SAP.  
12.2 Analysis Sets   
12.2.1 Full Analysis Set   
Three FAS will be defined: one for Toddlers (FAS1), one for Infants at Primary series (ie, after 3 doses) (FAS2) and one for Infants at Booster (FAS3): 
• The full analysis set (FAS)1 – Toddlers: is defined as the subset of randomized subjects to 
Groups [ADDRESS_1222027]-
vaccination blood sample result (serotype specific IgG concentration or serotype specific OPA titer for at least 1 serotype, or titer/concentration for at least one antigen on the concomitant vaccines)  
• The FAS2 – Infants: is defined as the subset of randomized subjects to Groups [ADDRESS_1222028] -primary 
series vaccination blood sample result (serotype specific IgG concentration or serotype specific OPA titer fo r at least 1 serotype, or titer/concentration for at least one antigen on the 
concomitant vaccines)   
• The FAS3 – Infants: is defined as the subset of randomized subjects to Groups [ADDRESS_1222029]-booster 
vaccination blood sample result (serotype specific IgG concentration or serotype specific OPA titer for at least 1 serotype, or titer/concentration for at least one antigen on the concomitant vaccines)   
12.2.2 Safety Analysis Set  
The safety analysis set (SafAS) is defined as those subjects who have received at least one dose of  
the study vaccines and have any safety data available. All subjects will have their safety analyzed after each dose according to the vaccine they actually received, and after any dose according to the vaccine received at the 1st dose.  
 
a Not applicable from protocol Version 5.0  
b Immunogenicity to ENGERIX -B will be presented according to the number of doses received  
[COMPANY_011]  Pasteur PSK00008  
515 – PNEUMOPCV Protocol  Version  6.0 
 
Confidential/Proprietary Information  
Page 115  of 126 Safety data recorded  for a vaccine received out of the protocol design will be excluded from the 
analysis (and listed separately).  
12.2.3 Per-Protocol Analysis Set   
The per-protocol analysis set (PPAS) is a subset of the FAS. Three PPAS will be defined: one for 
Toddlers (PPAS1), one for Infants at Primary series (PPAS2) and one for Infants at Booster 
(PPAS3).  
The subjects presenting with at least one of the following relevant protocol deviations will be excluded from the PPAS1-Toddlers: 
• Subject did not meet all protocol- specified inclusion criteria or met at least one of the 
protocol- specified exclusion criteria  
• Subject did not receive vaccine  
• Subject received a vaccine other than the one that he / she was randomized to receive 
• Preparation and / or administration of vaccine was not done as per-protocol 
• Subject did not provide the post-dose serology sample V02 in the proper time window or a post-dose serology sample was not drawn 
• Subject received a protocol -prohibited medication or vaccine (identified among category 2 
and 3, see Section  6.7) 
In addition to the reasons listed above, subjects will also be excluded from the PPAS1 if their V02 serology sample did not produce a valid serotype specific IgG test result (ie, results for all serotypes are missing).  
The subjects presenting with at least one of the following relevant protocol deviations will be excluded from the PPAS2 Infants Primary series:  
• Subject did not meet all protocol- specified inclusion criteria or met at least one of the 
protocol- specified exclusion criteria  
• Subject did not complete the vaccination schedule 
• Subject received a vaccine schedule other than the one that he / she was randomized to receive  
• Preparation and / or administration of vaccine was not done as per-protocol 
• Subject did not receive vaccine in the proper time window 
• Subject did not provide the post-dose serology sample V04 in the proper time window or a 
post-dose serology sample was not drawn 
• Subject received a protocol -prohibited medication or vaccine (identified among category 2 
and 3, see Section  6.7) 
In addition to the reasons listed above, subjects will also be excluded from the PPAS2 if their V04 
serology sample did not produce a valid serotype specific IgG test result (ie, results for all serotypes are missing).  
[COMPANY_011]  Pasteur PSK00008  
515 – PNEUMOPCV Protocol  Version  6.0 
 
Confidential/Proprietary Information  
Page [ADDRESS_1222030] one of the following relevant protocol deviations will be 
excluded from the PPAS3- Infants Booster dose:  
• Subject did not meet all protocol- specified inclusion criteria or met at least one of the 
protocol-specified exclusion criteria  
• Subject did not complete the vaccination schedule 
• Subject received a schedule other than the one that he / she was randomized to receive  
• Preparation and / or administration of vaccine was not done as per-protocol 
• Subject did not receive booster vaccine in the proper time window, ie, at 12-[ADDRESS_1222031] at V03 +180 days (±14) 
• Subject did not provide the post-dose serology sample V06 in the proper time window or a post-dose serology sample was not drawn 
• Subject received a protocol -prohibited medication or vaccine (identified among category 2 
and 3, see Section  6.7) 
In addition to the reasons listed above, subjects will also be excluded from the PPAS3 if their V06 serology sample did not produce a valid serotype specific IgG test result (ie, results for all serotypes are missing).  
The list can be completed at the time of SAP writing and before database lock. 
In the event of a local or national immunization program with a pandemic influenza vaccine or a 
COVID- 19 vaccine, subjects who receive pandemic influenza vaccine or COVID -19 vaccine at 
any time during the study will not be withdrawn from the study. 
12.2.4 Populations Used in Analyses   
The primary and secondary immunogenicity analyses will be performed on the PPAS (PPAS1, 
PPAS2, PPAS3) analysis set and the FAS (FAS1, FAS2, and FAS3). In the FAS, subjects will be analyzed by [CONTACT_394304]. 
The safety analysis will be performed on the SafAS. Subjects will be analyzed according to the 
vaccine they actually received.  
12.[ADDRESS_1222032] or search for outliers will be performed.  
[COMPANY_011]  Pasteur PSK00008  
515 – PNEUMOPCV Protocol  Version  6.0 
 
Confidential/Proprietary Information  
Page 117  of 126 For the calculation of GMTs / GMCs and percentage above cut -offs, any pre -vaccination or 
post-vaccination value reported as < LLOQ will be converted to a value of 0.5 LLOQ.  
For the calculation of GMTR / GMCR, any pre- vaccination value reported as < LLOQ will be 
converted to LLOQ, and any post-vaccination value reported as < LLOQ will be converted to a 
titer of 0.5 LLOQ when only either the numerator or the denominator is < LLOQ. If both numerator and denominator are < LLOQ, then both will be converted in the same way so that the increa se is defined as 1.  
Any value reported as > ULOQ (upper limit of quantitation) will be converted to ULOQ. 
12.4 Interim / Preliminary Analysis   
Early Safety data Review 
 
 
 
 
The DMC review will be in an unblinded manner and the Sponsor SMT review will be blinded. The DMC reports will be provided by [CONTACT_875054]’t be communicated to the Sponsor. 
Statistical analysis  

[COMPANY_011]  Pasteur PSK00008  
515 – PNEUMOPCV Protocol  Version  6.0 
 
Confidential/Proprietary Information  
Page 118  of 126 12.5 Determin ation of Sample Size and Power Calculation   
The number of subjects is designed to provide immunogenicity and safety data on the 3 SP0202 
formulations and on Prevnar 13 after each and any injection, as applicable in toddlers, and infants. 
The sample size was set at 35  subjects per group (140 toddlers) in Stage I and 175 subjects per 
group (700 infants) in Stage II. Assuming a drop -out rate of approximatively 10% in the toddlers, 
20% (PD3) and 30% (PD4) in infants, a total of 31, 140, and 122 evaluable subjects per group is 
anticipated for toddlers, infants at PD3, and infants at PD4, respectively. 

[COMPANY_011]  Pasteur PSK00008  
515 – PNEUMOPCV Protocol  Version  6.0 
 
Confidential/Proprietary Information  
Page 119  of 126 13 Ethical and Legal Issues and Investigator / Sponsor Responsibilities   
13.[ADDRESS_1222033] of the Study / Good Clinical Practice   
The conduct of this study will be consistent with the standards established by [CONTACT_875055] c ompliant with the ICH guidelines for GCP as well as with all local and / or national 
regulations and directives.  
13.2 Source Data and Source Documents   
“Source data” are the data contained in source documents. Source documents are original documents or certified copi[INVESTIGATOR_014], and include, but are not limited to, diary cards, medical and 
hospi[INVESTIGATOR_1097], screening logs, informed consent / assent forms, telephone contact [CONTACT_29543], and 
worksheets. The purpose of study source documents is to document the existence of subjects and to substantiate the integrity of the study data collected. Investigators must maintain source documents so that they are accurate, complete, legible, and up to date. 
For missing or discrepant data on a diary card, the study coordinator will obtain verbal clarification  
from the subject, enter the response into the “Investigator’s comment” page of the diary card, and 
transfer the information to the CRB.  
The subject pre -screenin g log should list all individuals contact[CONTACT_35379], regardless of the outcome.  
The Investigator must print
a any electronic records on an ongoing basis, sign and date them 
immediately after creation, and keep the printouts on file as source documents that can be verified by [CONTACT_167547]. Any subsequent changes of an electronic record require the record to be re -printed, dated (with an indication of the date of 
change), and signed. Such records must also be kept together with the original printed copy. 
Good Documentation Practice should be followed by [CONTACT_167549].  
13.[ADDRESS_1222034]’s medical records are not at the investigational site, it is the responsibility of the Investigator, with the parent’s / guardian’s consent, to obtain those records if needed. 
All personal data collected related to subjects, Investigators, or any person involved in the study, 
which may be included in the Sponsor’s databases, shall be treated in compliance with all applicable laws and regulations, including the GDPR (Global Data Protection Regulation). Data 
 
a  Unless t he electronic medical records are managed by [CONTACT_35385] 
21 CFR Part 11, in which case they are acceptable on their own.  
[COMPANY_011]  Pasteur PSK00008  
515 – PNEUMOPCV Protocol  Version  6.0 
 
Confidential/Proprietary Information  
Page [ADDRESS_1222035] be properly justified and in line with the study objective. 
Subjects’ race and ethnicity will be collected in this study because these data are required by 
[CONTACT_17513] (eg, on a African -American population for the Food and Drug Administration 
[FDA]).  
Subjects will be assigned a unique identifier by [CONTACT_1034]. Any subject records or datasets that are transferred to the Sponsor will contain the identifier only; subject names or any information that would make the subject identifiable will not be transferred.  
The subject must be informed that his/her personal study -related data will be used by [CONTACT_35382]. The level of disclosure must a lso be explained to the 
subject. 
The subject must be informed that his/her medical records may be examined by [CONTACT_35383], by [CONTACT_6667]/IEC members, and by [CONTACT_6668]. 
When archiving or processing personal data pertaining to the Investigator and/or to the subjects, 
the Sponsor shall take all appropriate measures to safeguard and prevent access to this data by [CONTACT_13159]. 
13.4 Monitor ing, Auditing, and Archiving   
13.4.1 Monitoring   
Before the start of the study (ie, before the inclusion of the first subject in the first center), the Investigators and the Sponsor’s staff or a representative will meet at the site -initiation visit to 
discuss the study protocol and the detailed study procedures. Emphasis will be placed on inclusion and exclusion criteria, visit timing, safety procedures, informed consent procedures, SAE reporting procedures, CRB completion, and the handling of samples and products. The Sponsor’s staff or a representative will ensure and document that all material to be used during the study has been received at the site; and that the study Investigator team and local Sponsor/delegate staff have been properly informed about the study, GCP and regulatory requirements, and the Sponsor’s procedures. Specific training sessions for the study Investigator team and the CRAs on these topi[INVESTIGATOR_35291], and should be documented.  
The following instruction manuals will be provided: the CRF Completion Instructions for entering data into the CRB, and the Operating Guidelines for detailed study procedures such as the product management and sample-handling procedures. 
After the start of the stu dy, the Sponsor’s staff or a representative will be in regular contact [CONTACT_35386]-up visits. The Investigator or 
delegate must be available for these visits, and must allow the Sponsor/delegate staff direct access to subject medical files and CRBs. During these visits, the Sponsor/delegate staff will:  
• Evaluate the quality of the study progress (adherence to protocol and any study- specific 
guidelines, quality of data collection and document comple tion, signature [CONTACT_35396], 
occurrence of SAEs, sample and product management, cold- chain monitoring, archiving)  
[COMPANY_011]  Pasteur PSK00008  
515 – PNEUMOPCV Protocol  Version  6.0 
 
Confidential/Proprietary Information  
Page 121  of 126 • Source-verify completed CRBs and any corresponding answered queries 
• Determine the number of complete or ongoing issues identified at monitoring visits (eg,, 
protocol deviations, SAEs). Any identified problems will be discussed with the Investigator, and corrective or preventive actions will be determined, as appropriate.  
• After all protocol procedures have been completed an d the data have been entered into the 
CRB, the Investigator must still be available to answer any queries forwarded by [CONTACT_1034]. All data -related queries must be completed prior to database lock.  
At the end of the study, a close- out visit will be perfor med to ensure that:  
• The center has all the documents necessary for archiving  
• All samples have been shipped to the appropriate laboratories 
• All unused materials and products have been either destroyed or returned to the Sponsor 
13.4.2 Audits and Inspections   
A quality assurance audit may be performed at any time by [CONTACT_1034]’s Clinical Quality Assessment department (CQA) or by [CONTACT_875056], GCP and ICH requirements, and other applicable regulations. An inspection may be conducted by [CONTACT_12721]. The Investigator must allow direct access to study documents during these inspections and audits.  
13.4.3 Archiving   
The Investigator and the study site shall retain and preserve 1 copy of the study file containing the essential documents related to the study and records generated during the study (“Study File”) for the longer of the 2 following periods (“Retention Period”): 
• 25 years after the signature [CONTACT_875063]  
• Such longer period as required by [CONTACT_875057], the study si te is no longer able to retain the Study File due to 
exceptional circumstances (such as bankruptcy), the study site shall contact [CONTACT_875058]’s designee at the Sponsor’s expense. Following the Retention Period, the Investigator and/or the study site are responsible to dispose of the Study File according to the applicable regulations. Patient medical records shall be retained in compliance with local regulations. 
Archived data may be held on electronic records, provided that a back-up exists and that a hard 
copy can be obtained if required. The protocol, documentation, approvals, and all other documents related to the study will be kept by [CONTACT_35389] (TMF). Data on AEs are inc luded in the TMF. All data and documents will be made available if requested by 
[CONTACT_190660].  
[COMPANY_011]  Pasteur PSK00008  
515 – PNEUMOPCV Protocol  Version  6.0 
 
Confidential/Proprietary Information  
Page [ADDRESS_1222036] and Insurance Coverage   
A Clinical Trial Agreement will be  signed by [CONTACT_35391]’s performance, 
if relevant. The Sponsor has an insurance policy to cover any liabilities that may arise from use of 
the product and / or the study protocol. 
13.[ADDRESS_1222037] 90  days prior to submission for publication / 
presentation. Any information identified by [CONTACT_875059], it being understood that the results of this study are not to be considered confidential. 
[COMPANY_011] Pas teur’s review can be expedited to meet publication guidelines. 
[COMPANY_011]  Pasteur PSK00008  
515 – PNEUMOPCV Protocol  Version  6.0 
 
Confidential/Proprietary Information  
Page [ADDRESS_1222038]   
1. Geno KA, Gilbert GL, Song JY, Skovsted IC, Klugman KP, Jones C, et al. Pneumoco ccal 
Capsules and Their Types: Past, Present, and Future. Clinical Microbiology Reviews. 
2015;28(3):871-99. 
2. Klugman KP, Dagan R, Malley R, Whitney CG. Pneumococcal conjugate vaccine and 
pneumococcal common protein vaccines. In: Plotkin SA, Orenstein WA, Offit PA, Edwards KM, editors. Vaccines. 7 ed. Philadelphia: Elsevier; 2018. p. 773-815. 
3. Weiser JN, Ferreira DM, Paton JC. Streptococcus pneumoniae: transmission, colonization 
and invasion. Nat Rev Microbiol. 2018;16(6):355-67. 4. Black S, Shinefield H, Fireman B, Lewis E, Ray P, Hansen JR, et al. Efficacy, safety and 
immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Northern [LOCATION_004] Kaiser Permanente Vaccine Study Center Group. Pediatr Infect Dis J. 2000; 19(3):187-95. 
5. Eskola J, Kilpi T, Palmu A, Jokinen J, Haapakoski J, Herva E, et al. Efficacy of a pneumococcal conjugate vaccine against acute otitis media. N Engl J Med. 2001;344(6):403-9. 
6. Black SB, Shinefield HR, Ling S, Hansen J, Fireman B, Spring D, et al. Effectiveness of 
heptavalent pneumococcal conjugate vaccine in children younger than five years of age for prevention of pneumonia. Pediatr Infect Dis J. 2002;21(9):810-5. 
7. O'Brien KL, Moulton LH, Reid R, Weatherholtz R, Oski J, Brown L, et al. Efficacy and 
safety of seven -valent conjugate pneumococcal vaccine in American Indian children: group 
randomized trial. Lancet. 2003;362(9381):355- 61. 
8. Cutts FT, Zaman SM, Enwere G, Jaffar S, Levine OS, Okoko JB, et al. Efficacy of nine-valent pneumococ cal conjugate vaccine against pneumonia and invasive pneumococcal disease in 
The Gambia: randomized, double-blind, placebo- controlled trial. Lancet. 2005;365(9465):1139-
46. 
9. Tregnaghi MW, Sáez-Llorens X, López P, Abate H, Smith E, Pósleman A, et al. Effi cacy 
of Pneumococcal Nontypable Haemophilus influenzae Protein D Conjugate Vaccine (PHiD -CV) 
in Young Latin American Children: A Double-Blind Randomized Controlled Trial. PLOS 
Medicine. 2014;11(6):e1001657. 
10. Whitney CG, Farley MM, Hadler J, Harrison LH, Bennett NM, Lynfield R, et al. Decline 
in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine. N Engl J Med. 2003;348(18):1737-46. 
11. Fitzwater SP, Chandran A, Santosham M, Johnson HL. The worldwide impact of the 
seven -valent pneumococcal conjugate vaccine. Pediatr Infect Dis J. 2012;31(5):501-8. 
12. Miller E, Andrews NJ, Waight PA, Slack MP, George RC. Herd immunity and serotype replacement 4 years after seven -valent pneumococcal conjugate vaccination in England and 
Wales: an observational cohort study. Lancet Infect Dis. 2011;11(10):760-8. 
13. Flasche S, Van Hoek AJ, Goldblatt D, Edmunds WJ, O'Brien KL, Scott JA, et al. The 
Potential for Reducing the Number of Pneumococcal Conjugate Vaccine Doses While Sustain ing 
Herd Immunity in High -Income Countries. PLoS Med. 2015;12(6):e1001839. 
[COMPANY_011]  Pasteur PSK00008  
515 – PNEUMOPCV Protocol  Version  6.0 
 
Confidential/Proprietary Information  
Page [ADDRESS_1222039], Sato R, Bloom DE. The full benefits of adult 
pneumococcal vaccination: A systematic review. PloS one. 2017;12(10):e0186903. 
15. Wroe P C, Lee GM, Finkelstein JA, Pelton SI, Hanage WP, Lipsitch M, et al. 
Pneumococcal carriage and antibiotic resistance in young children before 13- valent conjugate 
vaccine. Pediatr Infect Dis J. 2012;31(3):249-54. 16. Lewnard JA, Hanage WP. Making sense of di fferences in pneumococcal serotype 
replacement. Lancet Infect Dis. 2019;19(6):e213-e20. 17. Stockmann C, Ampofo K, Pavia AT, Blaschke AJ, Mason EO, Presson AP, et al. Clinical 
and Epi[INVESTIGATOR_875003] e 
Dynamics. Clin Infect Dis. 2016;63(5):619 -26. 
18. Isturiz R, Sings HL, Hilton B, Arguedas A, Reinert RR, Jodar L. Streptococcus pneumoniae serotype 19A: worldwide epi[INVESTIGATOR_623]. Expert Rev Vaccines. 2017;16(10):1007- 27. 
19. Jones CH, Zhang G, Nayerhoda R, Beitelshees M, Hill A, Rostami P, et al. Comprehensive vaccine design for commensal disease progression. Sci Adv. 2017;3(10):e1701797. 
20. Grabenstein JD, Musey LK. Differences in serious clinical outcomes of infection caused 
by [CONTACT_875060]. Vaccine. 2014;32(21):2399-405. 
21. Park M, Kim HS, Shin KS, Kim HS, Park JY, Song W, et al. Changes in the incidence of 
Streptococcus pneumoniae bacteremia and its serotypes over 10 years in one hospi[INVESTIGATOR_875004]. Vaccine. 2014;32(48):6403-7. 
22. Waight PA, Andrews NJ, Ladhani SN, Sheppard CL, Slack MP, Miller E. Effect of the 13-
valent pneumococcal conjugate vaccine on invasive pneumococcal disease in England and Wales 4 years after its introduction: an observational cohort study. Lancet Infect Dis. 2015;15(5):535- 43. 
23. Imohl M, Moller J, Reinert RR, Perniciaro S, van der Linden M, Aktas O. Pneumococcal meningitis and vaccine effects in the era of conjugate vaccination: results of [ADDRESS_1222040] Dis. 2015;15:61. 
24. Balsells E, Guillot L, Nair H, Kyaw MH. Serotype distribution of Streptococcus pneumoniae causing invasive disease in children in the post- PCV era: A systematic review and 
meta -analysis. PLoS One. 2017;12(5):e0177113. 
25. Makarewicz O, Lucas M, Brandt C, Herrmann L, Albersmeier A, Ruckert C, et al. Whole 
Genome Sequencing of 39 Invasive Streptococcus pneumoniae Sequence Type 199 Isolates Revealed Switches from Serotype 19A to 15B. PloS one. 2017;12(1):e0169370. 
26. Yildirim I,  Little BA, Finkelstein J, Lee G, Hanage WP, Shea K, et al. Surveillance of 
pneumococcal colonization and invasive pneumococcal disease reveals shift in prevalent carriage 
serotypes in [LOCATION_005]' children to relatively low invasiveness. Vaccine. 2017;35(32):4002-9. 
27. Cui YA, Patel H, O'Neil WM, Li S, Saddier P. Pneumococcal serotype distribution: A 
snapshot of recent data in pediatric and adult populations around the world. Hum Vaccin Immunother. 2017;13(6):1-13. 
28. Broker M, Berti F, Schneider J, Vojtek I. Polysaccharide conjugate vaccine protein 
carriers as a "neglected valency" - Potential and limitations. Vaccine. 2017;35(25):3286-94. 
[COMPANY_011]  Pasteur PSK00008  
515 – PNEUMOPCV Protocol  Version  6.0 
 
Confidential/Proprietary Information  
Page 125  of 126 29. Principi N, Esposito S. Vaccine- preventable diseases, vaccines and Guillain -Barré' 
syndrome. Vaccine. 2018:DOI : 10.1016/j.vaccine.2018.05.119. 
30. Centers for Disease Control and Prevention. Tetanus. In: J H, A K, S W, editors. 
Epi[INVESTIGATOR_167492]-Preventable Diseases. 13 ed. Washington DC: Public Health Foundation; 2015. p. 341-50. 
31. National Center for Immunization and Respi[INVESTIGATOR_146044]. General recommendations on 
immunization --- recommendations of the Advisory Committee on Immunization Practices 
(ACIP). MMWR Recomm Rep. 2011;60(2):1- 64. 
32. Prevnar 13[package insert]. Wyeth Pharm aceuticals, Inc., a subsidiary of [COMPANY_007] Inc. 
https://www.fda.gov/files/vaccines%2C%20blood%20%26%20biologics/published/Package-
Insert ------Prevnar-13.pdf. 
33. Pentacel[package insert]. [COMPANY_011] Pasteur Inc. https://www.fda.gov/vaccines-blood-
biologics/vacci nes/pentacel . 
34. ENGERIX-B[package insert]. GlaxoSmithKline 
https://www.fda.gov/media/[ZIP_CODE]/download. 
35. RotaTeq[package insert]. [COMPANY_006] & Co., Inc. 
https://www.merck.com/product/usa/pi_circulars/r/rotateq/rotateq_pi.pdf. 
36. MMR II [package insert]. [COMPANY_006] & Co., Inc 
http://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM123789.pdf. 
37. VARIVAX[package insert]. [COMPANY_006] & Co., Inc. 
https://www.fda.gov/media/[ZIP_CODE]/download. 
38. Pi[INVESTIGATOR_19276]. Protein carriers of conjugate vaccines: characteristics, development, and 
clinical trials. Hum Vaccin Immunother. 2013;9(12):[ADDRESS_1222041] Reference Serum, 007sp. Clin Vaccine Immunol. 2015;22(11):1154-9. 
40. Center for Disease Control and Prevention. Admnister the vaccine  [cited 2019 2019]. 
Available from: https://www.cdc.gov/vaccines/hcp/admin/administer- vaccines.html . 
41. Lead exposure in children: prevention, detection, and management. Pediatrics. 
2005;116(4):1036-46. 
42. Rüggeberg JU, Gold MS, Bayas J- M, Blum M D, Bonhoeffer J, Friedlander S, et al. 
Anaphylaxis: Case definition and guidelines for data collection, analysis, and presentation of 
immunization safety data. Vaccine. 2007;25(31):5675-84. 
43. Newcombe RG. Two -sided confidence intervals for the single proportion: comparison of 
seven methods. Stat Med. 1998;17(8):857-72.  
[COMPANY_011]  Pasteur PSK00008  
515 – PNEUMOPCV Protocol  Version  6.0 
 
Confidential/Proprietary Information  
Page 126  of 126 15 Signature [CONTACT_3490]  
 
 